≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Systemic atrophies primarily affecting the central nervous system

DOID EFO Endpoint Browser PheWeb

G6_NEUATR

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — G10-G13
  • Cause of death: ICD-10 — G10-G13

2 out of 7 registries used, show all original rules.

1504

4. Check minimum number of events

None

1504

5. Include endpoints

1694

6. Filter based on genotype QC (FinnGen only)

1649

Control definitions (FinnGen only)

Controls for this endpoint are individuals that are not cases.

Extra metadata

Level in the ICD hierarchy
2
First used in FinnGen datafreeze
DF2

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 16815 7755 8724
Only index persons 10265 4914 5351
Unadjusted period prevalence (%)
Whole population 0.24 0.22 0.24
Only index persons 0.19 0.18 0.20
Median age at first event (years)
Whole population 61.80 62.97 60.68
Only index persons 60.13 60.86 59.47

-FinnGen-

Key figures

All Female Male
Number of individuals 1649 719 930
Unadjusted period prevalence (%) 0.35 0.26 0.43
Median age at first event (years) 63.05 61.03 64.62

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
1694
Matched controls
16940
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
JDB10
NOMESCO Finland
Percutaneous gastrostomy
31.3
311.1
207
75
R47.1
ICD-10 Finland
Dysarthria and anarthria
34.9
308.5
198
64
504
Kela drug reimbursment
Conditions requiring daily forced enteral nutrition
30.5
307.7
255
98
G12.2
ICD-10 Finland
Motor neuron disease
14263.2
307.7
794
*
N99
ICPC
Neurological disease other
52.9
307.7
319
74
J96.1
ICD-10 Finland
Chronic respiratory failure
16.0
283.1
255
185
N28
ICPC
Limited function/disability (N)
18.9
260.2
213
128
G11.9
ICD-10 Finland
Hereditary ataxia, unspecified
+∞
248.2
232
*
N07XX02
ATC
riluzole; oral
+∞
238.3
223
*
R27.0
ICD-10 Finland
Ataxia, unspecified
48.3
199.9
117
26
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
6.2
193.3
385
762
G12.9
ICD-10 Finland
Spinal muscular atrophy, unspecified
+∞
162.1
153
*
R4130
NOMESCO Finland
Speech therapy
10.5
158.7
184
195
G11.2
ICD-10 Finland
Late-onset cerebellar ataxia
+∞
139.5
132
*
M03BX01
ATC
baclofen; systemic
12.3
133.3
136
119
Z51.5
ICD-10 Finland
Palliative care
4.4
127.6
380
1037
TAB00
NOMESCO Finland
Lumbar puncture
6.9
126.8
211
343
G62.9
ICD-10 Finland
Polyneuropathy, unspecified
7.0
126.4
207
331
R13
ICD-10 Finland
Dysphagia
5.0
122.8
304
715
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
5.9
121.5
237
451
Z31.5
ICD-10 Finland
Genetic counselling
6.8
118.5
199
326
G12.8
ICD-10 Finland
Other spinal muscular atrophies and related syndromes
+∞
107.4
102
*
N29
ICPC
Neurological sympt/complt other
9.5
97.4
119
134
N03AE01
ATC
clonazepam; systemic
5.1
94.5
219
483
R26.8
ICD-10 Finland
Other and unspecified abnormalities of gait and mobility
8.0
93.0
131
176
B91
ICD-10 Finland
Sequelae of poliomyelitis
31.6
88.8
58
19
TJD20
NOMESCO Finland
Change of gastrostomy tube
29.1
88.0
59
21
G11.8
ICD-10 Finland
Other hereditary ataxias
+∞
84.1
80
*
G72.9
ICD-10 Finland
Myopathy, unspecified
14.0
84.0
78
58
L28
ICPC
Limited function/disability (L)
2.9
82.8
536
2336
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
3.7
79.5
289
891
R1250
NOMESCO Finland
Evaluation of functional capability
7.0
79.3
125
190
1380A
ICD-9 Finland
Late effects of acute poliomyelitis[SEQUELAE POLIOMYELITIDIS]
+∞
76.6
73
*
G12.1
ICD-10 Finland
Other inherited spinal muscular atrophy
706.3
69.6
68
*
A28
ICPC
Limited function/disability NOS
2.7
69.3
511
2351
SPAT1229
SPAT
Assessment of need for aid
3.5
63.4
242
765
WX725
NOMESCO Finland
Noninvasive ventilation
4.0
61.1
186
503
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
3.9
60.3
191
531
Z46.8
ICD-10 Finland
Fitting and adjustment of other specified devices
5.7
57.3
111
207
NXL00
NOMESCO Finland
Biopsy of muscle
21.0
56.7
43
21
N18
ICPC
Paralysis/weakness
6.1
55.8
100
173
N02AA01
ATC
morphine; systemic, rectal
6.1
53.6
96
166
R25.3
ICD-10 Finland
Fasciculation
22.2
52.6
39
18
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
3.4
52.4
210
681
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
3.3
52.1
223
753
N19
ICPC
Speech disorder
8.0
52.1
72
94
R26.0
ICD-10 Finland
Ataxic gait
22.8
51.9
38
17
R4120
NOMESCO Finland
Occupational therapy
3.6
51.8
188
572
G11.4
ICD-10 Finland
Hereditary spastic paraplegia
+∞
49.2
47
*
XG466
NOMESCO Finland
Sleep oxymetry
4.8
46.2
109
241
G10
ICD-10 Finland
Huntington disease
+∞
46.0
44
*
JC2KB
NOMESCO Finland
Functional X-ray examination of swallowing
8.3
45.0
60
75
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
2.6
44.8
318
1404
R1260
NOMESCO Finland
Evaluation of communicative skills
6.2
44.8
78
131
Z50.9
ICD-10 Finland
Care involving use of rehabilitation procedure, unspecified
4.2
44.6
124
312
R4190
NOMESCO Finland
Nutritional therapy
4.1
43.2
125
324
D21
ICPC
Swallowing problem
6.5
42.6
71
114
R47.8
ICD-10 Finland
Other and unspecified speech disturbances
8.0
41.0
56
72
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
2.3
37.8
365
1836
R5599
NOMESCO Finland
Other rehabilitation service
4.5
36.9
93
217
F80.1
ICD-10 Finland
Expressive language disorder
9.2
36.1
44
49
SPAT1215
SPAT
Assessment of need for medical rehabilitation
3.7
34.3
111
311
NA2BG
NOMESCO Finland
Thoracal spine MRI examination with high intensity magnet
4.7
34.3
80
175
SPAT1231
SPAT
Assessment of adjustments needed in living environment
4.9
33.4
74
155
R5110, ,
SPAT
2.5
30.9
212
912
G31.0
ICD-10 Finland
Circumscribed brain atrophy
9.9
29.5
34
35
34899
ICD-8 Finland
Motor neurone disease, Other and unspecified manifestations
+∞
29.2
28
*
UDQ42
NOMESCO Finland
Endoscopic assessment of swallowing function
28.5
29.0
39
14
SPAT1226
SPAT
Implementation of occupational therapy rehabilitation plan
4.1
27.8
77
193
XA402
NOMESCO Finland
ENMG
4.5
27.8
69
159
G31.9
ICD-10 Finland
Degenerative disease of nervous system, unspecified
24.3
27.0
38
16
NA7CG
NOMESCO Finland
Spine and spinal cord extensive MRI examination with high intensity magnet
5.9
26.3
47
81
XG416
NOMESCO Finland
Measurement of maximal airway pressure
+∞
26.1
25
*
R2120
NOMESCO Finland
Counselling and guidance concerning rehabilitation services and social security
7.4
25.5
37
51
SPAT1297
SPAT
Other function in accordance with speech therapy nomenclature
10.5
25.4
28
27
R4120, ,
SPAT
5.5
25.0
49
92
J69.0
ICD-10 Finland
Pneumonitis due to food and vomit
4.4
24.8
63
148
OAB74
NOMESCO Finland
Nutritional guidance related to treatment and rehabilitation for medical condition
6.3
24.5
41
66
3342A
ICD-9 Finland
Spinocerebellar disease, Primary cerebellar degeneration
+∞
23.0
22
*
Z50.5
ICD-10 Finland
Speech therapy
5.4
22.8
45
85
Z71.3
ICD-10 Finland
Dietary counselling and surveillance
3.1
22.7
96
319
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
1.8
21.8
397
2447
04499
ICD-8 Finland
Late effects of actue poliomyelitis
222.8
21.6
22
*
G62.8
ICD-10 Finland
Other specified polyneuropathies
5.8
21.5
39
68
SPAT1137
SPAT
Taking care of patient’s/customer’s hygiene
2.5
21.1
145
622
SPAT1220
SPAT
Assessment of need for rehabilitation and/or rehabilitation plan
2.5
20.8
133
551
SPAT1217
SPAT
Assessment of need for services (elderly/care support)
2.3
20.7
174
814
N03AX12
ATC
[U] gabapentin; oral
1.9
20.7
301
1726
SPAT1224
SPAT
Implementation of speech therapy rehabilitation plan
4.8
20.6
47
101
GX2D5
NOMESCO Finland
Sleep oximetry
8.1
20.0
27
34
NA7DG
NOMESCO Finland
Spine and spinal cord very extensive MRI examination with high intensity magnet
5.4
20.0
39
73
G35
ICD-10 Finland
Multiple sclerosis
5.7
20.0
37
66
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
2.4
19.7
143
628
Z82.0
ICD-10 Finland
Family history of epilepsy and other diseases of the nervous system
26.4
19.1
26
10
XG467
NOMESCO Finland
Nocturnal CO2 monitoring
34.7
18.9
24
7
G12.0
ICD-10 Finland
Infantile spinal muscular atrophy, type I [Werdnig-Hoffman]
+∞
18.8
18
*
SPAT1216
SPAT
Assessment of functional ability
1.8
18.3
307
1836
WYA30
NOMESCO Finland
Treatment of a patient needing special arrangements
2.3
18.1
150
698
XA800
NOMESCO Finland
Neuropsychological investigation
2.8
18.0
90
329
R26.2
ICD-10 Finland
Difficulty in walking, not elsewhere classified
4.3
17.9
46
109
G11.18
ICD-10 Finland
Early-onset cerebellar ataxia
181.8
17.5
18
*
WPA13
NOMESCO Finland
Palliative consultation
7.8
17.4
24
31
N70
ICPC
Poliomyelitis
42.5
17.3
21
5
Z50.1
ICD-10 Finland
Other physical therapy
2.5
17.2
115
487
XX9TE
NOMESCO Finland
Compementary ultrasound examination
7.2
17.0
25
35
L99
ICPC
Musculoskeletal disease other
3.6
16.9
55
155
ZXE17
NOMESCO Finland
Procedure duration 150 to 179 minutes
5.9
16.2
29
50
NJ3BG
NOMESCO Finland
MRI examination of extremities with high intensity magnet
15.5
16.2
26
17
M62.5
ICD-10 Finland
Muscle wasting and atrophy, not elsewhere classified
21.2
16.0
23
11
JDB01
NOMESCO Finland
Laparoscopic gastrostomy
60.6
15.8
18
*
L19
ICPC
Muscle symptom/complaint NOS
3.2
15.7
61
193
UDQ12
NOMESCO Finland
Flexible laryngoscopy
2.3
15.7
116
514
3352A
ICD-9 Finland
Anterior horn cell disease, Motor neuron disease[SCLEROSIS LATERALIS AMYOTROPHICA]
+∞
15.6
15
*
G57.3
ICD-10 Finland
Lesion of lateral popliteal nerve
4.2
15.6
41
99
W01
ICD-10 Finland
Fall on same level from slipping, tripping and stumbling
1.6
15.2
561
4094
WPA10
NOMESCO Finland
Proactive palliative care treatment plan
5.3
15.2
30
57
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
1.6
15.1
514
3683
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
1.8
15.0
275
1683
T05
ICPC
Feeding problem of adult
5.2
14.9
30
58
J18.9
ICD-10 Finland
Pneumonia, unspecified
1.6
14.8
500
3574
OAB73
NOMESCO Finland
Prevention and treatment of malnutrition
4.9
14.8
32
66
N02AA05
ATC
oxycodone; systemic
1.6
14.6
364
2417
G11.00
ICD-10 Finland
Cerebellar dysplasia and aplasia
+∞
14.6
14
*
SPAT1222
SPAT
Counselling/guidance promoting independent living
1.7
14.6
282
1750
IAZ97
NOMESCO Finland
Psychiatric consultation in another specialty
4.3
14.6
37
87
G71.08
ICD-10 Finland
Other muscular dystrophy
36.4
14.4
18
5
A98
ICPC
Health maint/preventive medicine
0.6
14.3
1336
14562
G60.0
ICD-10 Finland
Hereditary motor and sensory neuropathy
17.1
14.3
22
13
XW5WT
NOMESCO Finland
Other blood specimen with radiologicl guidance
27.4
14.3
19
7
NJ3CG
NOMESCO Finland
Extensive MRI examination of extremities with median high magnet
14.6
14.1
23
16
N05BA06
ATC
lorazepam; systemic, sublingual
2.3
13.7
108
491
WX781
NOMESCO Finland
Remote monitoring, noninvasive ventilation
34.3
13.5
17
5
RS314, ,
NOMESCO Finland
26.0
13.4
18
7
G82.1
ICD-10 Finland
Spastic paraplegia
40.4
13.2
16
*
G97.0
ICD-10 Finland
Cerebrospinal fluid leak from spinal puncture
5.5
13.1
25
46
H55
ICD-10 Finland
Nystagmus and other irregular eye movements
11.1
12.5
23
21
G11.02
ICD-10 Finland
Dysequilibrium syndrome
+∞
12.5
12
*
3343A
ICD-9 Finland
Spinocerebellar disease, Other cerebellar ataxia
+∞
12.5
12
*
Z3229
NOMESCO Finland
Other healthcare associate professional
1.9
12.5
156
846
GX1P5
NOMESCO Finland
Nocturnal CO2 monitoring
130.9
12.4
13
*
G71.3
ICD-10 Finland
Mitochondrial myopathy, not elsewhere classified
37.8
12.2
15
*
SPAT1234
SPAT
Support of social functional capacity
2.2
12.1
106
504
M54.1
ICD-10 Finland
Radiculopathy
2.5
12.1
75
307
RS340, ,
NOMESCO Finland
26.9
12.0
16
6
R1100
NOMESCO Finland
General evaluation of the need for rehabilitation
3.7
12.0
37
101
G31.2
ICD-10 Finland
Degeneration of nervous system due to alcohol
4.9
11.9
26
54
ZXE15
NOMESCO Finland
Procedure duration 120 to 149 minutes
3.7
11.6
37
103
G13.0
ICD-10 Finland
Paraneoplastic neuromyopathy and neuropathy
+∞
11.5
11
*
3351X
ICD-9 Finland
Anterior horn cell disease, Spinal muscular atrophy[ATROPHIA MUSCULORUM SPINALIS NUD]
+∞
11.5
11
*
G11
ICD-10 Finland
Hereditary ataxia
+∞
11.5
11
*
Z02.4
ICD-10 Finland
Examination for driving licence
0.6
11.4
265
3902
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
1.5
11.2
459
3383
ABC60
NOMESCO Finland
Decompression of cervical spinal cord
4.8
11.2
25
53
N05BA04
ATC
oxazepam; oral
1.5
11.2
413
2981
SPAT1296
SPAT
Other function in accordance with occupational therapy nomenclature
4.4
11.0
27
62
RS222, ,
NOMESCO Finland
4.1
11.0
30
75
SPAT1167
SPAT
Insertion of urinary catheter
2.4
10.9
72
303
TKC10
NOMESCO Finland
Percutaneous puncture of bladder
3.4
10.9
38
113
N06AA09
ATC
amitriptyline; systemic
1.8
10.8
160
915
SPAT1295
SPAT
Other function in accordance with physical therapy nomenclature
2.2
10.8
87
400
Z3226
NOMESCO Finland
Physiotherapist
1.6
10.8
296
2000
A06AD11
ATC
lactulose; oral
1.6
10.8
278
1851
WPA42
NOMESCO Finland
Family-centered psychosocial intervention in palliative care
28.2
10.7
14
5
R49.08
ICD-10 Finland
Other specified dysphonia
3.1
10.7
44
145
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
1.8
10.6
177
1049
TNX05
NOMESCO Finland
Simple incision of soft tissue, unspecified region
14.3
10.5
17
12
ABD40
NOMESCO Finland
Implantation of spinal injection device
110.7
10.4
11
*
34898
ICD-8 Finland
Motor neurone disease, Alii definiti
+∞
10.4
10
*
A120_, ,
NOMESCO Finland
+∞
10.4
10
*
3349X
ICD-9 Finland
Spinocerebellar disease, unspecified
+∞
10.4
10
*
A210_, ,
NOMESCO Finland
+∞
10.4
10
*
7812A
ICD-9 Finland
Symptoms involving nervous and musculoskeletal systems, Abnormality of gait
+∞
10.4
10
*
NA7BG
NOMESCO Finland
Spine and spinal cord MRI examination with high intensity magnet
7.8
10.4
23
30
TAW99
NOMESCO Finland
Other minor neurosurgical procedure
8.8
10.3
21
24
N04BA02
ATC
levodopa and decarboxylase inhibitor; oral
2.3
10.3
75
331
G61.8
ICD-10 Finland
Other inflammatory polyneuropathies
18.9
10.3
15
8
G82.2
ICD-10 Finland
Paraplegia, unspecified
9.6
10.3
20
21
XKD06
NOMESCO Finland
Physiologic investigation of micturition
2.5
10.3
64
263
OAB43, ,
SPAT
0.5
10.2
119
2112
XQ858
NOMESCO Finland
Oxygen partial pressure measurement
3.7
10.2
31
84
NA1CG
NOMESCO Finland
Cervical spine extensive MRI examination with high intensity magnet
3.2
10.1
40
129
SPAT1245
SPAT
Provision of support and information to patient’s family members
2.2
9.9
85
402
N81
ICPC
Injury nervous system other
10.7
9.8
18
17
N06AX21
ATC
duloxetine; oral
1.7
9.7
180
1100
WPA15
NOMESCO Finland
Palliative care consultation with the patient and loved ones
5.3
9.6
19
36
WPA43
NOMESCO Finland
A doctor's home visit to perform palliative care
15.1
9.5
15
10
R5140
NOMESCO Finland
Monitoring the use of the aid
1.7
9.5
191
1193
Z01.8
ICD-10 Finland
Other specified special examinations
1.5
9.5
354
2551
RP120, ,
NOMESCO Finland
+∞
9.4
9
*
F02.29*G10
ICD-10 Finland
Dementia in Huntington's disease without information on additional symptoms
+∞
9.4
9
*
RK110, ,
NOMESCO Finland
4.4
9.3
23
53
Z46.9
ICD-10 Finland
Fitting and adjustment of unspecified device
3.5
9.2
31
90
G25.9
ICD-10 Finland
Extrapyramidal and movement disorder, unspecified
4.2
9.2
24
58
J96.9
ICD-10 Finland
Respiratory failure, unspecified
4.4
9.1
22
50
M47.1
ICD-10 Finland
Other spondylosis with myelopathy
3.5
9.1
30
86
RS221, ,
NOMESCO Finland
3.5
9.1
31
91
RS142, ,
NOMESCO Finland
18.7
8.9
13
7
AA1AD
NOMESCO Finland
CT of head and brain
1.4
8.9
497
3854
N03AF01
ATC
carbamazepine; oral, rectal
2.0
8.9
91
460
JDB00
NOMESCO Finland
Gastrostomy
24.1
8.9
12
5
SPAT1221
SPAT
Guidance concerning rehabilitation services and livelihood
3.1
8.8
35
113
E78.0
ICD-10 Finland
Pure hypercholesterolaemia
0.6
8.8
173
2670
G40.9
ICD-10 Finland
Epilepsy, unspecified
2.3
8.7
63
277
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
1.6
8.7
197
1267
N94
ICPC
Peripheral neuritis/neuropathy
14.1
8.7
14
10
M41.4
ICD-10 Finland
Neuromuscular scoliosis
50.2
8.7
10
*
N06AB04
ATC
citalopram; systemic
1.5
8.6
306
2178
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
2.5
8.6
54
223
Z99.8
ICD-10 Finland
Dependence on other enabling machines and devices
16.4
8.6
13
8
R4110
NOMESCO Finland
Physiotherapy
1.4
8.5
439
3352
N05BA01
ATC
diazepam; systemic, rectal
1.6
8.5
206
1347
N04BB01
ATC
amantadine; oral
3.5
8.5
29
85
G71.9
ICD-10 Finland
Primary disorder of muscle, unspecified
20.1
8.5
12
6
XKC03
NOMESCO Finland
Water cystometry
2.4
8.4
54
225
G04BD12
ATC
mirabegron; oral
1.6
8.4
208
1369
G13.2*E03.9
ICD-10 Finland
Systemic atrophy primarily affecting central nervous system in myxoedema
+∞
8.3
8
*
A220_, ,
NOMESCO Finland
+∞
8.3
8
*
ZXE11
NOMESCO Finland
Procedure duration 60 to 89 minutes
2.1
8.2
81
405
N87
ICPC
Parkinsonism
3.1
8.1
33
108
N06AB10
ATC
escitalopram; oral
1.5
8.1
261
1818
WYA20, ,
SPAT
4.6
8.1
19
42
OAA67, ,
SPAT
0.4
8.1
50
1106
Z93.1
ICD-10 Finland
Gastrostomy status
17.3
8.1
12
7
R33
ICD-10 Finland
Retention of urine
1.7
8.0
160
996
XG410
NOMESCO Finland
Flow-volume spirometry
2.1
8.0
72
347
NGA20
NOMESCO Finland
Exploration of soft tissue knee or lower leg, open
10.1
8.0
15
15
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
2.0
8.0
86
443
WPA40
NOMESCO Finland
Individual-centered psychosocial intervention in palliative care
22.1
8.0
11
5
ZY010
NOMESCO Finland
Hospital outpatient
2.1
8.0
74
361
R42
ICD-10 Finland
Dizziness and giddiness
1.4
8.0
368
2752
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
1.7
8.0
136
812
M62.9
ICD-10 Finland
Disorder of muscle, unspecified
9.4
7.8
15
16
Z2446
NOMESCO Finland
Social worker
1.8
7.7
106
593
N06DX01
ATC
memantine; oral
0.4
7.6
39
929
R1420
NOMESCO Finland
Assessment of rehabilitation needs and/or compilation of rehabilitation plan
11.9
7.6
13
11
R25.1
ICD-10 Finland
Tremor, unspecified
2.3
7.5
53
231
R1410
NOMESCO Finland
Drawing up a rehabilitation plan
6.2
7.5
19
31
TKC20, ,
SPAT
4.3
7.5
19
45
R1420, ,
SPAT
6.5
7.4
18
28
N05BA09
ATC
clobazam; oral
6.5
7.4
18
28
R4130, ,
SPAT
7.7
7.4
16
21
34800
ICD-8 Finland
Motor neurone disease, Amyotrophic lateral sclerosis
+∞
7.3
7
*
SPAT1254
SPAT
Administration of medicine
1.5
7.3
235
1638
TNH33
NOMESCO Finland
Custom moulded brace, ankle or foot
3.2
7.3
28
89
Z73.6
ICD-10 Finland
Limitation of activities due to disability
3.9
7.3
21
55
SPAT1262
SPAT
Handing over of treatment supplies
1.5
7.2
275
1980
S12
ICPC
Insect bite/sting
0.4
7.2
36
867
OAA80, ,
SPAT
0.3
7.1
18
602
R5210
NOMESCO Finland
Assessment of the improvements needed in the living environment
8.0
7.1
15
19
WPA10, ,
SPAT
8.0
7.1
15
19
TJD10
NOMESCO Finland
Insertion of other tube into stomach or duodenum
12.1
7.1
12
10
C10AA07
ATC
rosuvastatin; oral
0.7
7.0
319
4180
Z2445
NOMESCO Finland
Psychologist
2.2
6.9
55
253
XA421
NOMESCO Finland
Nocturnal polygraphy
7.6
6.9
15
20
K11.72
ICD-10 Finland
Xerostomia
13.8
6.9
11
8
R26
ICD-10 Finland
Abnormalities of gait and mobility
13.8
6.9
11
8
G72.8
ICD-10 Finland
Other specified myopathies
2.7
6.8
36
137
AA5EN
NOMESCO Finland
Brain reseptor or transprot protein distribution isotope imaging
8.3
6.8
14
17
N04BC05
ATC
pramipexole; oral
1.7
6.8
121
731
N06AX11
ATC
mirtazapine; oral
1.3
6.8
499
4017
G60.9
ICD-10 Finland
Hereditary and idiopathic neuropathy, unspecified
40.2
6.8
8
*
ZX120, ,
SPAT
3.1
6.7
27
88
111
Kela drug reimbursment
Epilepsy and comparable convulsive disorders
1.9
6.7
81
435
N31.9
ICD-10 Finland
Neuromuscular dysfunction of bladder, unspecified
3.9
6.7
19
49
U04
ICPC
Incontinence urine
1.8
6.7
102
591
JN3AA
NOMESCO Finland
Abdominal X-ray examination without contrast
2.0
6.7
73
380
GD1AA, ,
SPAT
0.5
6.6
79
1398
R63.4
ICD-10 Finland
Abnormal weight loss
2.0
6.6
70
360
R99
ICD-10 Finland
Other ill-defined and unspecified causes of mortality
2.2
6.6
50
226
RT274, ,
NOMESCO Finland
12.3
6.6
11
9
RS310, ,
NOMESCO Finland
12.3
6.6
11
9
A29
ICPC
General symptom/complaint other
1.5
6.6
220
1544
NA3CG
NOMESCO Finland
Lumbar spine extensive MRI examination with high intensity magnet
2.0
6.6
66
333
M47.2
ICD-10 Finland
Other spondylosis with radiculopathy
1.8
6.6
99
571
G81.9
ICD-10 Finland
Hemiplegia, unspecified
3.4
6.6
23
69
GX1D5
NOMESCO Finland
Flow volume spirometry
8.7
6.6
13
15
N02BF01
ATC
gabapentin; oral
1.6
6.5
157
1025
SPAT1125
SPAT
Stoma care and guidance
2.7
6.5
33
123
WX320
NOMESCO Finland
Spinalanesthesy
0.7
6.4
214
2973
N03AX16
ATC
[U] pregabalin
1.4
6.4
340
2595
RP130, ,
NOMESCO Finland
70.1
6.4
7
*
N07XX06
ATC
tetrabenazine; oral
70.1
6.4
7
*
ZXE05
NOMESCO Finland
Procedure duration 40 to 49 minutes
1.9
6.4
73
385
V700A
ICD-9 Finland
General medical examination, Routine general medical examination at a health care facility
2.4
6.4
41
172
NH1AA
NOMESCO Finland
Ankle X-ray examination without contrast
1.7
6.4
110
660
R4110, ,
SPAT
1.5
6.4
204
1419
R69
ICD-10 Finland
Unknown and unspecified causes of morbidity
2.7
6.3
33
125
RS122, ,
NOMESCO Finland
8.2
6.3
13
16
WPA44
NOMESCO Finland
Nursing home for palliative care
8.2
6.3
13
16
N07AA02
ATC
pyridostigmine; systemic
5.5
6.3
17
31
UJC01
NOMESCO Finland
Scopy of lower throat
3.3
6.3
23
71
3350A
ICD-9 Finland
Anterior horn cell disease, Werdnig-Hoffmann disease[MORBUS WERDNIG-HOFFMANN]
+∞
6.3
6
*
A222_, ,
NOMESCO Finland
+∞
6.3
6
*
33098
ICD-8 Finland
Hereditary neuromuscular disorders, Alii definiti
+∞
6.3
6
*
3348X
ICD-9 Finland
Spinocerebellar disease, Other spinocerebellar diseases
+∞
6.3
6
*
A211_, ,
NOMESCO Finland
+∞
6.3
6
*
M89.6
ICD-10 Finland
Osteopathy after poliomyelitis
+∞
6.3
6
*
H02AB02
ATC
dexamethasone; systemic
0.5
6.2
64
1185
Z99.1
ICD-10 Finland
Dependence on respirator
26.8
6.2
8
*
G98
ICD-10 Finland
Other disorders of nervous system, not elsewhere classified
26.8
6.2
8
*
WPA43, ,
SPAT
7.0
6.2
14
20
RS230, ,
NOMESCO Finland
5.4
6.2
17
32
N31.2
ICD-10 Finland
Flaccid neuropathic bladder, not elsewhere classified
3.4
6.1
21
62
R4160
NOMESCO Finland
Other therapy enhancing rehabilitation
2.8
6.1
29
105
J96.0
ICD-10 Finland
Acute respiratory failure
2.7
6.0
30
111

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Neurology
13 [38004458]
1.2e+00
2.9e+00
3.5e+00
8.8e+00
4.1e+00
3.9e+00
2.7e+00
cases:27.30%
controls:10.12%
cases:45.44%
controls:4.23%
cases:19.03%
controls:0.72%
cases:73.78%
controls:0.04%
cases:30.46%
controls:0.76%
cases:69.36%
controls:4.19%
cases:64.86%
controls:10.91%
440
1624
1172
14426
733
679
880
15381
307
115
1306
15945
1190
7
423
16053
480
121
1096
15903
971
652
429
14912
600
1422
325
11606
Polyneuropathy, unspecified
G62.9 [45566898]
2.2e+00
3.4e+00
—
1.0e+50
4.0e+00
3.4e+00
2.6e+00
cases:4.09%
controls:0.45%
cases:5.89%
controls:0.22%
—
—
cases:2.67%
controls:0.00%
cases:1.97%
controls:0.04%
cases:5.43%
controls:0.19%
cases:6.27%
controls:0.49%
66
72
1546
15978
95
35
1518
16025
—
43
0
1570
16060
31
6
1545
16018
76
29
1324
15535
58
64
867
12964
Chronic respiratory failure
J96.1 [45557632]
1.3e+00
1.8e+00
3.0e+00
—
3.8e+00
3.7e+00
3.0e+00
cases:0.62%
controls:0.17%
cases:0.87%
controls:0.15%
cases:0.87%
controls:0.04%
—
—
cases:1.97%
controls:0.04%
cases:6.86%
controls:0.17%
cases:5.08%
controls:0.25%
10
27
1602
16023
14
24
1599
16036
14
7
1599
16053
—
31
7
1545
16017
96
27
1304
15537
47
33
878
12995
Neurological disease other
N99 [2002000796]
2.0e+00
3.0e+00
1.0e+50
—
1.0e+50
5.7e+00
4.6e+00
cases:0.68%
controls:0.09%
cases:0.99%
controls:0.05%
cases:0.81%
controls:0.00%
—
—
cases:2.86%
controls:0.00%
cases:8.64%
controls:0.03%
cases:8.32%
controls:0.09%
11
15
1601
16035
16
8
1597
16052
13
0
1600
16060
—
45
0
1531
16024
121
5
1279
15559
77
12
848
13016
Dysphagia
R13 [45573013]
1.3e+00
3.1e+00
4.5e+00
1.0e+50
—
3.4e+00
1.7e+00
cases:2.48%
controls:0.67%
cases:6.26%
controls:0.29%
cases:2.73%
controls:0.03%
cases:1.74%
controls:0.00%
—
—
cases:7.07%
controls:0.26%
cases:4.76%
controls:0.87%
40
107
1572
15943
101
46
1512
16014
44
5
1569
16055
28
0
1585
16060
—
99
41
1301
15523
44
113
881
12915
Inpatient Hospital
21 [8717]
2.5e-01
7.9e-01
1.4e+00
6.3e+00
2.0e+00
1.3e+00
9.2e-01
cases:34.80%
controls:29.41%
cases:19.34%
controls:9.80%
cases:5.70%
controls:1.45%
cases:15.00%
controls:0.03%
cases:8.88%
controls:1.30%
cases:26.93%
controls:9.26%
cases:44.65%
controls:24.36%
561
4720
1051
11330
312
1574
1301
14486
92
233
1521
15827
242
5
1371
16055
140
209
1436
15815
377
1441
1023
14123
413
3173
512
9855
Other and unspecified abnormalities of gait and mobility
R26.8 [45597174]
2.3e+00
4.5e+00
—
1.0e+50
—
3.7e+00
2.4e+00
cases:2.11%
controls:0.21%
cases:4.59%
controls:0.06%
—
—
cases:0.81%
controls:0.00%
—
—
cases:1.50%
controls:0.04%
cases:1.73%
controls:0.16%
34
34
1578
16016
74
9
1539
16051
—
13
0
1600
16060
—
21
6
1379
15558
16
21
909
13007
Limited function/disability (N)
N28 [2002000733]
1.7e+00
2.9e+00
1.0e+50
—
1.0e+50
4.4e+00
3.3e+00
cases:0.62%
controls:0.12%
cases:1.12%
controls:0.06%
cases:0.62%
controls:0.00%
—
—
cases:0.95%
controls:0.00%
cases:4.86%
controls:0.06%
cases:4.43%
controls:0.17%
10
19
1602
16031
18
10
1595
16050
10
0
1603
16060
—
15
0
1561
16024
68
10
1332
15554
41
22
884
13006
Physical Medicine And Rehabilitation
25 [38004468]
7.4e-01
1.7e+00
2.1e+00
—
3.1e+00
2.5e+00
1.3e+00
cases:11.54%
controls:5.85%
cases:10.48%
controls:2.12%
cases:2.60%
controls:0.31%
—
—
cases:6.15%
controls:0.29%
cases:18.43%
controls:1.79%
cases:18.59%
controls:6.04%
186
939
1426
15111
169
340
1444
15720
42
50
1571
16010
—
97
47
1479
15977
258
278
1142
15286
172
787
753
12241
Conditions requiring daily forced enteral nutrition
504 [2001600363]
—
2.3e+00
—
—
—
5.5e+00
3.6e+00
—
—
cases:0.43%
controls:0.04%
—
—
—
—
—
—
cases:7.43%
controls:0.03%
cases:3.24%
controls:0.09%
—
7
7
1606
16053
—
—
—
104
5
1296
15559
30
12
895
13016
General Practice
1 [38004446]
7.0e-02
9.3e-01
1.2e+00
5.0e+00
1.8e+00
1.5e+00
8.0e-01
cases:13.34%
controls:12.55%
cases:11.72%
controls:4.99%
cases:2.85%
controls:0.88%
cases:4.22%
controls:0.03%
cases:4.89%
controls:0.82%
cases:20.36%
controls:5.43%
cases:29.51%
controls:15.79%
215
2014
1397
14036
189
802
1424
15258
46
141
1567
15919
68
5
1545
16055
77
131
1499
15893
285
845
1115
14719
273
2057
652
10971
Creatine kinase [Enzymatic activity/volume] in Serum or Plasma
2157-6 [3007220]
5.8e-01
2.1e+00
3.4e+00
1.0e+50
3.2e+00
1.4e+00
5.2e-01
cases:10.30%
controls:6.04%
cases:16.12%
controls:2.33%
cases:5.70%
controls:0.21%
cases:2.79%
controls:0.00%
cases:6.03%
controls:0.26%
cases:8.07%
controls:2.18%
cases:12.00%
controls:7.47%
166
969
1446
15081
260
374
1353
15686
92
34
1521
16026
45
0
1568
16060
95
41
1481
15983
113
339
1287
15225
111
973
814
12055
Standard MRI examination of brain with high intensity magnet
AA1BG [2001300112]
1.2e+00
2.8e+00
3.1e+00
1.0e+50
—
2.5e+00
1.4e+00
cases:2.92%
controls:0.93%
cases:4.71%
controls:0.29%
cases:0.81%
controls:0.04%
cases:2.11%
controls:0.00%
—
—
cases:2.57%
controls:0.21%
cases:2.81%
controls:0.73%
47
149
1565
15901
76
46
1537
16014
13
6
1600
16054
34
0
1579
16060
—
36
33
1364
15531
26
95
899
12933
Protein electrophoresis panel - Serum or Plasma
24351-9 [3004588]
8.6e-01
2.6e+00
2.7e+00
—
3.5e+00
1.3e+00
5.4e-01
cases:3.16%
controls:1.36%
cases:5.77%
controls:0.47%
cases:1.36%
controls:0.09%
—
—
cases:2.41%
controls:0.07%
cases:1.86%
controls:0.49%
cases:2.59%
controls:1.54%
51
218
1561
15832
93
75
1520
15985
22
15
1591
16045
—
38
12
1538
16012
26
77
1374
15487
24
200
901
12828
pH of Capillary blood
2745-8 [3009343]
-4.2e-02
9.9e-01
3.5e+00
1.0e+50
2.9e+00
2.4e+00
1.2e+00
cases:0.99%
controls:1.03%
cases:1.55%
controls:0.58%
cases:0.99%
controls:0.03%
cases:0.50%
controls:0.00%
cases:1.65%
controls:0.09%
cases:5.64%
controls:0.56%
cases:5.08%
controls:1.58%
16
166
1596
15884
25
93
1588
15967
16
5
1597
16055
8
0
1605
16060
26
15
1550
16009
79
87
1321
15477
47
206
878
12822
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
R29.8 [45587505]
1.7e+00
3.9e+00
—
—
—
3.2e+00
2.0e+00
cases:4.84%
controls:0.88%
cases:11.72%
controls:0.26%
—
—
—
—
—
—
cases:5.00%
controls:0.21%
cases:5.08%
controls:0.74%
78
141
1534
15909
189
41
1424
16019
—
—
—
70
32
1330
15532
47
97
878
12931
Limited function/disability (L)
L28 [2002000647]
6.4e-01
1.5e+00
2.6e+00
—
3.0e+00
2.1e+00
1.1e+00
cases:4.28%
controls:2.30%
cases:5.15%
controls:1.16%
cases:2.23%
controls:0.17%
—
—
cases:2.98%
controls:0.16%
cases:9.14%
controls:1.25%
cases:9.73%
controls:3.60%
69
369
1543
15681
83
187
1530
15873
36
28
1577
16032
—
47
25
1529
15999
128
194
1272
15370
90
469
835
12559
Carbon dioxide [Partial pressure] in Capillary blood
2020-6 [3023024]
-4.2e-02
9.9e-01
3.3e+00
1.0e+50
2.9e+00
2.3e+00
1.2e+00
cases:0.99%
controls:1.03%
cases:1.61%
controls:0.60%
cases:0.99%
controls:0.04%
cases:0.50%
controls:0.00%
cases:1.71%
controls:0.09%
cases:5.71%
controls:0.58%
cases:5.19%
controls:1.60%
16
166
1596
15884
26
97
1587
15963
16
6
1597
16054
8
0
1605
16060
27
15
1549
16009
80
91
1320
15473
48
208
877
12820
Spinal stenosis
M48.0 [45557888]
8.2e-01
1.5e+00
1.8e+00
3.6e+00
1.9e+00
1.1e+00
5.7e-01
cases:4.65%
controls:2.11%
cases:3.91%
controls:0.89%
cases:1.24%
controls:0.20%
cases:1.12%
controls:0.03%
cases:1.27%
controls:0.20%
cases:3.00%
controls:0.99%
cases:4.11%
controls:2.36%
75
339
1537
15711
63
143
1550
15917
20
32
1593
16028
18
5
1595
16055
20
32
1556
15992
42
154
1358
15410
38
308
887
12720
Borrelia burgdorferi IgG Ab [Units/volume] in Serum
7817-0 [3016888]
1.2e+00
3.4e+00
3.9e+00
1.0e+50
—
2.2e+00
-3.8e-02
cases:3.47%
controls:1.05%
cases:7.38%
controls:0.27%
cases:1.55%
controls:0.03%
cases:0.50%
controls:0.00%
—
—
cases:2.36%
controls:0.27%
cases:0.86%
controls:0.90%
56
168
1556
15882
119
44
1494
16016
25
5
1588
16055
8
0
1605
16060
—
33
42
1367
15522
8
117
917
12911
Care involving use of other rehabilitation procedures
Z50.8 [45556842]
7.8e-01
1.9e+00
—
—
3.2e+00
3.5e+00
2.1e+00
cases:1.30%
controls:0.60%
cases:1.24%
controls:0.18%
—
—
—
—
cases:1.02%
controls:0.04%
cases:5.07%
controls:0.15%
cases:5.30%
controls:0.71%
21
97
1591
15953
20
29
1593
16031
—
—
16
7
1560
16017
71
24
1329
15540
49
93
876
12935
baclofen; oral, parenteral
M03BX01 [21604115]
8.6e-01
1.6e+00
1.2e+00
—
2.8e+00
3.2e+00
3.0e+00
cases:0.56%
controls:0.24%
cases:0.93%
controls:0.19%
cases:0.31%
controls:0.09%
—
—
cases:0.82%
controls:0.05%
cases:3.71%
controls:0.16%
cases:5.51%
controls:0.28%
9
38
1603
16012
15
30
1598
16030
5
15
1608
16045
—
13
8
1563
16016
52
25
1348
15539
51
37
874
12991
Palliative care
Z51.5 [45547323]
—
9.7e-01
1.9e+00
—
3.2e+00
3.6e+00
2.0e+00
—
—
cases:0.31%
controls:0.12%
cases:0.50%
controls:0.07%
—
—
cases:2.28%
controls:0.10%
cases:9.43%
controls:0.30%
cases:5.51%
controls:0.82%
—
5
19
1608
16041
8
12
1605
16048
—
36
16
1540
16008
132
46
1268
15518
51
107
874
12921
Borrelia burgdorferi IgM Ab [Units/volume] in Serum
7818-8 [3008230]
1.2e+00
3.4e+00
3.8e+00
1.0e+50
—
2.2e+00
-7.1e-02
cases:3.72%
controls:1.18%
cases:8.06%
controls:0.30%
cases:1.61%
controls:0.04%
cases:0.50%
controls:0.00%
—
—
cases:2.57%
controls:0.29%
cases:0.97%
controls:1.04%
60
189
1552
15861
130
48
1483
16012
26
6
1587
16054
8
0
1605
16060
—
36
45
1364
15519
9
136
916
12892
Alpha 1 globulin [Mass/volume] in Serum or Plasma by Electrophoresis
2865-4 [3015322]
7.3e-01
2.7e+00
2.6e+00
—
3.8e+00
1.4e+00
4.4e-01
cases:1.55%
controls:0.75%
cases:3.84%
controls:0.26%
cases:0.81%
controls:0.06%
—
—
cases:1.71%
controls:0.04%
cases:1.21%
controls:0.31%
cases:1.41%
controls:0.91%
25
121
1587
15929
62
41
1551
16019
13
10
1600
16050
—
27
6
1549
16018
17
49
1383
15515
13
119
912
12909
Pulmonary Disease
29 [38004472]
2.6e-01
5.1e-01
1.3e+00
3.8e+00
1.9e+00
1.9e+00
9.4e-01
cases:11.85%
controls:9.35%
cases:8.12%
controls:5.06%
cases:3.35%
controls:0.90%
cases:1.98%
controls:0.04%
cases:6.41%
controls:0.97%
cases:25.79%
controls:4.77%
cases:22.92%
controls:10.39%
191
1501
1421
14549
131
813
1482
15247
54
144
1559
15916
32
7
1581
16053
101
155
1475
15869
361
743
1039
14821
212
1354
713
11674
Beta 1 globulin [Mass/volume] in Serum or Plasma by Electrophoresis
32730-4 [3043723]
6.6e-01
2.7e+00
2.6e+00
—
3.8e+00
1.4e+00
3.3e-01
cases:1.55%
controls:0.80%
cases:3.91%
controls:0.28%
cases:0.81%
controls:0.06%
—
—
cases:1.71%
controls:0.04%
cases:1.29%
controls:0.33%
cases:1.41%
controls:1.01%
25
129
1587
15921
63
45
1550
16015
13
10
1600
16050
—
27
6
1549
16018
18
52
1382
15512
13
132
912
12896
Alpha 2 globulin [Mass/volume] in Serum or Plasma by Electrophoresis
2868-8 [3005229]
6.6e-01
2.7e+00
2.6e+00
—
3.8e+00
1.3e+00
3.2e-01
cases:1.55%
controls:0.80%
cases:3.91%
controls:0.28%
cases:0.81%
controls:0.06%
—
—
cases:1.71%
controls:0.04%
cases:1.29%
controls:0.34%
cases:1.41%
controls:1.02%
25
129
1587
15921
63
45
1550
16015
13
10
1600
16050
—
27
6
1549
16018
18
53
1382
15511
13
133
912
12895
Beta 2 globulin [Mass/volume] in Serum or Plasma by Electrophoresis
32731-2 [3043747]
6.6e-01
2.7e+00
2.6e+00
—
3.8e+00
1.3e+00
3.3e-01
cases:1.55%
controls:0.80%
cases:3.91%
controls:0.28%
cases:0.81%
controls:0.06%
—
—
cases:1.71%
controls:0.04%
cases:1.29%
controls:0.34%
cases:1.41%
controls:1.01%
25
129
1587
15921
63
45
1550
16015
13
10
1600
16050
—
27
6
1549
16018
18
53
1382
15511
13
132
912
12896
Physiotherapist
Z3226 [2001311560]
7.5e-02
1.5e+00
2.5e+00
1.0e+50
2.8e+00
2.2e+00
1.4e+00
cases:2.23%
controls:2.07%
cases:2.05%
controls:0.46%
cases:0.74%
controls:0.06%
cases:1.12%
controls:0.00%
cases:1.33%
controls:0.08%
cases:3.71%
controls:0.43%
cases:4.97%
controls:1.30%
36
333
1576
15717
33
74
1580
15986
12
10
1601
16050
18
0
1595
16060
21
13
1555
16011
52
67
1348
15497
46
170
879
12858
Protein.monoclonal band 2 [Mass/volume] in Serum or Plasma by Electrophoresis
35559-4 [3035797]
7.6e-01
2.7e+00
2.9e+00
—
3.4e+00
1.4e+00
3.6e-01
cases:1.30%
controls:0.61%
cases:2.73%
controls:0.19%
cases:0.81%
controls:0.04%
—
—
cases:0.89%
controls:0.03%
cases:0.86%
controls:0.22%
cases:0.97%
controls:0.68%
21
98
1591
15952
44
30
1569
16030
13
7
1600
16053
—
14
5
1562
16019
12
34
1388
15530
9
89
916
12939
Outpatient Visit
OP [9202]
2.4e-01
7.7e-01
9.1e-01
5.2e+00
1.3e+00
1.3e+00
6.1e-01
cases:72.77%
controls:67.66%
cases:67.27%
controls:48.64%
cases:21.95%
controls:10.19%
cases:45.88%
controls:0.45%
cases:28.11%
controls:9.94%
cases:76.79%
controls:47.69%
cases:84.00%
controls:74.08%
1173
10859
439
5191
1085
7811
528
8249
354
1637
1259
14423
740
73
873
15987
443
1593
1133
14431
1075
7423
325
8141
777
9651
148
3377
Aldolase [Enzymatic activity/volume] in Serum or Plasma
1761-6 [3027953]
1.6e+00
3.5e+00
1.0e+50
—
—
2.7e+00
2.5e+00
cases:0.62%
controls:0.13%
cases:1.43%
controls:0.04%
cases:0.37%
controls:0.00%
—
—
—
—
cases:0.50%
controls:0.03%
cases:1.08%
controls:0.09%
10
21
1602
16029
23
7
1590
16053
6
0
1607
16060
—
—
7
5
1393
15559
10
12
915
13016
Gamma globulin [Mass/volume] in Serum or Plasma by Electrophoresis
2874-6 [3023465]
5.8e-01
2.6e+00
2.6e+00
—
3.8e+00
1.2e+00
2.4e-01
cases:1.36%
controls:0.77%
cases:3.16%
controls:0.24%
cases:0.74%
controls:0.06%
—
—
cases:1.59%
controls:0.04%
cases:1.00%
controls:0.30%
cases:1.08%
controls:0.85%
22
123
1590
15927
51
38
1562
16022
12
9
1601
16051
—
25
6
1551
16018
14
47
1386
15517
10
111
915
12917
Clinical Cytogenetics and Genomics
OMOP4822000 [32411]
1.1e+00
2.6e+00
1.5e+00
1.0e+50
—
3.4e+00
3.0e+00
cases:1.67%
controls:0.57%
cases:2.29%
controls:0.17%
cases:0.31%
controls:0.07%
cases:2.05%
controls:0.00%
—
—
cases:5.71%
controls:0.19%
cases:5.62%
controls:0.30%
27
92
1585
15958
37
28
1576
16032
5
11
1608
16049
33
0
1580
16060
—
80
30
1320
15534
52
39
873
12989
Protein [Mass/volume] in Serum or Plasma
2885-2 [3020630]
6.3e-01
2.4e+00
2.7e+00
—
3.1e+00
1.3e+00
4.0e-01
cases:2.98%
controls:1.61%
cases:6.26%
controls:0.63%
cases:1.36%
controls:0.09%
—
—
cases:2.66%
controls:0.12%
cases:2.43%
controls:0.68%
cases:2.70%
controls:1.83%
48
259
1564
15791
101
101
1512
15959
22
15
1591
16045
—
42
19
1534
16005
34
106
1366
15458
25
239
900
12789
Speech therapy
R4130 [2001310235]
1.3e+00
3.5e+00
1.0e+50
1.0e+50
1.0e+50
3.9e+00
2.6e+00
cases:0.62%
controls:0.16%
cases:2.29%
controls:0.07%
cases:0.99%
controls:0.00%
cases:0.68%
controls:0.00%
cases:1.59%
controls:0.00%
cases:5.21%
controls:0.11%
cases:3.35%
controls:0.25%
10
26
1602
16024
37
11
1576
16049
16
0
1597
16060
11
0
1602
16060
25
0
1551
16024
73
17
1327
15547
31
32
894
12996
Lumbar puncture
TAB00 [2001300538]
1.9e+00
4.0e+00
—
1.0e+50
—
4.1e+00
1.4e+00
cases:2.48%
controls:0.37%
cases:4.46%
controls:0.09%
—
—
cases:0.62%
controls:0.00%
—
—
cases:1.86%
controls:0.03%
cases:0.97%
controls:0.25%
40
59
1572
15991
72
14
1541
16046
—
10
0
1603
16060
—
26
5
1374
15559
9
33
916
12995
Genetic counselling
Z31.5 [45590715]
9.5e-01
2.5e+00
1.8e+00
1.0e+50
—
3.4e+00
2.9e+00
cases:1.12%
controls:0.44%
cases:1.80%
controls:0.14%
cases:0.31%
controls:0.05%
cases:1.36%
controls:0.00%
—
—
cases:3.79%
controls:0.13%
cases:3.78%
controls:0.21%
18
70
1594
15980
29
23
1584
16037
5
8
1608
16052
22
0
1591
16060
—
53
21
1347
15543
35
27
890
13001
Office Visit
OMOP4822458 [581477]
3.5e-01
1.3e+00
2.3e+00
—
2.7e+00
2.0e+00
1.2e+00
cases:10.61%
controls:7.69%
cases:8.18%
controls:2.34%
cases:2.79%
controls:0.30%
—
—
cases:4.57%
controls:0.34%
cases:13.00%
controls:1.98%
cases:17.95%
controls:6.26%
171
1234
1441
14816
132
376
1481
15684
45
48
1568
16012
—
72
54
1504
15970
182
308
1218
15256
166
815
759
12213
Protein.monoclonal band 1 [Mass/volume] in Serum or Plasma by Electrophoresis
51435-6 [3029713]
7.0e-01
2.5e+00
2.6e+00
—
3.4e+00
1.3e+00
3.5e-01
cases:1.43%
controls:0.71%
cases:2.91%
controls:0.25%
cases:0.81%
controls:0.06%
—
—
cases:1.08%
controls:0.04%
cases:1.00%
controls:0.28%
cases:1.19%
controls:0.84%
23
114
1589
15936
47
40
1566
16020
13
10
1600
16050
—
17
6
1559
16018
14
43
1386
15521
11
110
914
12918
Occupational therapy
R4120 [2001310234]
1.6e-01
2.2e+00
3.0e+00
—
—
3.1e+00
1.4e+00
cases:0.93%
controls:0.80%
cases:1.92%
controls:0.22%
cases:0.62%
controls:0.03%
—
—
—
—
cases:3.93%
controls:0.19%
cases:2.81%
controls:0.68%
15
128
1597
15922
31
36
1582
16024
10
5
1603
16055
—
—
55
29
1345
15535
26
88
899
12940
Aid fitting and borrowing and monitoring of use
SPAT1230 [2001700331]
2.1e-01
1.3e+00
2.3e+00
—
2.4e+00
2.1e+00
1.4e+00
cases:2.92%
controls:2.37%
cases:3.22%
controls:0.94%
cases:0.93%
controls:0.09%
—
—
cases:1.21%
controls:0.11%
cases:6.93%
controls:0.87%
cases:9.19%
controls:2.39%
47
380
1565
15670
52
151
1561
15909
15
15
1598
16045
—
19
17
1557
16007
97
136
1303
15428
85
312
840
12716
Limited function/disability NOS
A28 [2002000162]
2.0e-01
1.2e+00
1.7e+00
1.4e+00
1.9e+00
2.1e+00
1.1e+00
cases:2.48%
controls:2.04%
cases:4.22%
controls:1.25%
cases:2.60%
controls:0.49%
cases:0.68%
controls:0.17%
cases:3.30%
controls:0.49%
cases:9.86%
controls:1.39%
cases:11.14%
controls:3.89%
40
328
1572
15722
68
201
1545
15859
42
78
1571
15982
11
27
1602
16033
52
79
1524
15945
138
216
1262
15348
103
507
822
12521
Psychiatry
26 [38004469]
4.0e-01
1.0e+00
1.2e+00
2.7e+00
1.5e+00
1.5e+00
1.1e+00
cases:5.71%
controls:3.88%
cases:4.84%
controls:1.83%
cases:2.05%
controls:0.63%
cases:0.74%
controls:0.05%
cases:3.17%
controls:0.70%
cases:7.36%
controls:1.77%
cases:10.81%
controls:3.84%
92
623
1520
15427
78
294
1535
15766
33
101
1580
15959
12
8
1601
16052
50
112
1526
15912
103
275
1297
15289
100
500
825
12528
Neurological sympt/complt other
N29 [2002000734]
7.5e-01
2.5e+00
—
—
—
4.0e+00
2.8e+00
cases:0.43%
controls:0.21%
cases:0.93%
controls:0.07%
—
—
—
—
—
—
cases:1.71%
controls:0.03%
cases:2.92%
controls:0.18%
7
33
1605
16017
15
12
1598
16048
—
—
—
24
5
1376
15559
27
23
898
13005
Internal Medicine
11 [38004456]
2.7e-01
6.6e-01
1.1e+00
4.5e+00
1.1e+00
9.3e-01
5.4e-01
cases:26.99%
controls:21.96%
cases:15.81%
controls:8.82%
cases:4.40%
controls:1.49%
cases:5.33%
controls:0.06%
cases:4.00%
controls:1.37%
cases:19.14%
controls:8.55%
cases:32.65%
controls:22.01%
435
3525
1177
12525
255
1416
1358
14644
71
240
1542
15820
86
10
1527
16050
63
219
1513
15805
268
1330
1132
14234
302
2868
623
10160
Gas panel - Arterial blood
24336-0 [3019060]
6.0e-02
7.7e-01
2.8e+00
1.0e+50
2.4e+00
2.6e+00
1.2e+00
cases:1.30%
controls:1.23%
cases:0.99%
controls:0.46%
cases:0.62%
controls:0.04%
cases:0.74%
controls:0.00%
cases:0.57%
controls:0.05%
cases:5.57%
controls:0.44%
cases:4.00%
controls:1.21%
21
197
1591
15853
16
74
1597
15986
10
6
1603
16054
12
0
1601
16060
9
8
1567
16016
78
69
1322
15495
37
157
888
12871
Other rehabilitation service
R5599 [2001310270]
—
2.1e+00
—
1.0e+50
1.0e+50
4.3e+00
2.6e+00
—
—
cases:0.37%
controls:0.04%
—
—
cases:0.31%
controls:0.00%
cases:0.63%
controls:0.00%
cases:2.79%
controls:0.04%
cases:1.95%
controls:0.15%
—
6
7
1607
16053
—
5
0
1608
16060
10
0
1566
16024
39
6
1361
15558
18
19
907
13009
Alpha tocopherol [Moles/volume] in Serum or Plasma
14590-4 [3000208]
3.0e+00
3.3e+00
—
—
—
2.7e+00
1.8e+00
cases:0.87%
controls:0.04%
cases:0.87%
controls:0.03%
—
—
—
—
—
—
cases:0.57%
controls:0.04%
cases:0.65%
controls:0.11%
14
7
1598
16043
14
5
1599
16055
—
—
—
8
6
1392
15558
6
14
919
13014
Angiotensin converting enzyme [Enzymatic activity/volume] in Serum or Plasma
2742-5 [3034780]
6.5e-01
2.4e+00
2.4e+00
—
2.8e+00
1.4e+00
-4.2e-01
cases:1.55%
controls:0.82%
cases:3.41%
controls:0.33%
cases:0.56%
controls:0.05%
—
—
cases:0.82%
controls:0.05%
cases:0.86%
controls:0.21%
cases:0.54%
controls:0.82%
25
131
1587
15919
55
53
1558
16007
9
8
1604
16052
—
13
8
1563
16016
12
32
1388
15532
5
107
920
12921
General psychiatric examination, not elsewhere classified
Z00.4 [45605094]
-1.3e-01
1.9e+00
—
—
3.5e+00
2.2e+00
1.3e+00
cases:0.62%
controls:0.70%
cases:1.12%
controls:0.16%
—
—
—
—
cases:1.27%
controls:0.04%
cases:1.86%
controls:0.21%
cases:2.27%
controls:0.61%
10
113
1602
15937
18
26
1595
16034
—
—
20
6
1556
16018
26
33
1374
15531
21
80
904
12948
Base excess in Arterial blood by calculation
1925-7 [3003396]
1.7e-01
7.9e-01
2.4e+00
1.0e+50
2.9e+00
2.0e+00
7.9e-01
cases:2.23%
controls:1.88%
cases:1.80%
controls:0.83%
cases:0.99%
controls:0.09%
cases:1.12%
controls:0.00%
cases:1.90%
controls:0.11%
cases:5.71%
controls:0.80%
cases:5.41%
controls:2.53%
36
302
1576
15748
29
133
1584
15927
16
15
1597
16045
18
0
1595
16060
30
17
1546
16007
80
124
1320
15440
50
330
875
12698
Oxygen [Partial pressure] in Arterial blood
2703-7 [3027801]
2.0e-01
7.9e-01
2.2e+00
1.0e+50
3.0e+00
2.2e+00
7.4e-01
cases:2.30%
controls:1.88%
cases:1.80%
controls:0.82%
cases:0.93%
controls:0.11%
cases:1.12%
controls:0.00%
cases:2.09%
controls:0.11%
cases:6.36%
controls:0.78%
cases:5.08%
controls:2.50%
37
302
1575
15748
29
132
1584
15928
15
17
1598
16043
18
0
1595
16060
33
17
1543
16007
89
121
1311
15443
47
326
878
12702
Carbon dioxide [Partial pressure] in Arterial blood
2019-8 [3027946]
2.0e-01
7.9e-01
2.2e+00
1.0e+50
3.0e+00
2.2e+00
7.4e-01
cases:2.30%
controls:1.89%
cases:1.80%
controls:0.82%
cases:0.93%
controls:0.11%
cases:1.12%
controls:0.00%
cases:2.09%
controls:0.11%
cases:6.36%
controls:0.78%
cases:5.08%
controls:2.50%
37
303
1575
15747
29
132
1584
15928
15
17
1598
16043
18
0
1595
16060
33
17
1543
16007
89
121
1311
15443
47
326
878
12702
Nuclear Ab [Titer] in Serum
29953-7 [3037522]
5.4e-01
1.7e+00
2.3e+00
—
3.3e+00
9.5e-01
-3.9e-02
cases:3.85%
controls:2.28%
cases:4.59%
controls:0.85%
cases:0.68%
controls:0.07%
—
—
cases:1.33%
controls:0.05%
cases:1.71%
controls:0.67%
cases:2.38%
controls:2.47%
62
366
1550
15684
74
137
1539
15923
11
11
1602
16049
—
21
8
1555
16016
24
104
1376
15460
22
322
903
12706
Acetylcholine receptor Ab [Moles/volume] in Serum
20427-1 [3006257]
2.0e+00
3.9e+00
—
1.0e+50
1.0e+50
2.8e+00
—
cases:0.81%
controls:0.11%
cases:2.79%
controls:0.06%
—
—
cases:0.31%
controls:0.00%
cases:1.02%
controls:0.00%
cases:0.64%
controls:0.04%
—
—
13
17
1599
16033
45
9
1568
16051
—
5
0
1608
16060
16
0
1560
16024
9
6
1391
15558
—
Functional capacity evaluation
443351003 [40481051]
6.1e-01
1.2e+00
1.5e+00
—
2.1e+00
2.2e+00
1.2e+00
cases:3.72%
controls:2.05%
cases:3.22%
controls:1.01%
cases:0.81%
controls:0.18%
—
—
cases:1.52%
controls:0.19%
cases:8.93%
controls:1.05%
cases:8.11%
controls:2.69%
60
329
1552
15721
52
163
1561
15897
13
29
1600
16031
—
24
31
1552
15993
125
163
1275
15401
75
351
850
12677
Physiotherapy
R4110 [2001310233]
1.3e-01
1.2e+00
1.8e+00
1.0e+50
2.8e+00
2.0e+00
1.0e+00
cases:5.58%
controls:4.92%
cases:5.21%
controls:1.67%
cases:1.49%
controls:0.26%
cases:1.74%
controls:0.00%
cases:2.79%
controls:0.18%
cases:8.64%
controls:1.27%
cases:10.59%
controls:4.05%
90
789
1522
15261
84
268
1529
15792
24
42
1589
16018
28
0
1585
16060
44
29
1532
15995
121
198
1279
15366
98
528
827
12500
Protein.monoclonal band 3 [Mass/volume] in Serum or Plasma by Electrophoresis
50796-2 [3029338]
6.3e-01
2.7e+00
2.8e+00
—
3.2e+00
1.3e+00
2.6e-01
cases:1.05%
controls:0.57%
cases:2.48%
controls:0.17%
cases:0.74%
controls:0.04%
—
—
cases:0.89%
controls:0.04%
cases:0.79%
controls:0.22%
cases:0.86%
controls:0.67%
17
91
1595
15959
40
28
1573
16032
12
7
1601
16053
—
14
6
1562
16018
11
35
1389
15529
8
87
917
12941
Emergency Medicine
93 [38004510]
7.4e-02
7.3e-01
1.5e+00
4.4e+00
1.3e+00
6.8e-01
1.9e-01
cases:14.76%
controls:13.86%
cases:13.52%
controls:7.02%
cases:4.65%
controls:1.03%
cases:2.42%
controls:0.03%
cases:3.24%
controls:0.91%
cases:13.86%
controls:7.52%
cases:22.81%
controls:19.70%
238
2225
1374
13825
218
1127
1395
14933
75
165
1538
15895
39
5
1574
16055
51
146
1525
15878
194
1170
1206
14394
211
2566
714
10462
Home Visit
OMOP4822459 [581476]
3.1e-01
1.1e+00
1.5e+00
9.6e-01
1.8e+00
2.0e+00
1.2e+00
cases:6.02%
controls:4.49%
cases:7.81%
controls:2.81%
cases:4.46%
controls:1.05%
cases:1.12%
controls:0.43%
cases:6.60%
controls:1.12%
cases:21.64%
controls:3.44%
cases:22.49%
controls:7.89%
97
721
1515
15329
126
451
1487
15609
72
168
1541
15892
18
69
1595
15991
104
179
1472
15845
303
536
1097
15028
208
1028
717
12000
pH of Arterial blood
2744-1 [3019977]
1.9e-01
7.3e-01
2.2e+00
1.0e+50
2.8e+00
2.1e+00
7.8e-01
cases:2.30%
controls:1.90%
cases:1.67%
controls:0.82%
cases:0.87%
controls:0.10%
cases:1.12%
controls:0.00%
cases:1.84%
controls:0.11%
cases:5.93%
controls:0.79%
cases:5.41%
controls:2.56%
37
305
1575
15745
27
131
1586
15929
14
16
1599
16044
18
0
1595
16060
29
18
1547
16006
83
123
1317
15441
50
334
875
12694
Supplier / Service Provider
OMOP5117446 [33004]
-5.0e-01
-2.5e-01
1.1e-01
2.1e+00
3.0e+00
3.1e+00
2.9e+00
cases:18.73%
controls:27.54%
cases:7.01%
controls:8.84%
cases:1.12%
controls:1.00%
cases:0.31%
controls:0.04%
cases:1.52%
controls:0.07%
cases:9.29%
controls:0.48%
cases:15.35%
controls:1.00%
302
4420
1310
11630
113
1419
1500
14641
18
160
1595
15900
5
6
1608
16054
24
12
1552
16012
130
75
1270
15489
142
130
783
12898
Observation for suspected nervous system disorder
Z03.3 [45609903]
1.7e+00
3.1e+00
—
1.0e+50
—
2.1e+00
1.4e+00
cases:2.67%
controls:0.48%
cases:3.97%
controls:0.18%
—
—
cases:0.37%
controls:0.00%
—
—
cases:1.57%
controls:0.19%
cases:2.27%
controls:0.54%
43
77
1569
15973
64
29
1549
16031
—
6
0
1607
16060
—
22
29
1378
15535
21
71
904
12957
Speech disorder
N19 [2002000730]
2.3e+00
3.7e+00
—
—
—
—
2.5e+00
cases:0.50%
controls:0.05%
cases:1.43%
controls:0.04%
—
—
—
—
—
—
—
—
cases:1.19%
controls:0.10%
8
8
1604
16042
23
6
1590
16054
—
—
—
—
11
13
914
13015
clonazepam; oral, parenteral
N03AE01 [21604415]
7.1e-01
1.6e+00
1.3e+00
—
1.7e+00
2.2e+00
2.1e+00
cases:1.74%
controls:0.86%
cases:2.67%
controls:0.54%
cases:0.62%
controls:0.17%
—
—
cases:0.89%
controls:0.16%
cases:5.21%
controls:0.59%
cases:7.89%
controls:1.04%
28
138
1584
15912
43
87
1570
15973
10
28
1603
16032
—
14
26
1562
15998
73
92
1327
15472
73
136
852
12892
Percutaneous gastrostomy
JDB10 [2001304713]
—
—
—
—
1.0e+50
4.9e+00
3.4e+00
—
—
—
—
—
—
—
—
cases:0.89%
controls:0.00%
cases:5.79%
controls:0.04%
cases:3.03%
controls:0.11%
—
—
—
—
14
0
1562
16024
81
7
1319
15557
28
14
897
13014
Glucose [Moles/volume] in Cerebral spinal fluid
14744-7 [3020044]
1.6e+00
3.5e+00
—
—
—
3.0e+00
—
cases:1.92%
controls:0.40%
cases:4.22%
controls:0.13%
—
—
—
—
—
—
cases:1.57%
controls:0.08%
—
—
31
64
1581
15986
68
21
1545
16039
—
—
—
22
12
1378
15552
—
Protein [Mass/volume] in Cerebral spinal fluid
2880-3 [3019473]
1.5e+00
3.5e+00
—
—
—
3.1e+00
8.0e-01
cases:2.11%
controls:0.48%
cases:4.77%
controls:0.15%
—
—
—
—
—
—
cases:1.86%
controls:0.08%
cases:0.65%
controls:0.29%
34
77
1578
15973
77
24
1536
16036
—
—
—
26
13
1374
15551
6
38
919
12990
Bicarbonate [Moles/volume] in Arterial blood
1960-4 [3008152]
1.5e-01
7.9e-01
2.6e+00
1.0e+50
2.7e+00
2.0e+00
7.7e-01
cases:1.30%
controls:1.13%
cases:0.99%
controls:0.45%
cases:0.74%
controls:0.06%
cases:0.87%
controls:0.00%
cases:1.14%
controls:0.08%
cases:3.57%
controls:0.49%
cases:3.14%
controls:1.47%
21
181
1591
15869
16
73
1597
15987
12
9
1601
16051
14
0
1599
16060
18
13
1558
16011
50
76
1350
15488
29
192
896
12836
Oxygen saturation in Arterial blood
2708-6 [3016502]
1.3e-01
7.8e-01
2.3e+00
1.0e+50
2.9e+00
2.0e+00
5.7e-01
cases:1.92%
controls:1.69%
cases:1.61%
controls:0.75%
cases:0.81%
controls:0.08%
cases:0.99%
controls:0.00%
cases:1.40%
controls:0.07%
cases:4.64%
controls:0.69%
cases:4.00%
controls:2.30%
31
271
1581
15779
26
120
1587
15940
13
13
1600
16047
16
0
1597
16060
22
12
1554
16012
65
107
1335
15457
37
299
888
12729
Supine thorax X-ray examination
GD1QA [2001303648]
3.6e-02
8.7e-01
2.7e+00
—
2.0e+00
1.5e+00
8.5e-01
cases:2.23%
controls:2.16%
cases:1.74%
controls:0.73%
cases:1.12%
controls:0.07%
—
—
cases:0.63%
controls:0.09%
cases:3.71%
controls:0.84%
cases:7.35%
controls:3.29%
36
346
1576
15704
28
118
1585
15942
18
12
1595
16048
—
10
14
1566
16010
52
130
1348
15434
68
429
857
12599
Assessment of adjustments needed in living environment
SPAT1231 [2001700332]
9.1e-01
2.3e+00
—
—
—
3.6e+00
2.0e+00
cases:0.31%
controls:0.12%
cases:0.43%
controls:0.04%
—
—
—
—
—
—
cases:1.43%
controls:0.04%
cases:1.41%
controls:0.20%
5
20
1607
16030
7
7
1606
16053
—
—
—
20
6
1380
15558
13
26
912
13002
Cell count panel - Cerebral spinal fluid
34563-7 [3044290]
1.2e+00
3.3e+00
—
—
—
3.4e+00
7.6e-01
cases:1.24%
controls:0.38%
cases:3.78%
controls:0.14%
—
—
—
—
—
—
cases:1.50%
controls:0.05%
cases:0.54%
controls:0.25%
20
61
1592
15989
61
23
1552
16037
—
—
—
21
8
1379
15556
5
33
920
12995
Leukocytes [#/volume] in Cerebral spinal fluid
26465-5 [3016543]
1.4e+00
3.4e+00
—
—
—
2.9e+00
9.8e-01
cases:1.67%
controls:0.42%
cases:4.03%
controls:0.14%
—
—
—
—
—
—
cases:1.36%
controls:0.08%
cases:0.65%
controls:0.25%
27
68
1585
15982
65
22
1548
16038
—
—
—
19
12
1381
15552
6
32
919
12996
Erythrocytes [#/volume] in Cerebral spinal fluid
26454-9 [3027475]
1.3e+00
3.4e+00
—
—
—
2.9e+00
9.8e-01
cases:1.61%
controls:0.42%
cases:4.09%
controls:0.14%
—
—
—
—
—
—
cases:1.36%
controls:0.08%
cases:0.65%
controls:0.25%
26
68
1586
15982
66
22
1547
16038
—
—
—
19
12
1381
15552
6
32
919
12996
Anesthesiology Critical Care Medicine
OMOP4821991 [45756751]
5.1e-01
9.2e-01
2.1e+00
—
3.0e+00
2.7e+00
1.9e+00
cases:1.36%
controls:0.82%
cases:0.81%
controls:0.32%
cases:0.31%
controls:0.04%
—
—
cases:1.27%
controls:0.06%
cases:4.14%
controls:0.28%
cases:4.11%
controls:0.64%
22
132
1590
15918
13
52
1600
16008
5
6
1608
16054
—
20
10
1556
16014
58
43
1342
15521
38
84
887
12944
Cervical spine MRI examination with high intensity magnet
NA1BG [2001306990]
1.4e+00
3.6e+00
—
1.0e+50
—
2.6e+00
8.6e-01
cases:2.17%
controls:0.56%
cases:4.34%
controls:0.12%
—
—
cases:2.48%
controls:0.00%
—
—
cases:1.93%
controls:0.14%
cases:0.86%
controls:0.37%
35
90
1577
15960
70
19
1543
16041
—
40
0
1573
16060
—
27
22
1373
15542
8
48
917
12980
Base excess.100% oxygenated [Moles/volume] standard in Capillary blood by calculation
72720-6 [43055554]
-1.1e-02
1.0e+00
—
1.0e+50
2.9e+00
2.4e+00
1.3e+00
cases:0.99%
controls:1.00%
cases:1.36%
controls:0.49%
—
—
cases:0.50%
controls:0.00%
cases:1.46%
controls:0.08%
cases:5.00%
controls:0.48%
cases:4.54%
controls:1.30%
16
161
1596
15889
22
79
1591
15981
—
8
0
1605
16060
23
13
1553
16011
70
74
1330
15490
42
170
883
12858
Fitting and adjustment of other specified devices
Z46.8 [45581035]
1.2e+00
1.9e+00
—
—
—
3.4e+00
2.2e+00
cases:0.50%
controls:0.16%
cases:0.43%
controls:0.06%
—
—
—
—
—
—
cases:2.29%
controls:0.08%
cases:2.59%
controls:0.29%
8
25
1604
16025
7
10
1606
16050
—
—
—
32
12
1368
15552
24
38
901
12990
ENMG
XA402 [2001300405]
1.4e+00
3.1e+00
—
1.0e+50
—
3.0e+00
—
cases:0.74%
controls:0.19%
cases:1.12%
controls:0.05%
—
—
cases:0.31%
controls:0.00%
—
—
cases:0.79%
controls:0.04%
—
—
12
30
1600
16020
18
8
1595
16052
—
5
0
1608
16060
—
11
6
1389
15558
—
Radiculopathy
M54.1 [45577287]
1.6e+00
2.3e+00
—
—
—
2.2e+00
1.4e+00
cases:1.55%
controls:0.32%
cases:1.12%
controls:0.12%
—
—
—
—
—
—
cases:0.64%
controls:0.07%
cases:1.19%
controls:0.28%
25
51
1587
15999
18
19
1595
16041
—
—
—
9
11
1391
15553
11
37
914
12991
Other specified special examinations
Z01.8 [45581003]
3.4e-01
1.4e+00
2.2e+00
—
2.0e+00
1.2e+00
6.5e-01
cases:3.78%
controls:2.72%
cases:3.29%
controls:0.83%
cases:0.93%
controls:0.10%
—
—
cases:0.76%
controls:0.11%
cases:2.93%
controls:0.89%
cases:5.73%
controls:3.09%
61
437
1551
15613
53
134
1560
15926
15
16
1598
16044
—
12
17
1564
16007
41
138
1359
15426
53
402
872
12626
Implementation of physical therapy rehabilitation plan
SPAT1223 [2001700324]
4.2e-01
1.1e+00
1.6e+00
—
1.9e+00
1.7e+00
7.5e-01
cases:7.63%
controls:5.16%
cases:5.21%
controls:1.87%
cases:1.98%
controls:0.41%
—
—
cases:2.35%
controls:0.36%
cases:9.07%
controls:1.81%
cases:9.73%
controls:4.84%
123
828
1489
15222
84
300
1529
15760
32
66
1581
15994
—
37
58
1539
15966
127
281
1273
15283
90
631
835
12397
Myoglobin [Mass/volume] in Serum or Plasma
2639-3 [3005895]
7.7e-01
2.0e+00
—
1.0e+50
3.5e+00
1.9e+00
6.9e-01
cases:1.24%
controls:0.58%
cases:1.86%
controls:0.26%
—
—
cases:0.43%
controls:0.00%
cases:1.02%
controls:0.03%
cases:1.43%
controls:0.21%
cases:1.73%
controls:0.88%
20
93
1592
15957
30
42
1583
16018
—
7
0
1606
16060
16
5
1560
16019
20
33
1380
15531
16
114
909
12914
Paediatric neurology
421 [44777781]
1.0e+00
1.9e+00
—
—
—
2.8e+00
2.6e+00
cases:0.50%
controls:0.17%
cases:0.81%
controls:0.12%
—
—
—
—
—
—
cases:1.29%
controls:0.08%
cases:1.73%
controls:0.13%
8
28
1604
16022
13
20
1600
16040
—
—
—
18
12
1382
15552
16
17
909
13011
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
R5110 [2001310246]
2.0e-01
7.4e-01
—
—
3.1e+00
2.5e+00
1.6e+00
cases:2.05%
controls:1.69%
cases:1.12%
controls:0.54%
—
—
—
—
cases:0.95%
controls:0.04%
cases:6.00%
controls:0.50%
cases:7.89%
controls:1.70%
33
271
1579
15779
18
86
1595
15974
—
—
15
7
1561
16017
84
78
1316
15486
73
221
852
12807
Angiotensin converting enzyme [Enzymatic activity/volume] in Cerebral spinal fluid
12480-0 [3009991]
3.1e+00
4.1e+00
—
—
—
—
-1.0e+50
cases:1.18%
controls:0.06%
cases:2.23%
controls:0.04%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.05%
19
9
1593
16041
36
6
1577
16054
—
—
—
—
0
6
925
13022
Protein.monoclonal band 4 [Mass/volume] in Serum or Plasma by Electrophoresis
50797-0 [3029379]
6.4e-01
2.8e+00
3.0e+00
—
—
1.3e+00
3.4e-01
cases:1.05%
controls:0.56%
cases:2.48%
controls:0.16%
cases:0.74%
controls:0.04%
—
—
—
—
cases:0.79%
controls:0.21%
cases:0.86%
controls:0.61%
17
90
1595
15960
40
25
1573
16035
12
6
1601
16054
—
—
11
32
1389
15532
8
80
917
12948
Hemoglobin [Mass/volume] in Arterial blood
30313-1 [3002173]
1.5e-01
8.5e-01
2.0e+00
1.0e+50
2.6e+00
1.6e+00
4.1e-01
cases:1.80%
controls:1.56%
cases:1.55%
controls:0.67%
cases:0.68%
controls:0.09%
cases:0.81%
controls:0.00%
cases:1.21%
controls:0.09%
cases:3.21%
controls:0.66%
cases:3.35%
controls:2.24%
29
250
1583
15800
25
107
1588
15953
11
15
1602
16045
13
0
1600
16060
19
14
1557
16010
45
102
1355
15462
31
292
894
12736
Inpatient Visit
IP [9201]
1.8e-01
7.1e-01
1.3e+00
—
2.4e+00
1.9e+00
7.3e-01
cases:11.10%
controls:9.48%
cases:7.38%
controls:3.78%
cases:1.61%
controls:0.44%
—
—
cases:4.57%
controls:0.42%
cases:17.43%
controls:3.06%
cases:18.05%
controls:9.60%
179
1522
1433
14528
119
607
1494
15453
26
70
1587
15990
—
72
67
1504
15957
244
476
1156
15088
167
1251
758
11777
Fall on same level from slipping, tripping and stumbling
W01 [45756243]
4.3e-01
9.9e-01
1.6e+00
—
2.1e+00
1.3e+00
7.2e-01
cases:6.02%
controls:3.99%
cases:4.09%
controls:1.56%
cases:1.36%
controls:0.29%
—
—
cases:1.40%
controls:0.17%
cases:5.14%
controls:1.52%
cases:10.92%
controls:5.64%
97
640
1515
15410
66
251
1547
15809
22
46
1591
16014
—
22
28
1554
15996
72
237
1328
15327
101
735
824
12293
Noninvasive ventilation
WX725 [2001310828]
7.1e-01
6.4e-01
—
—
2.7e+00
2.9e+00
1.4e+00
cases:0.99%
controls:0.49%
cases:0.43%
controls:0.23%
—
—
—
—
cases:0.57%
controls:0.04%
cases:3.57%
controls:0.21%
cases:3.14%
controls:0.76%
16
79
1596
15971
7
37
1606
16023
—
—
9
6
1567
16018
50
33
1350
15531
29
99
896
12929
Treponema pallidum Ab [Presence] in Serum
22587-0 [3019832]
2.3e-01
1.8e+00
2.0e+00
—
3.1e+00
6.4e-01
-4.4e-01
cases:0.99%
controls:0.79%
cases:1.55%
controls:0.26%
cases:0.37%
controls:0.05%
—
—
cases:0.70%
controls:0.03%
cases:0.64%
controls:0.34%
cases:0.65%
controls:1.01%
16
127
1596
15923
25
42
1588
16018
6
8
1607
16052
—
11
5
1565
16019
9
53
1391
15511
6
131
919
12897
Orthopedic Surgery
20 [38004465]
2.9e-01
7.1e-01
1.3e+00
3.3e+00
7.6e-01
4.7e-01
1.5e-01
cases:18.67%
controls:14.69%
cases:10.54%
controls:5.49%
cases:2.85%
controls:0.81%
cases:0.87%
controls:0.03%
cases:1.78%
controls:0.84%
cases:8.50%
controls:5.47%
cases:17.30%
controls:15.20%
301
2357
1311
13693
170
882
1443
15178
46
130
1567
15930
14
5
1599
16055
28
134
1548
15890
119
851
1281
14713
160
1980
765
11048
Paralysis/weakness
N18 [2002000729]
1.0e+00
2.0e+00
—
—
—
3.2e+00
1.7e+00
cases:0.43%
controls:0.16%
cases:0.62%
controls:0.09%
—
—
—
—
—
—
cases:1.36%
controls:0.06%
cases:1.51%
controls:0.28%
7
25
1605
16025
10
14
1603
16046
—
—
—
19
9
1381
15555
14
37
911
12991
Care involving use of rehabilitation procedure, unspecified
Z50.9 [45595525]
4.4e-01
2.3e+00
—
—
—
2.7e+00
1.8e+00
cases:0.62%
controls:0.40%
cases:1.18%
controls:0.12%
—
—
—
—
—
—
cases:2.50%
controls:0.17%
cases:3.57%
controls:0.64%
10
64
1602
15986
19
20
1594
16040
—
—
—
35
26
1365
15538
33
83
892
12945
Essential (primary) hypertension
I10 [45591453]
3.0e-02
3.3e-01
1.0e+00
4.3e+00
1.1e+00
1.7e-01
-2.1e-01
cases:20.04%
controls:19.56%
cases:13.33%
controls:9.98%
cases:4.71%
controls:1.72%
cases:6.14%
controls:0.09%
cases:4.82%
controls:1.73%
cases:11.71%
controls:10.09%
cases:20.97%
controls:24.71%
323
3139
1289
12911
215
1602
1398
14458
76
277
1537
15783
99
14
1514
16046
76
278
1500
15746
164
1571
1236
13993
194
3219
731
9809
IgG [Mass/volume] in Cerebral spinal fluid
2464-6 [3007368]
2.0e+00
4.7e+00
—
—
—
—
—
cases:0.93%
controls:0.12%
cases:3.35%
controls:0.03%
—
—
—
—
—
—
—
—
—
—
15
20
1597
16030
54
5
1559
16055
—
—
—
—
—
Assessment of need for medical rehabilitation
SPAT1215 [2001700316]
-3.7e-02
1.9e+00
—
—
—
2.6e+00
2.2e+00
cases:0.37%
controls:0.39%
cases:0.74%
controls:0.11%
—
—
—
—
—
—
cases:1.64%
controls:0.13%
cases:2.49%
controls:0.27%
6
62
1606
15988
12
18
1601
16042
—
—
—
23
20
1377
15544
23
35
902
12993
Dysarthria and anarthria
R47.1 [45558471]
3.2e+00
—
1.0e+50
1.0e+50
—
—
3.5e+00
cases:1.24%
controls:0.05%
—
—
cases:3.53%
controls:0.00%
cases:2.60%
controls:0.00%
—
—
—
—
cases:2.59%
controls:0.08%
20
8
1592
16042
—
57
0
1556
16060
42
0
1571
16060
—
—
24
11
901
13017
Extensive MRI examination of brain with high intensity magnet
AA1CG [2001300116]
1.2e+00
2.4e+00
1.0e+50
1.0e+50
—
1.8e+00
1.2e+00
cases:2.42%
controls:0.75%
cases:2.98%
controls:0.27%
cases:0.62%
controls:0.00%
cases:1.92%
controls:0.00%
—
—
cases:1.57%
controls:0.25%
cases:2.38%
controls:0.74%
39
121
1573
15929
48
43
1565
16017
10
0
1603
16060
31
0
1582
16060
—
22
39
1378
15525
22
96
903
12932
Other healthcare associate professional
Z3229 [2001311561]
3.2e-01
8.3e-01
—
1.0e+50
2.8e+00
2.3e+00
1.6e+00
cases:1.30%
controls:0.95%
cases:0.56%
controls:0.24%
—
—
cases:0.31%
controls:0.00%
cases:0.70%
controls:0.04%
cases:2.14%
controls:0.22%
cases:3.68%
controls:0.78%
21
152
1591
15898
9
39
1604
16021
—
5
0
1608
16060
11
7
1565
16017
30
35
1370
15529
34
102
891
12926
Forced vital capacity [Volume] Respiratory system
19870-5 [3020158]
3.6e-01
9.6e-01
1.5e+00
—
2.2e+00
1.9e+00
1.5e+00
cases:2.92%
controls:2.05%
cases:1.92%
controls:0.75%
cases:0.31%
controls:0.07%
—
—
cases:0.57%
controls:0.06%
cases:3.14%
controls:0.48%
cases:4.22%
controls:1.00%
47
329
1565
15721
31
120
1582
15940
5
11
1608
16049
—
9
10
1567
16014
44
75
1356
15489
39
130
886
12898
FEV1
20150-9 [3024653]
3.6e-01
9.6e-01
1.5e+00
—
2.2e+00
1.9e+00
1.5e+00
cases:2.92%
controls:2.05%
cases:1.92%
controls:0.75%
cases:0.31%
controls:0.07%
—
—
cases:0.57%
controls:0.06%
cases:3.14%
controls:0.48%
cases:4.22%
controls:1.00%
47
329
1565
15721
31
120
1582
15940
5
11
1608
16049
—
9
10
1567
16014
44
75
1356
15489
39
130
886
12898
FEV1/FVC
19926-5 [3011505]
3.6e-01
9.6e-01
1.5e+00
—
2.2e+00
1.9e+00
1.5e+00
cases:2.92%
controls:2.05%
cases:1.92%
controls:0.75%
cases:0.31%
controls:0.07%
—
—
cases:0.57%
controls:0.06%
cases:3.14%
controls:0.48%
cases:4.22%
controls:1.00%
47
329
1565
15721
31
120
1582
15940
5
11
1608
16049
—
9
10
1567
16014
44
75
1356
15489
39
130
886
12898
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
1.6e-03
4.8e-01
1.2e+00
3.1e+00
1.2e+00
5.9e-01
2.6e-01
cases:15.26%
controls:15.24%
cases:11.16%
controls:7.19%
cases:3.91%
controls:1.22%
cases:1.12%
controls:0.05%
cases:3.36%
controls:1.08%
cases:12.43%
controls:7.26%
cases:22.16%
controls:18.07%
246
2446
1366
13604
180
1155
1433
14905
63
196
1550
15864
18
8
1595
16052
53
173
1523
15851
174
1130
1226
14434
205
2354
720
10674
Implementation of occupational therapy rehabilitation plan
SPAT1226 [2001700327]
—
2.1e+00
—
—
—
2.8e+00
1.7e+00
—
—
cases:0.74%
controls:0.09%
—
—
—
—
—
—
cases:1.64%
controls:0.10%
cases:1.30%
controls:0.25%
—
12
15
1601
16045
—
—
—
23
16
1377
15548
12
32
913
12996
gabapentin; oral
N02BF01 [955005]
6.3e-01
1.1e+00
1.4e+00
—
1.1e+00
1.2e+00
1.1e+00
cases:5.02%
controls:2.73%
cases:4.65%
controls:1.61%
cases:1.92%
controls:0.50%
—
—
cases:1.71%
controls:0.56%
cases:5.86%
controls:1.84%
cases:10.38%
controls:3.80%
81
438
1531
15612
75
258
1538
15802
31
80
1582
15980
—
27
89
1549
15935
82
287
1318
15277
96
495
829
12533
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
2.0e-01
9.8e-01
1.3e+00
2.6e+00
1.7e+00
7.9e-03
-8.1e-02
cases:22.39%
controls:19.08%
cases:21.76%
controls:9.48%
cases:4.71%
controls:1.36%
cases:0.50%
controls:0.04%
cases:6.09%
controls:1.22%
cases:9.43%
controls:9.36%
cases:20.54%
controls:21.89%
361
3063
1251
12987
351
1522
1262
14538
76
218
1537
15842
8
6
1605
16054
96
196
1480
15828
132
1457
1268
14107
190
2852
735
10176
Monocytes [#/volume] in Blood
26484-6 [3001604]
1.9e-01
7.6e-01
9.4e-01
3.2e+00
1.2e+00
3.9e-01
1.8e-01
cases:12.59%
controls:10.64%
cases:12.65%
controls:6.37%
cases:3.47%
controls:1.39%
cases:0.87%
controls:0.04%
cases:4.25%
controls:1.27%
cases:9.14%
controls:6.35%
cases:16.00%
controls:13.71%
203
1707
1409
14343
204
1023
1409
15037
56
223
1557
15837
14
6
1599
16054
67
203
1509
15821
128
989
1272
14575
148
1786
777
11242
amitriptyline; oral, parenteral
N06AA09 [21604696]
2.7e-01
7.9e-01
1.2e+00
—
1.9e+00
1.7e+00
9.1e-01
cases:5.21%
controls:4.02%
cases:4.15%
controls:1.94%
cases:1.49%
controls:0.45%
—
—
cases:3.05%
controls:0.47%
cases:9.57%
controls:1.93%
cases:8.97%
controls:3.83%
84
645
1528
15405
67
311
1546
15749
24
72
1589
15988
—
48
76
1528
15948
134
300
1266
15264
83
499
842
12529
Folate [Moles/volume] in Serum or Plasma
14732-2 [3021960]
5.1e-01
1.4e+00
2.2e+00
—
2.4e+00
5.3e-02
-2.1e-01
cases:4.90%
controls:3.01%
cases:7.44%
controls:1.89%
cases:1.80%
controls:0.21%
—
—
cases:2.66%
controls:0.26%
cases:2.57%
controls:2.44%
cases:6.59%
controls:8.03%
79
483
1533
15567
120
304
1493
15756
29
34
1584
16026
—
42
41
1534
15983
36
380
1364
15184
61
1046
864
11982
Overnight pulse oximetry
252568001 [4091874]
—
1.0e+00
—
—
—
3.6e+00
2.8e+00
—
—
cases:0.37%
controls:0.13%
—
—
—
—
—
—
cases:3.00%
controls:0.08%
cases:4.00%
controls:0.25%
—
6
21
1607
16039
—
—
—
42
13
1358
15551
37
32
888
12996
Folate [Moles/volume] in Red Blood Cells
14731-4 [3019309]
3.2e-01
1.3e+00
1.6e+00
—
2.7e+00
8.5e-01
4.8e-01
cases:5.71%
controls:4.22%
cases:4.34%
controls:1.20%
cases:0.62%
controls:0.13%
—
—
cases:1.08%
controls:0.07%
cases:2.29%
controls:0.99%
cases:4.65%
controls:2.92%
92
678
1520
15372
70
192
1543
15868
10
21
1603
16039
—
17
12
1559
16012
32
154
1368
15410
43
381
882
12647
Physiologic investigation of micturition
XKD06 [2001306098]
4.5e-01
2.2e+00
—
—
—
2.4e+00
1.8e+00
cases:0.50%
controls:0.32%
cases:0.56%
controls:0.06%
—
—
—
—
—
—
cases:0.64%
controls:0.06%
cases:0.97%
controls:0.17%
8
51
1604
15999
9
10
1604
16050
—
—
—
9
9
1391
15555
9
22
916
13006
Basophils [#/volume] in Blood
26444-0 [3006315]
1.9e-01
7.5e-01
9.3e-01
3.0e+00
1.2e+00
3.9e-01
1.8e-01
cases:12.59%
controls:10.67%
cases:12.65%
controls:6.42%
cases:3.47%
controls:1.40%
cases:0.87%
controls:0.04%
cases:4.25%
controls:1.27%
cases:9.21%
controls:6.41%
cases:16.11%
controls:13.81%
203
1713
1409
14337
204
1031
1409
15029
56
225
1557
15835
14
7
1599
16053
67
203
1509
15821
129
997
1271
14567
149
1799
776
11229
Eosinophils [#/volume] in Blood
26449-9 [3013115]
1.9e-01
7.3e-01
9.2e-01
3.0e+00
1.2e+00
4.1e-01
1.8e-01
cases:13.09%
controls:11.12%
cases:12.90%
controls:6.66%
cases:3.60%
controls:1.47%
cases:0.87%
controls:0.04%
cases:4.31%
controls:1.30%
cases:9.64%
controls:6.60%
cases:16.76%
controls:14.35%
211
1784
1401
14266
208
1070
1405
14990
58
236
1555
15824
14
7
1599
16053
68
208
1508
15816
135
1027
1265
14537
155
1869
770
11159
Gas panel - Capillary blood
24337-8 [3022313]
-1.6e-01
7.9e-01
—
—
2.6e+00
2.4e+00
1.1e+00
cases:0.68%
controls:0.80%
cases:1.05%
controls:0.48%
—
—
—
—
cases:1.02%
controls:0.07%
cases:4.21%
controls:0.38%
cases:3.68%
controls:1.20%
11
129
1601
15921
17
77
1596
15983
—
—
16
12
1560
16012
59
59
1341
15505
34
156
891
12872
Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma
2324-2 [3026910]
1.0e-01
7.5e-01
9.3e-01
2.4e+00
1.8e+00
3.4e-01
1.0e-02
cases:16.00%
controls:14.65%
cases:13.27%
controls:6.72%
cases:2.11%
controls:0.84%
cases:0.62%
controls:0.06%
cases:4.00%
controls:0.72%
cases:8.79%
controls:6.44%
cases:17.30%
controls:17.15%
258
2351
1354
13699
214
1079
1399
14981
34
135
1579
15925
10
9
1603
16051
63
115
1513
15909
123
1002
1277
14562
160
2234
765
10794
HIV 1 and 2 tests - Meaningful Use set
75622-1 [46235355]
4.0e-01
1.3e+00
1.8e+00
—
3.0e+00
4.5e-01
-2.3e-01
cases:3.04%
controls:2.06%
cases:3.10%
controls:0.83%
cases:0.56%
controls:0.09%
—
—
cases:1.27%
controls:0.06%
cases:1.29%
controls:0.82%
cases:1.95%
controls:2.45%
49
331
1563
15719
50
133
1563
15927
9
15
1604
16045
—
20
10
1556
16014
18
128
1382
15436
18
319
907
12709
Magnesium [Moles/volume] in Serum or Plasma
2601-3 [3012095]
3.8e-01
1.1e+00
1.6e+00
—
2.4e+00
9.3e-01
2.5e-01
cases:4.03%
controls:2.80%
cases:3.78%
controls:1.27%
cases:0.99%
controls:0.19%
—
—
cases:2.09%
controls:0.19%
cases:3.36%
controls:1.35%
cases:4.54%
controls:3.58%
65
449
1547
15601
61
204
1552
15856
16
31
1597
16029
—
33
30
1543
15994
47
210
1353
15354
42
466
883
12562
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
6.9e-02
5.1e-01
9.6e-01
3.0e+00
1.2e+00
4.0e-01
-3.2e-02
cases:30.40%
controls:28.97%
cases:27.28%
controls:18.42%
cases:9.30%
controls:3.77%
cases:5.21%
controls:0.26%
cases:10.60%
controls:3.44%
cases:25.00%
controls:18.33%
cases:34.49%
controls:35.21%
490
4649
1122
11401
440
2958
1173
13102
150
606
1463
15454
84
42
1529
16018
167
551
1409
15473
350
2853
1050
12711
319
4587
606
8441
Sleep apnoea
G47.3 [45562094]
8.8e-02
2.3e-01
1.0e+00
3.6e+00
8.5e-01
6.2e-01
3.9e-01
cases:5.33%
controls:4.91%
cases:3.72%
controls:2.97%
cases:1.43%
controls:0.50%
cases:1.12%
controls:0.03%
cases:1.52%
controls:0.66%
cases:5.14%
controls:2.84%
cases:8.32%
controls:5.80%
86
788
1526
15262
60
477
1553
15583
23
81
1590
15979
18
5
1595
16055
24
105
1552
15919
72
442
1328
15122
77
756
848
12272
Hospital outpatient
ZY010 [2001311599]
1.0e-01
1.5e+00
—
—
2.3e+00
2.2e+00
1.3e+00
cases:0.56%
controls:0.50%
cases:0.62%
controls:0.14%
—
—
—
—
cases:0.38%
controls:0.04%
cases:1.00%
controls:0.11%
cases:0.97%
controls:0.26%
9
81
1603
15969
10
22
1603
16038
—
—
6
6
1570
16018
14
17
1386
15547
9
34
916
12994
Methemoglobin/Hemoglobin.total in Arterial blood
2615-3 [3006217]
-1.1e-01
5.4e-01
2.0e+00
1.0e+50
2.5e+00
1.5e+00
2.4e-01
cases:0.87%
controls:0.97%
cases:0.81%
controls:0.47%
cases:0.37%
controls:0.05%
cases:0.50%
controls:0.00%
cases:0.63%
controls:0.05%
cases:1.71%
controls:0.40%
cases:1.84%
controls:1.45%
14
156
1598
15894
13
76
1600
15984
6
8
1607
16052
8
0
1605
16060
10
8
1566
16016
24
63
1376
15501
17
189
908
12839
Dyspnoea
R06.0 [45558449]
3.0e-01
1.2e+00
2.4e+00
1.0e+50
1.5e+00
9.8e-01
1.9e-01
cases:4.78%
controls:3.58%
cases:4.09%
controls:1.33%
cases:1.49%
controls:0.14%
cases:0.74%
controls:0.00%
cases:0.57%
controls:0.12%
cases:3.43%
controls:1.32%
cases:5.41%
controls:4.51%
77
574
1535
15476
66
214
1547
15846
24
23
1589
16037
12
0
1601
16060
9
20
1567
16004
48
205
1352
15359
50
587
875
12441
Lymphocytes [#/volume] in Blood
26474-7 [3019198]
1.7e-01
7.2e-01
9.2e-01
2.7e+00
1.2e+00
3.8e-01
1.9e-01
cases:12.84%
controls:11.05%
cases:12.71%
controls:6.59%
cases:3.47%
controls:1.42%
cases:0.87%
controls:0.06%
cases:4.31%
controls:1.32%
cases:9.29%
controls:6.56%
cases:16.65%
controls:14.23%
207
1774
1405
14276
205
1058
1408
15002
56
228
1557
15832
14
9
1599
16051
68
211
1508
15813
130
1021
1270
14543
154
1854
771
11174
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
1.8e-01
7.0e-01
9.2e-01
2.8e+00
1.1e+00
3.7e-01
2.1e-01
cases:11.79%
controls:10.05%
cases:11.59%
controls:6.10%
cases:3.22%
controls:1.31%
cases:0.74%
controls:0.04%
cases:3.74%
controls:1.24%
cases:8.29%
controls:5.89%
cases:15.03%
controls:12.58%
190
1613
1422
14437
187
980
1426
15080
52
211
1561
15849
12
7
1601
16053
59
199
1517
15825
116
916
1284
14648
139
1639
786
11389
Nutritional guidance related to treatment and rehabilitation for medical condition
OAB74 [2001308652]
-1.0e+50
—
—
—
—
3.5e+00
2.4e+00
cases:0.00%
controls:0.08%
—
—
—
—
—
—
—
—
cases:1.29%
controls:0.04%
cases:0.86%
controls:0.08%
0
13
1612
16037
—
—
—
—
18
6
1382
15558
8
10
917
13018
Basophils/Leukocytes in Blood
30180-4 [3022096]
1.9e-01
7.1e-01
8.8e-01
2.8e+00
1.1e+00
3.8e-01
1.8e-01
cases:11.85%
controls:10.00%
cases:11.66%
controls:6.08%
cases:3.10%
controls:1.31%
cases:0.74%
controls:0.04%
cases:3.74%
controls:1.24%
cases:8.36%
controls:5.87%
cases:14.81%
controls:12.63%
191
1605
1421
14445
188
977
1425
15083
50
210
1563
15850
12
7
1601
16053
59
199
1517
15825
117
914
1283
14650
137
1646
788
11382
Monocytes/Leukocytes in Blood
26485-3 [3019069]
1.8e-01
7.1e-01
8.8e-01
2.8e+00
1.1e+00
3.8e-01
2.0e-01
cases:11.85%
controls:10.11%
cases:11.66%
controls:6.09%
cases:3.10%
controls:1.31%
cases:0.74%
controls:0.04%
cases:3.74%
controls:1.25%
cases:8.36%
controls:5.88%
cases:15.03%
controls:12.64%
191
1623
1421
14427
188
978
1425
15082
50
210
1563
15850
12
7
1601
16053
59
200
1517
15824
117
915
1283
14649
139
1647
786
11381
Other specified dysphonia
R49.08 [2000503601]
1.5e+00
2.1e+00
—
—
—
2.3e+00
1.4e+00
cases:0.56%
controls:0.12%
cases:0.62%
controls:0.07%
—
—
—
—
—
—
cases:0.50%
controls:0.05%
cases:0.65%
controls:0.16%
9
20
1603
16030
10
12
1603
16048
—
—
—
7
8
1393
15556
6
21
919
13007
Erythrocytes [#/volume] in Urine
30391-7 [3002582]
-1.6e-01
4.4e-01
9.6e-01
2.9e+00
1.1e+00
5.3e-01
1.5e-01
cases:5.40%
controls:6.26%
cases:4.77%
controls:3.13%
cases:1.61%
controls:0.62%
cases:0.56%
controls:0.03%
cases:1.40%
controls:0.48%
cases:5.36%
controls:3.22%
cases:10.38%
controls:9.10%
87
1004
1525
15046
77
503
1536
15557
26
100
1587
15960
9
5
1604
16055
22
77
1554
15947
75
501
1325
15063
96
1186
829
11842
Carboxyhemoglobin/Hemoglobin.total in Arterial blood
2030-5 [3028653]
-1.3e-01
5.0e-01
2.0e+00
1.0e+50
2.4e+00
1.5e+00
2.8e-01
cases:0.87%
controls:0.98%
cases:0.81%
controls:0.49%
cases:0.37%
controls:0.05%
cases:0.62%
controls:0.00%
cases:0.63%
controls:0.06%
cases:1.79%
controls:0.42%
cases:1.95%
controls:1.48%
14
158
1598
15892
13
79
1600
15981
6
8
1607
16052
10
0
1603
16060
10
9
1566
16015
25
66
1375
15498
18
193
907
12835
Leukocytes [#/volume] in Urine
30405-5 [3018095]
-1.1e-01
5.0e-01
1.0e+00
2.9e+00
1.0e+00
4.3e-01
3.5e-02
cases:6.33%
controls:7.00%
cases:5.89%
controls:3.64%
cases:1.86%
controls:0.68%
cases:0.56%
controls:0.03%
cases:1.46%
controls:0.52%
cases:5.79%
controls:3.85%
cases:10.70%
controls:10.37%
102
1124
1510
14926
95
585
1518
15475
30
110
1583
15950
9
5
1604
16055
23
84
1553
15940
81
599
1319
14965
99
1351
826
11677
Cobalamin (Vitamin B12) [Moles/volume] in Serum or Plasma
14685-2 [3009035]
3.5e-01
1.4e+00
2.1e+00
—
2.4e+00
1.6e-01
1.7e-01
cases:6.39%
controls:4.59%
cases:5.33%
controls:1.43%
cases:1.18%
controls:0.14%
—
—
cases:1.14%
controls:0.11%
cases:1.79%
controls:1.53%
cases:6.05%
controls:5.17%
103
737
1509
15313
86
230
1527
15830
19
23
1594
16037
—
18
17
1558
16007
25
238
1375
15326
56
674
869
12354
Borrelia burgdorferi IgG Ab [Units/volume] in Cerebral spinal fluid
22126-7 [3010380]
1.7e+00
4.1e+00
—
—
—
—
-1.0e+50
cases:1.05%
controls:0.20%
cases:3.78%
controls:0.06%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.09%
17
32
1595
16018
61
10
1552
16050
—
—
—
—
0
12
925
13016
Myopathy, unspecified
G72.9 [45571825]
3.2e+00
—
—
1.0e+50
—
—
2.7e+00
cases:1.30%
controls:0.06%
—
—
—
—
cases:0.37%
controls:0.00%
—
—
—
—
cases:1.19%
controls:0.08%
21
9
1591
16041
—
—
6
0
1607
16060
—
—
11
11
914
13017
Differential panel, method unspecified - Blood
69738-3 [42870588]
1.1e-01
6.7e-01
8.2e-01
2.9e+00
9.7e-01
4.4e-01
1.8e-01
cases:7.63%
controls:6.87%
cases:8.12%
controls:4.33%
cases:2.17%
controls:0.97%
cases:0.56%
controls:0.03%
cases:2.54%
controls:0.97%
cases:6.14%
controls:4.03%
cases:10.16%
controls:8.67%
123
1102
1489
14948
131
695
1482
15365
35
155
1578
15905
9
5
1604
16055
40
156
1536
15868
86
627
1314
14937
94
1129
831
11899
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
2.0e-01
6.7e-01
9.2e-01
2.7e+00
1.1e+00
3.7e-01
1.5e-01
cases:11.91%
controls:9.93%
cases:11.35%
controls:6.13%
cases:3.16%
controls:1.29%
cases:0.81%
controls:0.06%
cases:3.74%
controls:1.22%
cases:8.29%
controls:5.87%
cases:14.59%
controls:12.79%
192
1594
1420
14456
183
984
1430
15076
51
207
1562
15853
13
9
1600
16051
59
196
1517
15828
116
914
1284
14650
135
1666
790
11362
Outpatient Hospital
22 [8756]
1.8e-01
6.5e-01
1.5e+00
—
1.7e+00
1.1e+00
8.7e-01
cases:26.86%
controls:23.43%
cases:12.65%
controls:7.04%
cases:3.47%
controls:0.78%
—
—
cases:4.25%
controls:0.84%
cases:16.07%
controls:6.10%
cases:33.84%
controls:17.59%
433
3761
1179
12289
204
1130
1409
14930
56
126
1557
15934
—
67
135
1509
15889
225
950
1175
14614
313
2292
612
10736
Evaluation of communicative skills
R1260 [2001310179]
1.4e+00
3.3e+00
1.0e+50
1.0e+50
—
—
2.5e+00
cases:0.56%
controls:0.14%
cases:0.81%
controls:0.03%
cases:0.31%
controls:0.00%
cases:0.37%
controls:0.00%
—
—
—
—
cases:1.19%
controls:0.10%
9
23
1603
16027
13
5
1600
16055
5
0
1608
16060
6
0
1607
16060
—
—
11
13
914
13015
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
1.7e-01
7.1e-01
9.1e-01
2.6e+00
1.1e+00
3.6e-01
1.5e-01
cases:11.97%
controls:10.31%
cases:11.84%
controls:6.20%
cases:3.22%
controls:1.32%
cases:0.74%
controls:0.06%
cases:3.81%
controls:1.28%
cases:8.43%
controls:6.01%
cases:14.92%
controls:13.07%
193
1655
1419
14395
191
995
1422
15065
52
212
1561
15848
12
9
1601
16051
60
205
1516
15819
118
936
1282
14628
138
1703
787
11325
Neurosurgery
14 [38004459]
5.9e-01
1.2e+00
9.2e-01
—
1.3e+00
1.6e+00
1.0e+00
cases:4.59%
controls:2.60%
cases:3.60%
controls:1.12%
cases:0.56%
controls:0.22%
—
—
cases:0.76%
controls:0.21%
cases:4.71%
controls:1.00%
cases:6.59%
controls:2.52%
74
418
1538
15632
58
180
1555
15880
9
36
1604
16024
—
12
33
1564
15991
66
156
1334
15408
61
328
864
12700
Adaptation disorder with mixed anxiety and depression
F43.22 [2000502003]
7.2e-01
1.9e+00
—
—
—
2.2e+00
1.5e+00
cases:0.37%
controls:0.18%
cases:0.43%
controls:0.06%
—
—
—
—
—
—
cases:0.86%
controls:0.10%
cases:1.41%
controls:0.31%
6
29
1606
16021
7
10
1606
16050
—
—
—
12
15
1388
15549
13
40
912
12988
Borrelia burgdorferi IgM Ab [Units/volume] in Cerebral spinal fluid
22133-3 [3014973]
1.6e+00
4.1e+00
—
—
—
—
—
cases:0.99%
controls:0.21%
cases:3.84%
controls:0.07%
—
—
—
—
—
—
—
—
—
—
16
33
1596
16017
62
11
1551
16049
—
—
—
—
—
Borrelia burgdorferi Ab [Presence] in Cerebral spinal fluid
22118-4 [3011166]
1.6e+00
4.0e+00
—
—
—
—
—
cases:0.87%
controls:0.17%
cases:3.60%
controls:0.07%
—
—
—
—
—
—
—
—
—
—
14
27
1598
16023
58
11
1555
16049
—
—
—
—
—
CXCL13 Ag [Mass/volume] in Cerebral spinal fluid
74917-6 [44816808]
2.2e+00
3.5e+00
—
—
—
—
—
cases:0.43%
controls:0.05%
cases:0.99%
controls:0.03%
—
—
—
—
—
—
—
—
—
—
7
8
1605
16042
16
5
1597
16055
—
—
—
—
—
Rheumatoid factor [Units/volume] in Serum or Plasma
11572-5 [3021614]
6.0e-02
1.3e+00
2.2e+00
—
2.1e+00
-5.6e-02
1.2e-01
cases:3.29%
controls:3.10%
cases:3.29%
controls:0.88%
cases:0.56%
controls:0.06%
—
—
cases:0.51%
controls:0.06%
cases:0.86%
controls:0.91%
cases:3.78%
controls:3.36%
53
498
1559
15552
53
142
1560
15918
9
10
1604
16050
—
8
10
1568
16014
12
141
1388
15423
35
438
890
12590
Functional X-ray examination of swallowing
JC2KB [2001304595]
1.5e+00
3.1e+00
—
—
—
—
2.6e+00
cases:0.43%
controls:0.10%
cases:0.93%
controls:0.04%
—
—
—
—
—
—
—
—
cases:1.08%
controls:0.08%
7
16
1605
16034
15
7
1598
16053
—
—
—
—
10
11
915
13017
Implementation of speech therapy rehabilitation plan
SPAT1224 [2001700325]
1.4e+00
3.3e+00
—
—
1.0e+50
—
2.4e+00
cases:0.43%
controls:0.11%
cases:0.81%
controls:0.03%
—
—
—
—
cases:0.38%
controls:0.00%
—
—
cases:0.65%
controls:0.06%
7
18
1605
16032
13
5
1600
16055
—
—
6
0
1570
16024
—
6
8
919
13020
Nursing episode
950 [44777714]
5.0e-02
7.9e-01
1.1e+00
1.6e+00
1.4e+00
1.5e+00
7.8e-01
cases:1.67%
controls:1.60%
cases:2.17%
controls:1.00%
cases:1.05%
controls:0.34%
cases:0.37%
controls:0.07%
cases:1.33%
controls:0.33%
cases:4.64%
controls:1.08%
cases:5.84%
controls:2.76%
27
256
1585
15794
35
160
1578
15900
17
54
1596
16006
6
12
1607
16048
21
53
1555
15971
65
168
1335
15396
54
360
871
12668
Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]
-1.5e-01
3.8e-01
1.1e+00
3.1e+00
9.4e-01
5.2e-01
2.9e-01
cases:6.70%
controls:7.70%
cases:5.21%
controls:3.62%
cases:1.86%
controls:0.65%
cases:0.68%
controls:0.03%
cases:1.46%
controls:0.57%
cases:5.79%
controls:3.51%
cases:12.43%
controls:9.63%
108
1236
1504
14814
84
581
1529
15479
30
105
1583
15955
11
5
1602
16055
23
92
1553
15932
81
546
1319
15018
115
1255
810
11773
Paralysis of vocal cords and larynx
J38.0 [45543265]
1.9e+00
1.9e+00
—
—
—
1.8e+00
—
cases:0.87%
controls:0.12%
cases:0.56%
controls:0.09%
—
—
—
—
—
—
cases:0.50%
controls:0.08%
—
—
14
20
1598
16030
9
14
1604
16046
—
—
—
7
13
1393
15551
—
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
-7.1e-02
2.4e-01
6.1e-01
3.1e+00
1.4e+00
4.9e-01
2.1e-01
cases:10.48%
controls:11.17%
cases:7.75%
controls:6.20%
cases:2.29%
controls:1.26%
cases:1.43%
controls:0.06%
cases:4.31%
controls:1.15%
cases:9.21%
controls:5.87%
cases:16.00%
controls:13.43%
169
1793
1443
14257
125
995
1488
15065
37
202
1576
15858
23
10
1590
16050
68
185
1508
15839
129
913
1271
14651
148
1750
777
11278
Bicarbonate [Moles/volume] standard in Capillary blood
19231-0 [3004490]
-5.8e-02
8.8e-01
—
—
2.2e+00
2.3e+00
1.1e+00
cases:0.68%
controls:0.72%
cases:0.87%
controls:0.36%
—
—
—
—
cases:0.63%
controls:0.07%
cases:3.14%
controls:0.33%
cases:2.38%
controls:0.83%
11
116
1601
15934
14
58
1599
16002
—
—
10
11
1566
16013
44
52
1356
15512
22
108
903
12920
Thoracal spine MRI examination with high intensity magnet
NA2BG [2001307013]
1.6e+00
4.0e+00
—
1.0e+50
—
—
—
cases:1.18%
controls:0.24%
cases:1.61%
controls:0.03%
—
—
cases:0.37%
controls:0.00%
—
—
—
—
—
—
19
39
1593
16011
26
5
1587
16055
—
6
0
1607
16060
—
—
—
morphine; oral, parenteral, rectal
N02AA01 [21604256]
—
—
—
—
—
3.7e+00
1.9e+00
—
—
—
—
—
—
—
—
—
—
cases:2.21%
controls:0.06%
cases:1.30%
controls:0.20%
—
—
—
—
—
31
9
1369
15555
12
26
913
13002
Bicarbonate [Moles/volume] standard in Arterial blood
19230-2 [3014218]
1.3e-01
7.2e-01
—
1.0e+50
2.9e+00
1.8e+00
7.7e-01
cases:0.87%
controls:0.76%
cases:0.81%
controls:0.39%
—
—
cases:0.37%
controls:0.00%
cases:0.70%
controls:0.04%
cases:2.00%
controls:0.32%
cases:2.49%
controls:1.17%
14
122
1598
15928
13
63
1600
15997
—
6
0
1607
16060
11
6
1565
16018
28
50
1372
15514
23
152
902
12876
Circumscribed brain atrophy
G31.0 [45591166]
—
—
1.0e+50
1.0e+50
1.0e+50
3.3e+00
2.2e+00
—
—
—
—
cases:0.43%
controls:0.00%
cases:0.50%
controls:0.00%
cases:0.32%
controls:0.00%
cases:1.00%
controls:0.04%
cases:0.86%
controls:0.09%
—
—
7
0
1606
16060
8
0
1605
16060
5
0
1571
16024
14
6
1386
15558
8
12
917
13016
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
2.5e-02
3.7e-01
8.9e-01
3.1e+00
1.1e+00
1.6e-01
-1.7e-01
cases:33.81%
controls:33.25%
cases:33.79%
controls:26.00%
cases:11.28%
controls:4.94%
cases:5.58%
controls:0.26%
cases:13.26%
controls:4.72%
cases:29.57%
controls:26.36%
cases:38.49%
controls:42.66%
545
5337
1067
10713
545
4175
1068
11885
182
794
1431
15266
90
42
1523
16018
209
757
1367
15267
414
4103
986
11461
356
5558
569
7470
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
1.2e-01
1.0e+00
1.4e+00
—
1.8e+00
9.1e-01
3.2e-01
cases:10.67%
controls:9.56%
cases:12.96%
controls:5.01%
cases:3.53%
controls:0.85%
—
—
cases:5.14%
controls:0.89%
cases:11.64%
controls:5.05%
cases:16.00%
controls:12.20%
172
1534
1440
14516
209
805
1404
15255
57
137
1556
15923
—
81
143
1495
15881
163
786
1237
14778
148
1589
777
11439
Thorax X-ray examination outside radiological department
GD1UA [2001303652]
-2.1e-01
5.1e-01
2.3e+00
1.0e+50
2.0e+00
1.2e+00
4.5e-01
cases:1.67%
controls:2.05%
cases:0.99%
controls:0.60%
cases:0.81%
controls:0.08%
cases:1.24%
controls:0.00%
cases:0.44%
controls:0.06%
cases:1.93%
controls:0.57%
cases:3.46%
controls:2.23%
27
329
1585
15721
16
96
1597
15964
13
13
1600
16047
20
0
1593
16060
7
10
1569
16014
27
89
1373
15475
32
291
893
12737
Flexible laryngoscopy
UDQ12 [2001301827]
1.1e+00
2.6e+00
—
—
—
1.8e+00
7.3e-01
cases:1.67%
controls:0.55%
cases:2.11%
controls:0.16%
—
—
—
—
—
—
cases:1.00%
controls:0.17%
cases:1.08%
controls:0.52%
27
89
1585
15961
34
26
1579
16034
—
—
—
14
27
1386
15537
10
68
915
12960
Pneumonia, unspecified
J18.9 [45601123]
-3.6e-02
5.7e-01
1.6e+00
1.0e+50
2.2e+00
1.3e+00
4.7e-01
cases:2.98%
controls:3.08%
cases:1.98%
controls:1.13%
cases:0.93%
controls:0.19%
cases:1.18%
controls:0.00%
cases:1.02%
controls:0.12%
cases:4.29%
controls:1.26%
cases:7.78%
controls:5.01%
48
495
1564
15555
32
182
1581
15878
15
31
1598
16029
19
0
1594
16060
16
19
1560
16005
60
196
1340
15368
72
653
853
12375
Holo-transcobalamin II [Moles/volume] in Serum
72160-5 [43054903]
3.5e-01
1.2e+00
1.8e+00
—
2.1e+00
2.8e-01
-2.0e-01
cases:11.41%
controls:8.30%
cases:12.59%
controls:4.21%
cases:2.85%
controls:0.49%
—
—
cases:3.43%
controls:0.42%
cases:5.93%
controls:4.56%
cases:11.14%
controls:13.28%
184
1332
1428
14718
203
676
1410
15384
46
79
1567
15981
—
54
68
1522
15956
83
710
1317
14854
103
1730
822
11298
Casts [#/volume] in Urine by Automated count
51483-6 [3030467]
-2.3e-01
4.3e-01
9.1e-01
2.8e+00
1.2e+00
5.0e-01
1.5e-01
cases:4.34%
controls:5.41%
cases:4.15%
controls:2.73%
cases:1.36%
controls:0.55%
cases:0.50%
controls:0.03%
cases:1.40%
controls:0.42%
cases:4.43%
controls:2.72%
cases:8.86%
controls:7.75%
70
869
1542
15181
67
439
1546
15621
22
89
1591
15971
8
5
1605
16055
22
67
1554
15957
62
424
1338
15140
82
1010
843
12018
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
2.0e-02
3.6e-01
8.8e-01
3.0e+00
1.1e+00
1.6e-01
-1.9e-01
cases:34.06%
controls:33.62%
cases:33.91%
controls:26.33%
cases:11.47%
controls:5.12%
cases:5.33%
controls:0.27%
cases:13.45%
controls:4.85%
cases:29.86%
controls:26.68%
cases:38.38%
controls:42.96%
549
5396
1063
10654
547
4229
1066
11831
185
822
1428
15238
86
43
1527
16017
212
777
1364
15247
418
4152
982
11412
355
5597
570
7431
Other spondylosis with radiculopathy
M47.2 [45591850]
1.0e+00
2.0e+00
—
—
2.3e+00
9.1e-01
3.6e-01
cases:1.92%
controls:0.71%
cases:1.61%
controls:0.21%
—
—
—
—
cases:0.38%
controls:0.04%
cases:0.57%
controls:0.23%
cases:1.08%
controls:0.76%
31
114
1581
15936
26
34
1587
16026
—
—
6
6
1570
16018
8
36
1392
15528
10
99
915
12929
Chloride [Moles/volume] in Serum or Plasma
2075-0 [3014576]
-2.5e-01
3.1e-01
2.1e+00
1.0e+50
2.2e+00
1.1e+00
-1.0e-01
cases:1.55%
controls:1.99%
cases:1.55%
controls:1.14%
cases:0.93%
controls:0.12%
cases:0.74%
controls:0.00%
cases:1.08%
controls:0.12%
cases:3.00%
controls:1.02%
cases:2.92%
controls:3.23%
25
319
1587
15731
25
183
1588
15877
15
19
1598
16041
12
0
1601
16060
17
20
1559
16004
42
158
1358
15406
27
421
898
12607
Thiamine [Moles/volume] in Blood
32554-8 [3006653]
2.0e+00
3.3e+00
—
—
1.0e+50
—
1.7e+00
cases:0.56%
controls:0.07%
cases:1.18%
controls:0.04%
—
—
—
—
cases:0.89%
controls:0.00%
—
—
cases:0.54%
controls:0.10%
9
12
1603
16038
19
7
1594
16053
—
—
14
0
1562
16024
—
5
13
920
13015
Counselling and guidance related to ageing
SPAT1304 [2001700405]
2.4e-01
6.9e-01
2.2e+00
—
1.9e+00
1.3e+00
2.9e-01
cases:0.87%
controls:0.69%
cases:0.62%
controls:0.31%
cases:0.43%
controls:0.05%
—
—
cases:0.44%
controls:0.07%
cases:1.14%
controls:0.33%
cases:1.41%
controls:1.05%
14
110
1598
15940
10
50
1603
16010
7
8
1606
16052
—
7
11
1569
16013
16
51
1384
15513
13
137
912
12891
Voluntary or Charitable Agency
251V00000X [38004202]
8.5e-01
1.5e+00
—
—
—
3.2e+00
2.1e+00
cases:0.50%
controls:0.21%
cases:0.56%
controls:0.13%
—
—
—
—
—
—
cases:3.71%
controls:0.16%
cases:4.76%
controls:0.61%
8
34
1604
16016
9
21
1604
16039
—
—
—
52
25
1348
15539
44
80
881
12948
Assessment of need for aid
SPAT1229 [2001700330]
4.3e-01
1.3e+00
—
—
—
2.4e+00
1.4e+00
cases:1.36%
controls:0.89%
cases:1.43%
controls:0.39%
—
—
—
—
—
—
cases:4.21%
controls:0.39%
cases:4.76%
controls:1.17%
22
143
1590
15907
23
62
1590
15998
—
—
—
59
61
1341
15503
44
153
881
12875
Procedure duration 60 to 89 minutes
ZXE11 [2001311402]
-1.3e-01
1.4e+00
—
—
—
2.0e+00
1.8e+00
cases:0.50%
controls:0.57%
cases:0.74%
controls:0.19%
—
—
—
—
—
—
cases:0.79%
controls:0.11%
cases:0.76%
controls:0.13%
8
91
1604
15959
12
30
1601
16030
—
—
—
11
17
1389
15547
7
17
918
13011
Nutritional therapy
R4190 [2001310243]
3.5e-01
1.2e+00
—
1.0e+50
—
3.4e+00
1.7e+00
cases:0.43%
controls:0.31%
cases:0.50%
controls:0.14%
—
—
cases:0.37%
controls:0.00%
—
—
cases:3.64%
controls:0.12%
cases:1.84%
controls:0.35%
7
49
1605
16001
8
23
1605
16037
—
6
0
1607
16060
—
51
19
1349
15545
17
45
908
12983
Emergency Room and Inpatient Visit
ERIP [262]
4.0e-02
7.2e-01
1.7e+00
—
1.9e+00
8.4e-01
3.4e-01
cases:4.90%
controls:4.72%
cases:5.27%
controls:2.63%
cases:2.05%
controls:0.40%
—
—
cases:2.16%
controls:0.34%
cases:7.00%
controls:3.15%
cases:12.32%
controls:9.09%
79
757
1533
15293
85
423
1528
15637
33
64
1580
15996
—
34
54
1542
15970
98
490
1302
15074
114
1184
811
11844
Emergency Room Visit
ER [9203]
1.8e-01
7.0e-01
1.5e+00
—
1.2e+00
8.4e-01
5.9e-01
cases:34.80%
controls:30.74%
cases:18.54%
controls:10.16%
cases:5.58%
controls:1.30%
—
—
cases:4.06%
controls:1.20%
cases:20.21%
controls:9.82%
cases:41.30%
controls:27.98%
561
4934
1051
11116
299
1631
1314
14429
90
209
1523
15851
—
64
193
1512
15831
283
1529
1117
14035
382
3645
543
9383
Cortisol [Moles/volume] in Serum or Plasma
14675-3 [3036481]
3.1e-01
8.5e-01
1.8e+00
—
2.4e+00
7.1e-01
2.2e-01
cases:2.11%
controls:1.56%
cases:1.24%
controls:0.54%
cases:0.43%
controls:0.07%
—
—
cases:0.57%
controls:0.05%
cases:1.14%
controls:0.57%
cases:2.27%
controls:1.83%
34
250
1578
15800
20
86
1593
15974
7
12
1606
16048
—
9
8
1567
16016
16
88
1384
15476
21
238
904
12790
Oxygen capacity [Volume Fraction] in Arterial blood
59275-8 [40762366]
3.4e-01
6.6e-01
—
—
3.2e+00
1.9e+00
2.4e-01
cases:1.30%
controls:0.93%
cases:0.74%
controls:0.39%
—
—
—
—
cases:1.21%
controls:0.05%
cases:2.21%
controls:0.35%
cases:1.62%
controls:1.28%
21
150
1591
15900
12
62
1601
15998
—
—
19
8
1557
16016
31
55
1369
15509
15
167
910
12861
INR in Blood by Coagulation assay
34714-6 [3032080]
-4.9e-02
4.1e-01
4.9e-01
2.9e+00
7.3e-01
6.6e-01
3.1e-01
cases:10.55%
controls:11.02%
cases:9.18%
controls:6.30%
cases:3.29%
controls:2.04%
cases:1.61%
controls:0.09%
cases:3.93%
controls:1.93%
cases:10.29%
controls:5.58%
cases:17.19%
controls:13.25%
170
1769
1442
14281
148
1012
1465
15048
53
327
1560
15733
26
14
1587
16046
62
310
1514
15714
144
869
1256
14695
159
1726
766
11302
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
1.8e-02
3.3e-01
7.7e-01
2.8e+00
1.1e+00
1.3e-01
-1.9e-01
cases:36.10%
controls:35.69%
cases:36.76%
controls:29.51%
cases:13.33%
controls:6.66%
cases:5.64%
controls:0.35%
cases:15.74%
controls:5.98%
cases:33.14%
controls:30.27%
cases:40.97%
controls:45.62%
582
5729
1030
10321
593
4740
1020
11320
215
1069
1398
14991
91
56
1522
16004
248
959
1328
15065
464
4712
936
10852
379
5944
546
7084
Swallowing problem
D21 [2002000320]
1.1e+00
2.8e+00
—
—
1.0e+50
—
2.2e+00
cases:0.31%
controls:0.10%
cases:0.81%
controls:0.05%
—
—
—
—
cases:0.70%
controls:0.00%
—
—
cases:1.08%
controls:0.12%
5
16
1607
16034
13
8
1600
16052
—
—
11
0
1565
16024
—
10
16
915
13012
Dizziness and giddiness
R42 [45568132]
8.2e-01
1.5e+00
2.6e+00
—
1.1e+00
5.0e-01
2.1e-01
cases:6.33%
controls:2.88%
cases:4.59%
controls:1.03%
cases:1.18%
controls:0.09%
—
—
cases:0.38%
controls:0.13%
cases:1.71%
controls:1.05%
cases:4.76%
controls:3.88%
102
462
1510
15588
74
165
1539
15895
19
14
1594
16046
—
6
21
1570
16003
24
163
1376
15401
44
506
881
12522
CBC panel - Blood by Automated count
58410-2 [40761511]
1.1e-02
3.0e-01
6.5e-01
2.8e+00
1.2e+00
1.6e-01
-1.0e-01
cases:31.95%
controls:31.71%
cases:26.10%
controls:20.71%
cases:7.25%
controls:3.91%
cases:3.29%
controls:0.20%
cases:10.91%
controls:3.63%
cases:23.50%
controls:20.72%
cases:34.70%
controls:37.03%
515
5089
1097
10961
421
3326
1192
12734
117
628
1496
15432
53
32
1560
16028
172
581
1404
15443
329
3225
1071
12339
321
4824
604
8204
IgG [Mass/volume] in Serum or Plasma
2465-3 [3005719]
3.4e-01
1.6e+00
1.4e+00
—
2.0e+00
1.3e+00
2.6e-01
cases:1.99%
controls:1.42%
cases:3.91%
controls:0.79%
cases:0.56%
controls:0.14%
—
—
cases:0.89%
controls:0.12%
cases:2.29%
controls:0.62%
cases:1.95%
controls:1.50%
32
228
1580
15822
63
127
1550
15933
9
22
1604
16038
—
14
19
1562
16005
32
97
1368
15467
18
196
907
12832
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
4.0e-02
3.4e-01
8.1e-01
2.4e+00
1.0e+00
3.6e-01
5.1e-02
cases:16.81%
controls:16.26%
cases:11.04%
controls:8.09%
cases:2.79%
controls:1.26%
cases:0.56%
controls:0.05%
cases:2.92%
controls:1.06%
cases:11.29%
controls:8.15%
cases:19.89%
controls:19.10%
271
2610
1341
13440
178
1299
1435
14761
45
203
1568
15857
9
8
1604
16052
46
170
1530
15854
158
1268
1242
14296
184
2488
741
10540
Case Management Agency
251B00000X [38004193]
2.6e-02
1.4e-01
6.3e-01
3.3e+00
6.9e-01
2.5e-01
-1.7e-01
cases:59.86%
controls:59.23%
cases:55.86%
controls:52.29%
cases:35.03%
controls:22.29%
cases:28.33%
controls:1.48%
cases:35.66%
controls:21.73%
cases:60.07%
controls:53.89%
cases:64.76%
controls:68.48%
965
9506
647
6544
901
8398
712
7662
565
3579
1048
12481
457
237
1156
15823
562
3482
1014
12542
841
8388
559
7176
599
8922
326
4106
Bicarbonate [Moles/volume] in Serum or Plasma
1963-8 [3016293]
-2.8e-01
6.7e-01
1.8e+00
—
2.9e+00
1.9e+00
6.6e-01
cases:0.74%
controls:0.98%
cases:0.99%
controls:0.51%
cases:0.37%
controls:0.06%
—
—
cases:0.89%
controls:0.05%
cases:2.86%
controls:0.42%
cases:2.49%
controls:1.30%
12
157
1600
15893
16
82
1597
15978
6
10
1607
16050
—
14
8
1562
16016
40
66
1360
15498
23
170
902
12858
Laboratory Visit
OMOP4822461 [32036]
4.1e-02
2.3e-01
8.0e-01
2.8e+00
9.4e-01
1.8e-01
-2.2e-01
cases:42.00%
controls:41.00%
cases:43.40%
controls:37.79%
cases:23.87%
controls:12.37%
cases:10.79%
controls:0.74%
cases:25.25%
controls:11.69%
cases:43.36%
controls:39.00%
cases:44.97%
controls:50.57%
677
6581
935
9469
700
6069
913
9991
385
1987
1228
14073
174
119
1439
15941
398
1873
1178
14151
607
6070
793
9494
416
6588
509
6440
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
4.3e-02
2.9e-01
6.6e-01
2.7e+00
1.1e+00
1.7e-01
-1.9e-01
cases:38.77%
controls:37.76%
cases:38.00%
controls:31.44%
cases:13.39%
controls:7.40%
cases:5.89%
controls:0.42%
cases:17.70%
controls:6.71%
cases:35.86%
controls:32.03%
cases:42.59%
controls:47.34%
625
6060
987
9990
613
5049
1000
11011
216
1188
1397
14872
95
67
1518
15993
279
1076
1297
14948
502
4985
898
10579
394
6168
531
6860
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
3.8e-02
2.9e-01
6.4e-01
2.7e+00
1.1e+00
1.7e-01
-1.9e-01
cases:38.71%
controls:37.80%
cases:38.13%
controls:31.51%
cases:13.21%
controls:7.42%
cases:5.95%
controls:0.42%
cases:17.64%
controls:6.72%
cases:35.86%
controls:32.09%
cases:42.59%
controls:47.40%
624
6067
988
9983
615
5060
998
11000
213
1191
1400
14869
96
67
1517
15993
278
1077
1298
14947
502
4994
898
10570
394
6175
531
6853
MCH [Entitic mass]
28539-5 [3035941]
3.7e-02
2.9e-01
6.5e-01
2.7e+00
1.1e+00
1.7e-01
-1.9e-01
cases:38.59%
controls:37.70%
cases:38.00%
controls:31.44%
cases:13.21%
controls:7.38%
cases:5.89%
controls:0.42%
cases:17.58%
controls:6.70%
cases:35.86%
controls:32.01%
cases:42.59%
controls:47.35%
622
6051
990
9999
613
5049
1000
11011
213
1185
1400
14875
95
67
1518
15993
277
1074
1299
14950
502
4982
898
10582
394
6169
531
6859
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
4.0e-02
2.9e-01
6.5e-01
2.7e+00
1.1e+00
1.7e-01
-1.9e-01
cases:38.71%
controls:37.76%
cases:38.00%
controls:31.44%
cases:13.21%
controls:7.38%
cases:5.89%
controls:0.42%
cases:17.58%
controls:6.70%
cases:35.86%
controls:32.02%
cases:42.59%
controls:47.36%
624
6061
988
9989
613
5049
1000
11011
213
1185
1400
14875
95
67
1518
15993
277
1074
1299
14950
502
4984
898
10580
394
6170
531
6858
Monitoring the use of the aid
R5140 [2001310249]
2.7e-01
-4.4e-02
—
—
2.0e+00
1.9e+00
8.6e-01
cases:2.05%
controls:1.58%
cases:0.62%
controls:0.65%
—
—
—
—
cases:0.44%
controls:0.06%
cases:3.79%
controls:0.58%
cases:3.89%
controls:1.68%
33
253
1579
15797
10
104
1603
15956
—
—
7
10
1569
16014
53
91
1347
15473
36
219
889
12809
Platelets [#/volume] in Blood
26515-7 [3007461]
3.9e-02
2.9e-01
6.5e-01
2.7e+00
1.1e+00
1.7e-01
-1.9e-01
cases:38.59%
controls:37.67%
cases:37.94%
controls:31.42%
cases:13.21%
controls:7.38%
cases:5.89%
controls:0.42%
cases:17.58%
controls:6.69%
cases:35.93%
controls:32.01%
cases:42.59%
controls:47.33%
622
6046
990
10004
612
5046
1001
11014
213
1186
1400
14874
95
67
1518
15993
277
1072
1299
14952
503
4982
897
10582
394
6166
531
6862
Leukocytes [#/volume] in Blood
26464-8 [3010813]
3.7e-02
2.9e-01
6.4e-01
2.7e+00
1.1e+00
1.6e-01
-1.9e-01
cases:38.65%
controls:37.78%
cases:38.07%
controls:31.48%
cases:13.14%
controls:7.40%
cases:5.89%
controls:0.42%
cases:17.64%
controls:6.70%
cases:35.71%
controls:32.05%
cases:42.59%
controls:47.34%
623
6064
989
9986
614
5055
999
11005
212
1188
1401
14872
95
67
1518
15993
278
1074
1298
14950
500
4989
900
10575
394
6167
531
6861
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
3.8e-02
2.9e-01
6.4e-01
2.7e+00
1.1e+00
1.7e-01
-1.9e-01
cases:38.65%
controls:37.76%
cases:38.00%
controls:31.47%
cases:13.21%
controls:7.40%
cases:5.89%
controls:0.42%
cases:17.58%
controls:6.71%
cases:35.86%
controls:32.04%
cases:42.59%
controls:47.37%
623
6060
989
9990
613
5054
1000
11006
213
1188
1400
14872
95
67
1518
15993
277
1075
1299
14949
502
4987
898
10577
394
6171
531
6857
Normoblasts [#/volume] in Blood
715-3 [3021589]
2.2e-02
3.4e-01
7.1e-01
2.7e+00
1.0e+00
1.9e-01
3.6e-02
cases:9.18%
controls:9.00%
cases:9.92%
controls:7.25%
cases:3.35%
controls:1.68%
cases:1.05%
controls:0.07%
cases:4.31%
controls:1.62%
cases:9.14%
controls:7.68%
cases:13.95%
controls:13.52%
148
1444
1464
14606
160
1165
1453
14895
54
270
1559
15790
17
12
1596
16048
68
260
1508
15764
128
1196
1272
14368
129
1762
796
11266
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
2.2e-01
1.0e+00
1.4e+00
—
1.8e+00
5.0e-01
1.9e-01
cases:12.72%
controls:10.49%
cases:14.14%
controls:5.60%
cases:4.03%
controls:1.03%
—
—
cases:5.58%
controls:0.98%
cases:9.21%
controls:5.78%
cases:17.08%
controls:14.54%
205
1684
1407
14366
228
900
1385
15160
65
166
1548
15894
—
88
157
1488
15867
129
900
1271
14664
158
1894
767
11134
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
-1.8e-03
2.5e-01
6.4e-01
2.7e+00
1.1e+00
1.1e-01
-2.4e-01
cases:25.12%
controls:25.16%
cases:25.85%
controls:21.36%
cases:8.68%
controls:4.79%
cases:3.84%
controls:0.26%
cases:11.48%
controls:4.29%
cases:24.07%
controls:22.06%
cases:29.73%
controls:34.98%
405
4038
1207
12012
417
3430
1196
12630
140
769
1473
15291
62
41
1551
16019
181
688
1395
15336
337
3434
1063
12130
275
4557
650
8471
Audiology
64 [38004489]
4.0e-01
1.1e+00
1.1e+00
—
1.3e+00
1.5e+00
7.7e-01
cases:4.03%
controls:2.75%
cases:4.03%
controls:1.38%
cases:0.68%
controls:0.24%
—
—
cases:0.82%
controls:0.23%
cases:5.50%
controls:1.29%
cases:7.35%
controls:3.55%
65
441
1547
15609
65
222
1548
15838
11
38
1602
16022
—
13
37
1563
15987
77
201
1323
15363
68
463
857
12565
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
-3.2e-02
2.7e-01
5.6e-01
2.7e+00
1.1e+00
1.0e-01
-2.3e-01
cases:22.95%
controls:23.52%
cases:23.81%
controls:19.29%
cases:7.94%
controls:4.68%
cases:3.91%
controls:0.27%
cases:11.61%
controls:4.24%
cases:21.57%
controls:19.89%
cases:26.92%
controls:31.77%
370
3775
1242
12275
384
3098
1229
12962
128
751
1485
15309
63
43
1550
16017
183
680
1393
15344
302
3095
1098
12469
249
4139
676
8889
Body temperature
8310-5 [3020891]
-8.3e-01
7.2e-01
—
1.0e+50
2.6e+00
2.0e+00
7.4e-01
cases:0.31%
controls:0.71%
cases:0.81%
controls:0.39%
—
—
cases:0.43%
controls:0.00%
cases:0.82%
controls:0.06%
cases:3.07%
controls:0.41%
cases:2.27%
controls:1.10%
5
114
1607
15936
13
63
1600
15997
—
7
0
1606
16060
13
10
1563
16014
43
64
1357
15500
21
143
904
12885
Lumbar spine extensive MRI examination with high intensity magnet
NA3CG [2001307039]
1.1e+00
2.1e+00
—
—
—
—
1.5e+00
cases:0.87%
controls:0.31%
cases:0.68%
controls:0.09%
—
—
—
—
—
—
—
—
cases:1.08%
controls:0.25%
14
49
1598
16001
11
14
1602
16046
—
—
—
—
10
32
915
12996
Other spondylosis with myelopathy
M47.1 [45606228]
2.3e+00
—
—
—
—
—
2.3e+00
cases:0.74%
controls:0.07%
—
—
—
—
—
—
—
—
—
—
cases:0.76%
controls:0.08%
12
12
1600
16038
—
—
—
—
—
7
10
918
13018
Carbon dioxide [Partial pressure] in Blood
11557-6 [3013290]
—
1.0e+00
—
—
—
2.5e+00
2.0e+00
—
—
cases:0.43%
controls:0.16%
—
—
—
—
—
—
cases:1.93%
controls:0.15%
cases:1.41%
controls:0.18%
—
7
25
1606
16035
—
—
—
27
24
1373
15540
13
24
912
13004
Base excess in Blood by calculation
11555-0 [3012501]
—
1.0e+00
—
—
—
2.5e+00
2.0e+00
—
—
cases:0.43%
controls:0.16%
—
—
—
—
—
—
cases:1.93%
controls:0.15%
cases:1.41%
controls:0.18%
—
7
25
1606
16035
—
—
—
27
24
1373
15540
13
24
912
13004
Lower urinary tract urodynamic studies
252896003 [4099392]
4.3e-01
—
—
—
—
2.7e+00
1.8e+00
cases:0.37%
controls:0.24%
—
—
—
—
—
—
—
—
cases:0.50%
controls:0.03%
cases:1.08%
controls:0.18%
6
39
1606
16011
—
—
—
—
7
5
1393
15559
10
23
915
13005
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
1.8e-01
8.9e-01
1.4e+00
—
1.8e+00
5.5e-01
2.3e-01
cases:11.29%
controls:9.63%
cases:11.41%
controls:5.01%
cases:3.60%
controls:0.93%
—
—
cases:4.70%
controls:0.85%
cases:8.50%
controls:5.08%
cases:15.14%
controls:12.36%
182
1545
1430
14505
184
804
1429
15256
58
150
1555
15910
—
74
136
1502
15888
119
791
1281
14773
140
1610
785
11418
Other function in accordance with physical therapy nomenclature
SPAT1295 [2001700396]
6.2e-01
1.6e+00
—
—
—
1.9e+00
1.1e+00
cases:1.12%
controls:0.60%
cases:1.05%
controls:0.22%
—
—
—
—
—
—
cases:1.07%
controls:0.16%
cases:1.51%
controls:0.53%
18
97
1594
15953
17
35
1596
16025
—
—
—
15
25
1385
15539
14
69
911
12959
Oxygen [Partial pressure] in Blood
11556-8 [3027315]
—
1.0e+00
—
—
—
2.5e+00
2.0e+00
—
—
cases:0.43%
controls:0.16%
—
—
—
—
—
—
cases:1.93%
controls:0.16%
cases:1.41%
controls:0.18%
—
7
25
1606
16035
—
—
—
27
25
1373
15539
13
24
912
13004
diazepam; oral, parenteral, rectal
N05BA01 [21604566]
5.0e-01
9.6e-01
1.2e+00
—
7.7e-01
1.1e+00
8.5e-01
cases:4.34%
controls:2.68%
cases:3.16%
controls:1.24%
cases:0.87%
controls:0.27%
—
—
cases:0.70%
controls:0.32%
cases:3.64%
controls:1.27%
cases:6.05%
controls:2.67%
70
430
1542
15620
51
199
1562
15861
14
44
1599
16016
—
11
52
1565
15972
51
198
1349
15366
56
348
869
12680
Pneumonitis due to food and vomit
J69.0 [45591562]
-1.0e+50
—
—
1.0e+50
—
2.8e+00
1.7e+00
cases:0.00%
controls:0.08%
—
—
—
—
cases:0.31%
controls:0.00%
—
—
cases:0.64%
controls:0.04%
cases:1.41%
controls:0.25%
0
13
1612
16037
—
—
5
0
1608
16060
—
9
6
1391
15558
13
33
912
12995
Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection
40987-0 [3043924]
5.5e-06
9.0e-01
1.2e+00
—
1.9e+00
1.2e+00
5.6e-01
cases:1.43%
controls:1.43%
cases:1.80%
controls:0.74%
cases:0.43%
controls:0.13%
—
—
cases:0.63%
controls:0.10%
cases:2.79%
controls:0.84%
cases:5.08%
controls:2.98%
23
229
1589
15821
29
119
1584
15941
7
21
1606
16039
—
10
16
1566
16008
39
130
1361
15434
47
388
878
12640
Thorax X-ray examination
GD1AA [2001303617]
1.4e-01
8.1e-01
1.6e+00
—
1.4e+00
7.3e-01
3.0e-01
cases:9.86%
controls:8.72%
cases:7.38%
controls:3.42%
cases:1.86%
controls:0.37%
—
—
cases:1.33%
controls:0.34%
cases:6.07%
controls:3.03%
cases:11.68%
controls:8.92%
159
1400
1453
14650
119
550
1494
15510
30
60
1583
16000
—
21
55
1555
15969
85
471
1315
15093
108
1162
817
11866
Influenza virus B RNA [Presence] in Specimen by NAA with probe detection
40982-1 [3038288]
-4.3e-02
8.2e-01
1.1e+00
—
2.0e+00
1.2e+00
5.5e-01
cases:1.43%
controls:1.49%
cases:1.61%
controls:0.72%
cases:0.37%
controls:0.12%
—
—
cases:0.63%
controls:0.09%
cases:2.50%
controls:0.80%
cases:4.86%
controls:2.86%
23
239
1589
15811
26
115
1587
15945
6
20
1607
16040
—
10
14
1566
16010
35
125
1365
15439
45
373
880
12655
Assessment of need for rehabilitation and/or rehabilitation plan
SPAT1220 [2001700321]
6.1e-01
1.2e+00
—
—
—
2.1e+00
1.2e+00
cases:1.55%
controls:0.85%
cases:1.12%
controls:0.34%
—
—
—
—
—
—
cases:1.93%
controls:0.24%
cases:2.27%
controls:0.68%
25
136
1587
15914
18
54
1595
16006
—
—
—
27
38
1373
15526
21
89
904
12939
Natriuretic peptide B [Mass/volume] in Serum or Plasma
30934-4 [3011960]
-2.4e-01
6.8e-01
1.7e+00
—
1.9e+00
8.6e-01
1.5e-01
cases:1.55%
controls:1.96%
cases:1.49%
controls:0.76%
cases:0.50%
controls:0.09%
—
—
cases:0.51%
controls:0.07%
cases:1.36%
controls:0.58%
cases:1.95%
controls:1.68%
25
314
1587
15736
24
122
1589
15938
8
15
1605
16045
—
8
12
1568
16012
19
90
1381
15474
18
219
907
12809
Assessment of need for services (elderly/care support)
SPAT1217 [2001700318]
1.1e-01
1.2e+00
2.1e+00
—
—
2.1e+00
1.1e+00
cases:0.68%
controls:0.61%
cases:1.24%
controls:0.36%
cases:0.31%
controls:0.04%
—
—
—
—
cases:2.93%
controls:0.37%
cases:3.14%
controls:1.11%
11
98
1601
15952
20
58
1593
16002
5
6
1608
16054
—
—
41
58
1359
15506
29
144
896
12884
Esophagoscopy, gastroscopy and duodenoscopy
UJD10 [2001304788]
2.7e-01
8.1e-01
1.5e+00
—
1.7e+00
1.3e+00
5.7e-01
cases:5.71%
controls:4.42%
cases:3.16%
controls:1.43%
cases:0.50%
controls:0.11%
—
—
cases:0.57%
controls:0.11%
cases:4.64%
controls:1.29%
cases:7.35%
controls:4.31%
92
709
1520
15341
51
229
1562
15831
8
17
1605
16043
—
9
17
1567
16007
65
200
1335
15364
68
561
857
12467
Dietary counselling and surveillance
Z71.3 [45552101]
-1.7e-02
6.5e-01
—
—
—
2.9e+00
1.5e+00
cases:0.50%
controls:0.50%
cases:0.31%
controls:0.16%
—
—
—
—
—
—
cases:2.43%
controls:0.13%
cases:1.73%
controls:0.41%
8
81
1604
15969
5
26
1608
16034
—
—
—
34
21
1366
15543
16
53
909
12975
Lactate [Moles/volume] in Arterial blood
2518-9 [3018405]
-4.8e-01
9.9e-01
—
1.0e+50
2.5e+00
1.9e+00
5.4e-01
cases:0.37%
controls:0.60%
cases:0.62%
controls:0.23%
—
—
cases:0.37%
controls:0.00%
cases:0.44%
controls:0.04%
cases:1.50%
controls:0.23%
cases:1.30%
controls:0.76%
6
96
1606
15954
10
37
1603
16023
—
6
0
1607
16060
7
6
1569
16018
21
36
1379
15528
12
99
913
12929
Asthma, unspecified
J45.9 [45562456]
1.5e-01
7.6e-01
1.2e+00
—
1.4e+00
9.4e-01
3.7e-01
cases:3.78%
controls:3.26%
cases:3.29%
controls:1.57%
cases:1.12%
controls:0.33%
—
—
cases:1.14%
controls:0.27%
cases:3.86%
controls:1.55%
cases:5.62%
controls:3.95%
61
523
1551
15527
53
252
1560
15808
18
53
1595
16007
—
18
44
1558
15980
54
241
1346
15323
52
514
873
12514
oxazepam; oral
N05BA04 [21604569]
2.5e-01
5.5e-01
1.0e+00
2.0e+00
1.2e+00
8.8e-01
6.8e-01
cases:5.65%
controls:4.44%
cases:4.34%
controls:2.54%
cases:1.92%
controls:0.69%
cases:0.31%
controls:0.04%
cases:2.22%
controls:0.69%
cases:6.21%
controls:2.67%
cases:9.51%
controls:5.04%
91
713
1521
15337
70
408
1543
15652
31
111
1582
15949
5
7
1608
16053
35
110
1541
15914
87
416
1313
15148
88
656
837
12372
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
9.8e-03
3.7e-01
5.9e-01
2.3e+00
1.0e+00
6.9e-02
-2.0e-01
cases:34.06%
controls:33.84%
cases:33.23%
controls:25.55%
cases:8.68%
controls:5.01%
cases:2.11%
controls:0.21%
cases:11.61%
controls:4.51%
cases:27.86%
controls:26.49%
cases:38.38%
controls:43.24%
549
5431
1063
10619
536
4103
1077
11957
140
804
1473
15256
34
33
1579
16027
183
723
1393
15301
390
4123
1010
11441
355
5633
570
7395
Gas panel - Central venous blood
97535-9 [1616796]
-2.0e-01
7.3e-01
—
1.0e+50
—
2.7e+00
1.6e+00
cases:0.31%
controls:0.38%
cases:0.31%
controls:0.15%
—
—
cases:0.31%
controls:0.00%
—
—
cases:2.43%
controls:0.17%
cases:1.73%
controls:0.35%
5
61
1607
15989
5
24
1608
16036
—
5
0
1608
16060
—
34
26
1366
15538
16
45
909
12983
lorazepam; oral, parenteral, sublingual
N05BA06 [21604571]
3.6e-01
5.9e-01
1.1e+00
—
1.4e+00
1.6e+00
1.4e+00
cases:1.30%
controls:0.92%
cases:0.99%
controls:0.55%
cases:0.62%
controls:0.21%
—
—
cases:0.76%
controls:0.19%
cases:3.00%
controls:0.65%
cases:4.54%
controls:1.21%
21
147
1591
15903
16
89
1597
15971
10
34
1603
16026
—
12
30
1564
15994
42
101
1358
15463
42
158
883
12870
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
-3.0e-02
2.6e-01
6.1e-01
2.7e+00
9.9e-01
7.0e-02
-2.8e-01
cases:26.92%
controls:27.51%
cases:25.79%
controls:21.21%
cases:8.56%
controls:4.84%
cases:4.22%
controls:0.29%
cases:11.42%
controls:4.56%
cases:22.64%
controls:21.44%
cases:28.43%
controls:34.42%
434
4416
1178
11634
416
3407
1197
12653
138
777
1475
15283
68
46
1545
16014
180
731
1396
15293
317
3337
1083
12227
263
4484
662
8544
Other physical therapy
Z50.1 [45600331]
6.3e-01
1.3e+00
—
—
—
2.9e+00
1.4e+00
cases:1.05%
controls:0.57%
cases:0.68%
controls:0.19%
—
—
—
—
—
—
cases:2.43%
controls:0.14%
cases:2.16%
controls:0.53%
17
91
1595
15959
11
31
1602
16029
—
—
—
34
22
1366
15542
20
69
905
12959
acetylcysteine; inhalant, oral
R05CB01 [21603380]
1.7e-01
—
—
—
—
2.8e+00
1.5e+00
cases:0.31%
controls:0.26%
—
—
—
—
—
—
—
—
cases:1.00%
controls:0.06%
cases:1.41%
controls:0.31%
5
42
1607
16008
—
—
—
—
14
10
1386
15554
13
40
912
12988
acetylcysteine
V03AB23 [21605248]
1.7e-01
—
—
—
—
2.8e+00
1.5e+00
cases:0.31%
controls:0.26%
—
—
—
—
—
—
—
—
cases:1.00%
controls:0.06%
cases:1.41%
controls:0.31%
5
42
1607
16008
—
—
—
—
14
10
1386
15554
13
40
912
12988
Counselling/guidance promoting independent living
SPAT1222 [2001700323]
-1.5e-01
7.6e-01
9.2e-01
—
1.1e+00
1.5e+00
9.0e-01
cases:1.67%
controls:1.95%
cases:2.05%
controls:0.97%
cases:0.81%
controls:0.32%
—
—
cases:0.95%
controls:0.32%
cases:4.14%
controls:0.93%
cases:5.73%
controls:2.41%
27
313
1585
15737
33
155
1580
15905
13
52
1600
16008
—
15
52
1561
15972
58
145
1342
15419
53
314
872
12714
Neuropsychological investigation
XA800 [2001300412]
5.6e-01
2.1e+00
—
—
—
2.1e+00
1.2e+00
cases:0.62%
controls:0.36%
cases:0.87%
controls:0.11%
—
—
—
—
—
—
cases:0.93%
controls:0.12%
cases:1.08%
controls:0.32%
10
57
1602
15993
14
17
1599
16043
—
—
—
13
18
1387
15546
10
42
915
12986
Ketones [Presence] in Urine by Test strip
2514-8 [3035350]
4.5e-02
3.5e-01
9.3e-01
2.2e+00
7.5e-01
2.0e-01
-4.5e-02
cases:10.30%
controls:9.89%
cases:7.44%
controls:5.38%
cases:2.23%
controls:0.90%
cases:0.43%
controls:0.05%
cases:1.78%
controls:0.85%
cases:7.14%
controls:5.93%
cases:14.92%
controls:15.51%
166
1587
1446
14463
120
864
1493
15196
36
144
1577
15916
7
8
1606
16052
28
136
1548
15888
100
923
1300
14641
138
2020
787
11008
Cervical spine X-ray examination without contrast
NA1AA [2001306981]
2.2e-01
2.3e+00
—
—
—
1.9e+00
—
cases:0.37%
controls:0.30%
cases:0.43%
controls:0.04%
—
—
—
—
—
—
cases:0.50%
controls:0.08%
—
—
6
48
1606
16002
7
7
1606
16053
—
—
—
7
12
1393
15552
—
Oxygen saturation in Capillary blood
2709-4 [3021901]
—
1.1e+00
—
—
—
2.5e+00
1.7e+00
—
—
cases:0.43%
controls:0.15%
—
—
—
—
—
—
cases:1.64%
controls:0.13%
cases:2.16%
controls:0.42%
—
7
24
1606
16036
—
—
—
23
21
1377
15543
20
55
905
12973
Other and unspecified symptoms and signs involving cognitive functions and awareness
R41.8 [45534452]
7.4e-01
1.2e+00
2.2e+00
1.0e+50
—
3.2e-01
-8.9e-01
cases:1.99%
controls:0.96%
cases:1.67%
controls:0.49%
cases:0.50%
controls:0.06%
cases:0.31%
controls:0.00%
—
—
cases:0.64%
controls:0.47%
cases:0.65%
controls:1.56%
32
154
1580
15896
27
79
1586
15981
8
9
1605
16051
5
0
1608
16060
—
9
73
1391
15491
6
203
919
12825
Influenza virus A RNA [Presence] in Specimen by NAA with probe detection
34487-9 [3044938]
-7.3e-02
7.8e-01
1.3e+00
—
1.6e+00
1.2e+00
5.7e-01
cases:2.05%
controls:2.20%
cases:2.23%
controls:1.04%
cases:0.56%
controls:0.16%
—
—
cases:0.57%
controls:0.12%
cases:3.71%
controls:1.12%
cases:6.81%
controls:3.97%
33
353
1579
15697
36
167
1577
15893
9
25
1604
16035
—
9
19
1567
16005
52
174
1348
15390
63
517
862
12511
Phosphorylated tau 181 [Mass/volume] in Cerebral spinal fluid by Immunoassay
72260-3 [43055225]
1.7e+00
2.5e+00
—
—
—
—
-1.0e+50
cases:0.81%
controls:0.16%
cases:0.37%
controls:0.03%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.12%
13
25
1599
16025
6
5
1607
16055
—
—
—
—
0
15
925
13013
Other specified counselling
Z71.8 [45581061]
1.9e-01
5.0e-01
1.1e+00
—
2.0e+00
1.0e+00
1.6e-01
cases:4.16%
controls:3.48%
cases:3.04%
controls:1.87%
cases:0.99%
controls:0.32%
—
—
cases:1.71%
controls:0.24%
cases:5.29%
controls:1.97%
cases:7.24%
controls:6.25%
67
558
1545
15492
49
300
1564
15760
16
52
1597
16008
—
27
39
1549
15985
74
307
1326
15257
67
814
858
12214
Decompression of lumbar nerve roots
ABC36 [2001300475]
9.4e-01
2.0e+00
—
—
—
1.4e+00
1.2e+00
cases:1.36%
controls:0.54%
cases:0.62%
controls:0.09%
—
—
—
—
—
—
cases:0.36%
controls:0.09%
cases:1.30%
controls:0.40%
22
86
1590
15964
10
14
1603
16046
—
—
—
5
14
1395
15550
12
52
913
12976
Open wound of scalp
S01.0 [45592468]
7.6e-02
1.3e+00
—
—
—
1.8e+00
1.0e+00
cases:0.81%
controls:0.75%
cases:0.99%
controls:0.27%
—
—
—
—
—
—
cases:1.29%
controls:0.22%
cases:2.27%
controls:0.84%
13
120
1599
15930
16
43
1597
16017
—
—
—
18
35
1382
15529
21
110
904
12918
Amyloid beta 42 peptide [Mass/volume] in Cerebral spinal fluid
33203-1 [3042810]
1.6e+00
2.5e+00
—
—
—
—
-1.0e+50
cases:0.74%
controls:0.16%
cases:0.37%
controls:0.03%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.12%
12
25
1600
16025
6
5
1607
16055
—
—
—
—
0
15
925
13013
Tau protein [Mass/volume] in Cerebral spinal fluid
30160-6 [3000242]
1.6e+00
2.5e+00
—
—
—
—
-1.0e+50
cases:0.74%
controls:0.16%
cases:0.37%
controls:0.03%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.12%
12
25
1600
16025
6
5
1607
16055
—
—
—
—
0
15
925
13013
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
1.1e-01
6.4e-01
1.3e+00
—
1.5e+00
6.0e-01
1.4e-01
cases:13.83%
controls:12.58%
cases:11.35%
controls:6.31%
cases:3.10%
controls:0.90%
—
—
cases:3.30%
controls:0.74%
cases:10.21%
controls:5.88%
cases:18.16%
controls:16.23%
223
2019
1389
14031
183
1014
1430
15046
50
145
1563
15915
—
52
118
1524
15906
143
915
1257
14649
168
2115
757
10913
Fractional oxyhemoglobin in Arterial blood
2714-4 [3014007]
-1.5e-01
5.6e-01
1.8e+00
1.0e+50
2.5e+00
1.5e+00
1.5e-01
cases:0.87%
controls:1.01%
cases:0.87%
controls:0.50%
cases:0.31%
controls:0.05%
cases:0.62%
controls:0.00%
cases:0.63%
controls:0.05%
cases:1.79%
controls:0.42%
cases:1.62%
controls:1.40%
14
162
1598
15888
14
80
1599
15980
5
8
1608
16052
10
0
1603
16060
10
8
1566
16016
25
65
1375
15499
15
182
910
12846
Other specified polyneuropathies
G62.8 [45595957]
2.0e+00
—
—
1.0e+50
—
—
2.0e+00
cases:0.50%
controls:0.07%
—
—
—
—
cases:0.37%
controls:0.00%
—
—
—
—
cases:0.86%
controls:0.12%
8
11
1604
16039
—
—
6
0
1607
16060
—
—
8
15
917
13013
tizanidine; oral
M03BX02 [21604116]
1.4e-01
4.6e-01
9.0e-01
—
1.3e+00
8.3e-01
4.9e-01
cases:12.16%
controls:10.76%
cases:5.21%
controls:3.35%
cases:1.30%
controls:0.54%
—
—
cases:1.78%
controls:0.49%
cases:7.36%
controls:3.33%
cases:15.14%
controls:9.81%
196
1727
1416
14323
84
538
1529
15522
21
86
1592
15974
—
28
78
1548
15946
103
519
1297
15045
140
1278
785
11750
combinations of penicillins
J01CR50 [21602867]
—
—
—
—
—
2.1e+00
1.9e+00
—
—
—
—
—
—
—
—
—
—
cases:0.43%
controls:0.05%
cases:1.08%
controls:0.17%
—
—
—
—
—
6
8
1394
15556
10
22
915
13006
Type 2 diabetes mellitus, without complications
E11.9 [45561952]
-2.3e-01
9.8e-02
7.8e-01
3.2e+00
5.8e-01
-8.5e-02
-2.0e-01
cases:4.90%
controls:6.07%
cases:3.47%
controls:3.16%
cases:1.43%
controls:0.66%
cases:1.05%
controls:0.04%
cases:1.08%
controls:0.61%
cases:3.29%
controls:3.57%
cases:6.70%
controls:8.06%
79
975
1533
15075
56
507
1557
15553
23
106
1590
15954
17
7
1596
16053
17
97
1559
15927
46
555
1354
15009
62
1050
863
11978
Ataxia, unspecified
R27.0 [45539329]
4.0e+00
1.0e+50
1.0e+50
1.0e+50
1.0e+50
—
—
cases:1.61%
controls:0.03%
cases:3.16%
controls:0.00%
cases:0.81%
controls:0.00%
cases:0.50%
controls:0.00%
cases:0.63%
controls:0.00%
—
—
—
—
26
5
1586
16045
51
0
1562
16060
13
0
1600
16060
8
0
1605
16060
10
0
1566
16024
—
—
Oxygen [Partial pressure] in Capillary blood
2704-5 [3028626]
—
8.3e-01
—
1.0e+50
—
2.4e+00
1.6e+00
—
—
cases:0.50%
controls:0.22%
—
—
cases:0.31%
controls:0.00%
—
—
cases:2.07%
controls:0.20%
cases:2.49%
controls:0.51%
—
8
35
1605
16025
—
5
0
1608
16060
—
29
31
1371
15533
23
67
902
12961
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
5.5e-02
5.0e-01
4.9e-01
1.8e+00
8.3e-01
3.1e-01
2.1e-01
cases:13.34%
controls:12.71%
cases:12.77%
controls:8.15%
cases:3.60%
controls:2.23%
cases:0.68%
controls:0.11%
cases:4.19%
controls:1.87%
cases:10.43%
controls:7.88%
cases:18.81%
controls:15.77%
215
2040
1397
14010
206
1309
1407
14751
58
358
1555
15702
11
18
1602
16042
66
300
1510
15724
146
1227
1254
14337
174
2055
751
10973
Glucose [Presence] in Urine by Test strip
25428-4 [3009261]
8.1e-02
3.2e-01
9.3e-01
2.2e+00
8.3e-01
2.0e-01
-5.0e-02
cases:10.73%
controls:9.98%
cases:7.25%
controls:5.39%
cases:2.29%
controls:0.92%
cases:0.43%
controls:0.05%
cases:1.90%
controls:0.84%
cases:7.21%
controls:5.96%
cases:14.92%
controls:15.57%
173
1602
1439
14448
117
865
1496
15195
37
147
1576
15913
7
8
1606
16052
30
134
1546
15890
101
928
1299
14636
138
2028
787
11000
Rehabilitation Hospital
283X00000X [38004285]
6.3e-01
—
—
1.0e+50
—
2.3e+00
1.6e+00
cases:0.56%
controls:0.30%
—
—
—
—
cases:0.43%
controls:0.00%
—
—
cases:0.57%
controls:0.06%
cases:1.41%
controls:0.28%
9
48
1603
16002
—
—
7
0
1606
16060
—
8
9
1392
15555
13
36
912
12992
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
2.0e-02
4.0e-01
6.4e-01
2.0e+00
8.3e-01
2.1e-01
4.1e-02
cases:20.04%
controls:19.71%
cases:17.67%
controls:12.52%
cases:4.71%
controls:2.55%
cases:1.05%
controls:0.14%
cases:5.20%
controls:2.34%
cases:14.07%
controls:11.76%
cases:24.86%
controls:24.11%
323
3164
1289
12886
285
2011
1328
14049
76
410
1537
15650
17
22
1596
16038
82
375
1494
15649
197
1830
1203
13734
230
3141
695
9887
pH of Serum or Plasma
2753-2 [3018418]
1.7e-01
9.9e-01
1.3e+00
—
1.6e+00
1.3e-01
4.7e-02
cases:7.01%
controls:5.98%
cases:7.63%
controls:2.99%
cases:2.29%
controls:0.64%
—
—
cases:2.73%
controls:0.54%
cases:3.71%
controls:3.28%
cases:8.65%
controls:8.28%
113
959
1499
15091
123
480
1490
15580
37
103
1576
15957
—
43
87
1533
15937
52
511
1348
15053
80
1079
845
11949
Nitrite [Presence] in Urine by Test strip
5802-4 [3021601]
5.9e-02
3.0e-01
9.5e-01
2.2e+00
7.9e-01
2.1e-01
-5.1e-02
cases:10.17%
controls:9.65%
cases:6.94%
controls:5.25%
cases:2.23%
controls:0.88%
cases:0.43%
controls:0.05%
cases:1.78%
controls:0.81%
cases:7.14%
controls:5.85%
cases:14.70%
controls:15.36%
164
1549
1448
14501
112
843
1501
15217
36
141
1577
15919
7
8
1606
16052
28
130
1548
15894
100
910
1300
14654
136
2001
789
11027
Musculoskeletal disease other
L99 [2002000718]
6.1e-01
—
—
—
—
2.2e+00
1.7e+00
cases:0.31%
controls:0.17%
—
—
—
—
—
—
—
—
cases:0.79%
controls:0.08%
cases:1.19%
controls:0.23%
5
27
1607
16023
—
—
—
—
11
13
1389
15551
11
30
914
12998
Prothrombin time (PT) actual/Normal
5894-1 [3033658]
-4.0e-02
4.7e-01
1.2e+00
—
1.6e+00
6.9e-01
9.4e-02
cases:5.15%
controls:5.35%
cases:4.09%
controls:2.61%
cases:1.49%
controls:0.46%
—
—
cases:1.59%
controls:0.34%
cases:4.43%
controls:2.28%
cases:6.59%
controls:6.04%
83
858
1529
15192
66
419
1547
15641
24
74
1589
15986
—
25
54
1551
15970
62
355
1338
15209
61
787
864
12241
Social worker
Z2446 [2001311559]
1.1e-01
1.3e+00
—
1.0e+50
—
2.4e+00
1.5e+00
cases:0.62%
controls:0.55%
cases:0.50%
controls:0.13%
—
—
cases:0.50%
controls:0.00%
—
—
cases:0.86%
controls:0.08%
cases:1.62%
controls:0.38%
10
89
1602
15961
8
21
1605
16039
—
8
0
1605
16060
—
12
12
1388
15552
15
50
910
12978
General Surgery
2 [38004447]
2.2e-01
5.0e-01
1.1e+00
—
9.4e-01
5.7e-01
5.0e-01
cases:22.02%
controls:18.54%
cases:9.49%
controls:6.00%
cases:2.36%
controls:0.79%
—
—
cases:1.90%
controls:0.76%
cases:9.36%
controls:5.53%
cases:24.86%
controls:16.75%
355
2976
1257
13074
153
964
1460
15096
38
127
1575
15933
—
30
121
1546
15903
131
860
1269
14704
230
2182
695
10846
Teaching
WZC30 [2001310891]
-1.9e-01
2.1e-01
—
1.0e+50
2.2e+00
1.7e+00
5.5e-01
cases:1.43%
controls:1.73%
cases:1.12%
controls:0.90%
—
—
cases:0.37%
controls:0.00%
cases:0.70%
controls:0.08%
cases:3.93%
controls:0.77%
cases:3.89%
controls:2.29%
23
277
1589
15773
18
145
1595
15915
—
6
0
1607
16060
11
13
1565
16011
55
120
1345
15444
36
298
889
12730
Malaise and fatigue
R53 [45553741]
4.6e-01
1.0e+00
2.8e+00
1.0e+50
1.4e+00
6.7e-01
1.2e-01
cases:3.60%
controls:2.29%
cases:2.98%
controls:1.10%
cases:1.30%
controls:0.08%
cases:0.62%
controls:0.00%
cases:0.44%
controls:0.11%
cases:2.07%
controls:1.07%
cases:4.76%
controls:4.26%
58
368
1554
15682
48
177
1565
15883
21
13
1592
16047
10
0
1603
16060
7
17
1569
16007
29
167
1371
15397
44
555
881
12473
Expressive language disorder
F80.1 [45595921]
2.1e+00
3.8e+00
—
1.0e+50
—
—
—
cases:0.31%
controls:0.04%
cases:1.61%
controls:0.04%
—
—
cases:0.31%
controls:0.00%
—
—
—
—
—
—
5
6
1607
16044
26
6
1587
16054
—
5
0
1608
16060
—
—
—
acetazolamide; oral, parenteral
S01EC01 [21603693]
8.5e-01
1.5e+00
—
—
—
2.2e+00
1.6e+00
cases:0.50%
controls:0.21%
cases:0.50%
controls:0.11%
—
—
—
—
—
—
cases:0.71%
controls:0.08%
cases:1.08%
controls:0.21%
8
34
1604
16016
8
18
1605
16042
—
—
—
10
13
1390
15551
10
28
915
13000
Counselling and guidance which enhance independent living
R2130 [2001310196]
9.5e-02
-1.5e-01
—
—
2.0e+00
1.7e+00
8.1e-01
cases:1.05%
controls:0.96%
cases:0.31%
controls:0.36%
—
—
—
—
cases:0.38%
controls:0.05%
cases:1.86%
controls:0.34%
cases:2.16%
controls:0.97%
17
154
1595
15896
5
58
1608
16002
—
—
6
8
1570
16016
26
53
1374
15511
20
127
905
12901
Abdominal X-ray examination without contrast
JN3AA [2001305553]
1.6e-01
—
—
—
—
2.0e+00
1.8e+00
cases:0.37%
controls:0.32%
—
—
—
—
—
—
—
—
cases:0.50%
controls:0.07%
cases:1.62%
controls:0.28%
6
51
1606
15999
—
—
—
—
7
11
1393
15553
15
37
910
12991
Bicarbonate [Moles/volume] in Capillary blood
1961-2 [3015235]
-6.3e-02
9.6e-01
—
1.0e+50
—
2.4e+00
1.3e+00
cases:0.31%
controls:0.33%
cases:0.68%
controls:0.26%
—
—
cases:0.31%
controls:0.00%
—
—
cases:2.64%
controls:0.24%
cases:2.92%
controls:0.81%
5
53
1607
15997
11
42
1602
16018
—
5
0
1608
16060
—
37
38
1363
15526
27
106
898
12922
temazepam; oral
N05CD07 [21604642]
4.6e-01
6.0e-01
1.0e+00
—
5.0e-01
8.4e-01
7.5e-01
cases:5.46%
controls:3.50%
cases:3.91%
controls:2.19%
cases:1.49%
controls:0.53%
—
—
cases:0.89%
controls:0.54%
cases:4.93%
controls:2.20%
cases:7.46%
controls:3.66%
88
562
1524
15488
63
352
1550
15708
24
85
1589
15975
—
14
87
1562
15937
69
342
1331
15222
69
477
856
12551
Influenza virus A and B and SARS-CoV-2 (COVID-19) and Respiratory syncytial virus RNA panel - Respiratory system specimen by NAA with probe detection
95941-1 [36031861]
4.5e-01
1.0e+00
—
—
2.0e+00
1.6e+00
5.5e-01
cases:0.68%
controls:0.44%
cases:0.87%
controls:0.32%
—
—
—
—
cases:0.38%
controls:0.05%
cases:1.57%
controls:0.31%
cases:2.70%
controls:1.58%
11
70
1601
15980
14
51
1599
16009
—
—
6
8
1570
16016
22
48
1378
15516
25
206
900
12822
Epithelial cells [#/volume] in Urine
30383-4 [3000850]
-3.0e-01
5.9e-01
1.1e+00
—
1.3e+00
5.8e-01
1.6e-01
cases:3.16%
controls:4.23%
cases:3.10%
controls:1.75%
cases:0.99%
controls:0.32%
—
—
cases:0.95%
controls:0.26%
cases:3.07%
controls:1.74%
cases:5.62%
controls:4.82%
51
679
1561
15371
50
281
1563
15779
16
51
1597
16009
—
15
41
1561
15983
43
271
1357
15293
52
628
873
12400
macrogol; oral
A06AD15 [21600575]
2.4e-01
5.3e-01
—
—
1.7e+00
1.2e+00
7.2e-01
cases:1.36%
controls:1.07%
cases:0.87%
controls:0.51%
—
—
—
—
cases:0.57%
controls:0.11%
cases:2.00%
controls:0.60%
cases:3.89%
controls:1.94%
22
172
1590
15878
14
82
1599
15978
—
—
9
17
1567
16007
28
93
1372
15471
36
253
889
12775
pH of Specimen
17433-4 [3019225]
2.9e-01
9.6e-01
1.2e+00
—
1.9e+00
7.6e-01
4.3e-01
cases:2.98%
controls:2.26%
cases:2.98%
controls:1.16%
cases:0.62%
controls:0.19%
—
—
cases:1.08%
controls:0.16%
cases:2.07%
controls:0.98%
cases:3.57%
controls:2.34%
48
362
1564
15688
48
187
1565
15873
10
31
1603
16029
—
17
26
1559
15998
29
152
1371
15412
33
305
892
12723
FVC percent change Respiratory system
69982-7 [42868471]
3.6e-01
9.2e-01
—
—
—
1.4e+00
1.3e+00
cases:2.61%
controls:1.84%
cases:1.61%
controls:0.65%
—
—
—
—
—
—
cases:1.57%
controls:0.40%
cases:3.14%
controls:0.88%
42
295
1570
15755
26
104
1587
15956
—
—
—
22
62
1378
15502
29
115
896
12913
Forced vital capacity [Volume] Respiratory system --post bronchodilation
19875-4 [3001668]
3.6e-01
9.2e-01
—
—
—
1.4e+00
1.3e+00
cases:2.61%
controls:1.84%
cases:1.61%
controls:0.65%
—
—
—
—
—
—
cases:1.57%
controls:0.40%
cases:3.14%
controls:0.88%
42
295
1570
15755
26
104
1587
15956
—
—
—
22
62
1378
15502
29
115
896
12913
FEV1 percent change
69983-5 [42868472]
3.6e-01
9.2e-01
—
—
—
1.4e+00
1.3e+00
cases:2.61%
controls:1.84%
cases:1.61%
controls:0.65%
—
—
—
—
—
—
cases:1.57%
controls:0.40%
cases:3.14%
controls:0.88%
42
295
1570
15755
26
104
1587
15956
—
—
—
22
62
1378
15502
29
115
896
12913
FEV1 --post bronchodilation
20155-8 [3023550]
3.6e-01
9.2e-01
—
—
—
1.4e+00
1.3e+00
cases:2.61%
controls:1.84%
cases:1.61%
controls:0.65%
—
—
—
—
—
—
cases:1.57%
controls:0.40%
cases:3.14%
controls:0.88%
42
295
1570
15755
26
104
1587
15956
—
—
—
22
62
1378
15502
29
115
896
12913
FEV1/FVC --post bronchodilation
69970-2 [42868459]
3.6e-01
9.2e-01
—
—
—
1.4e+00
1.3e+00
cases:2.61%
controls:1.84%
cases:1.61%
controls:0.65%
—
—
—
—
—
—
cases:1.57%
controls:0.40%
cases:3.14%
controls:0.88%
42
295
1570
15755
26
104
1587
15956
—
—
—
22
62
1378
15502
29
115
896
12913
Calcium [Moles/volume] in Serum or Plasma
2000-8 [3015377]
9.9e-02
9.0e-01
1.3e+00
—
1.4e+00
2.3e-01
5.6e-02
cases:7.26%
controls:6.62%
cases:7.32%
controls:3.11%
cases:1.80%
controls:0.48%
—
—
cases:1.84%
controls:0.48%
cases:3.57%
controls:2.85%
cases:8.32%
controls:7.91%
117
1062
1495
14988
118
499
1495
15561
29
77
1584
15983
—
29
77
1547
15947
50
444
1350
15120
77
1030
848
11998
Cerebral infarction, unspecified
I63.9 [45596216]
1.3e-02
1.2e+00
2.4e+00
1.0e+50
—
6.3e-01
5.3e-01
cases:1.43%
controls:1.41%
cases:1.55%
controls:0.49%
cases:0.56%
controls:0.05%
cases:0.31%
controls:0.00%
—
—
cases:0.86%
controls:0.46%
cases:3.03%
controls:1.81%
23
226
1589
15824
25
79
1588
15981
9
8
1604
16052
5
0
1608
16060
—
12
71
1388
15493
28
236
897
12792
Chronic laryngitis
J37.0 [45601128]
4.6e-01
1.7e+00
—
—
—
1.9e+00
—
cases:0.43%
controls:0.27%
cases:0.50%
controls:0.09%
—
—
—
—
—
—
cases:0.50%
controls:0.08%
—
—
7
44
1605
16006
8
15
1605
16045
—
—
—
7
12
1393
15552
—
Nonallergic asthma
J45.1 [45557625]
6.9e-01
1.0e+00
—
—
—
1.0e+00
8.1e-01
cases:1.80%
controls:0.91%
cases:1.12%
controls:0.41%
—
—
—
—
—
—
cases:1.00%
controls:0.36%
cases:2.27%
controls:1.02%
29
146
1583
15904
18
66
1595
15994
—
—
—
14
56
1386
15508
21
133
904
12895
Differential panel - Cerebral spinal fluid
29584-0 [3016018]
6.9e-01
3.5e+00
—
—
1.0e+50
—
—
cases:0.43%
controls:0.22%
cases:1.67%
controls:0.05%
—
—
—
—
cases:0.57%
controls:0.00%
—
—
—
—
7
35
1605
16015
27
8
1586
16052
—
—
9
0
1567
16024
—
—
pH of Venous blood
2746-6 [3012544]
-1.9e-01
5.1e-01
1.8e+00
—
1.7e+00
4.7e-01
2.6e-01
cases:1.30%
controls:1.56%
cases:1.55%
controls:0.94%
cases:0.74%
controls:0.12%
—
—
cases:0.63%
controls:0.12%
cases:1.57%
controls:0.99%
cases:3.46%
controls:2.69%
21
251
1591
15799
25
151
1588
15909
12
19
1601
16041
—
10
19
1566
16005
22
154
1378
15410
32
351
893
12677
Speech therapy
Z50.5 [45547321]
—
—
—
—
—
3.5e+00
—
—
—
—
—
—
—
—
—
—
—
cases:1.07%
controls:0.03%
—
—
—
—
—
—
—
15
5
1385
15559
—
Unspecified fall
W19 [45756257]
8.3e-03
8.3e-01
2.3e+00
—
—
1.2e+00
6.0e-01
cases:0.99%
controls:0.98%
cases:0.68%
controls:0.30%
cases:0.50%
controls:0.05%
—
—
—
—
cases:1.07%
controls:0.32%
cases:2.16%
controls:1.20%
16
158
1596
15892
11
48
1602
16012
8
8
1605
16052
—
—
15
50
1385
15514
20
156
905
12872
Tissue transglutaminase IgA Ab [Units/volume] in Serum
31017-7 [3019050]
2.5e-01
1.3e+00
1.5e+00
—
2.2e+00
-2.1e-01
8.2e-02
cases:4.59%
controls:3.61%
cases:4.22%
controls:1.20%
cases:0.37%
controls:0.08%
—
—
cases:0.95%
controls:0.11%
cases:1.00%
controls:1.23%
cases:4.54%
controls:4.20%
74
580
1538
15470
68
193
1545
15867
6
13
1607
16047
—
15
17
1561
16007
14
192
1386
15372
42
547
883
12481
Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture
13317-3 [3019902]
2.1e-01
3.0e-01
1.1e+00
1.0e+50
2.1e+00
1.4e+00
3.5e-01
cases:2.61%
controls:2.12%
cases:1.30%
controls:0.97%
cases:0.43%
controls:0.14%
cases:0.37%
controls:0.00%
cases:0.70%
controls:0.09%
cases:2.64%
controls:0.67%
cases:3.03%
controls:2.15%
42
341
1570
15709
21
155
1592
15905
7
23
1606
16037
6
0
1607
16060
11
14
1565
16010
37
104
1363
15460
28
280
897
12748
Carbon dioxide [Partial pressure] in Venous blood
2021-4 [3021447]
-1.5e-01
4.0e-01
1.8e+00
—
1.6e+00
3.9e-01
2.4e-01
cases:1.24%
controls:1.44%
cases:1.36%
controls:0.92%
cases:0.74%
controls:0.12%
—
—
cases:0.63%
controls:0.12%
cases:1.50%
controls:1.02%
cases:3.35%
controls:2.66%
20
231
1592
15819
22
147
1591
15913
12
19
1601
16041
—
10
20
1566
16004
21
159
1379
15405
31
347
894
12681
Multiple sclerosis
G35 [45571794]
9.4e-01
1.0e+00
1.9e+00
—
1.9e+00
1.9e+00
1.6e+00
cases:0.68%
controls:0.27%
cases:0.62%
controls:0.22%
cases:0.37%
controls:0.06%
—
—
cases:0.38%
controls:0.06%
cases:1.43%
controls:0.22%
cases:1.51%
controls:0.31%
11
43
1601
16007
10
35
1603
16025
6
9
1607
16051
—
6
9
1570
16015
20
35
1380
15529
14
40
911
12988
Leukocyte esterase [Presence] in Urine by Automated test strip
60026-2 [40763086]
5.3e-02
2.7e-01
1.0e+00
2.5e+00
6.7e-01
5.7e-02
5.1e-02
cases:8.75%
controls:8.33%
cases:5.21%
controls:4.01%
cases:1.74%
controls:0.64%
cases:0.43%
controls:0.04%
cases:1.27%
controls:0.66%
cases:4.71%
controls:4.47%
cases:12.00%
controls:11.47%
141
1337
1471
14713
84
644
1529
15416
28
103
1585
15957
7
6
1606
16054
20
105
1556
15919
66
695
1334
14869
111
1494
814
11534
Bacteria identified in Urine by Culture
630-4 [3026008]
7.1e-02
4.1e-01
9.6e-01
—
1.4e+00
6.6e-01
3.9e-01
cases:5.89%
controls:5.51%
cases:3.91%
controls:2.62%
cases:1.30%
controls:0.50%
—
—
cases:1.78%
controls:0.43%
cases:5.29%
controls:2.81%
cases:11.14%
controls:7.85%
95
885
1517
15165
63
420
1550
15640
21
81
1592
15979
—
28
69
1548
15955
74
438
1326
15126
103
1023
822
12005
Base excess in Venous blood by calculation
1927-3 [3002032]
-1.6e-01
5.2e-01
1.8e+00
—
1.6e+00
5.6e-01
2.5e-01
cases:1.24%
controls:1.45%
cases:1.49%
controls:0.89%
cases:0.74%
controls:0.12%
—
—
cases:0.63%
controls:0.12%
cases:1.71%
controls:0.98%
cases:3.35%
controls:2.63%
20
233
1592
15817
24
143
1589
15917
12
20
1601
16040
—
10
20
1566
16004
24
153
1376
15411
31
342
894
12686
Respiratory and circulatory monitoring
WX700 [2001310817]
1.4e-02
3.9e-01
1.2e+00
—
1.8e+00
1.0e+00
6.2e-01
cases:2.42%
controls:2.39%
cases:0.93%
controls:0.63%
cases:0.31%
controls:0.09%
—
—
cases:0.44%
controls:0.07%
cases:1.79%
controls:0.66%
cases:3.89%
controls:2.14%
39
383
1573
15667
15
101
1598
15959
5
15
1608
16045
—
7
12
1569
16012
25
102
1375
15462
36
279
889
12749
Albumin [Presence] in Urine by Test strip
50949-7 [3029937]
-5.2e-02
2.5e-01
9.2e-01
2.5e+00
8.3e-01
2.7e-01
4.6e-02
cases:5.83%
controls:6.12%
cases:3.97%
controls:3.11%
cases:1.24%
controls:0.50%
cases:0.37%
controls:0.03%
cases:1.08%
controls:0.47%
cases:4.14%
controls:3.18%
cases:8.54%
controls:8.19%
94
983
1518
15067
64
499
1549
15561
20
80
1593
15980
6
5
1607
16055
17
76
1559
15948
58
495
1342
15069
79
1067
846
11961
Exposure to unspecified factor
X59 [45756412]
-3.5e-02
5.3e-01
—
—
2.3e+00
1.1e+00
2.9e-01
cases:2.05%
controls:2.12%
cases:0.93%
controls:0.55%
—
—
—
—
cases:0.32%
controls:0.03%
cases:1.50%
controls:0.52%
cases:2.81%
controls:2.12%
33
340
1579
15710
15
88
1598
15972
—
—
5
5
1571
16019
21
81
1379
15483
26
276
899
12752

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
117
88
14.21
125.59
1.1
1.1
37.19
42.51
mg/l
0.43
99
74
115
85
14.44
124.68
1.1
1.1
270.11
292.82
mg/l
0.37
103
73
209
371
6.29
114.91
1.5
1.4
556.36
579.62
mg/l
0.09
202
348
109
97
11.94
105.38
1.1
1.1
0.09
4.93
nmol/l
1.54
13
17
183
330
6.10
98.64
1.5
1.4
3.76
3.79
mmol/l
0.08
172
310
317
915
4.03
96.92
2.6
2.5
17.93
19.50
au/ml
0.13
19
74
295
824
4.12
94.25
1.4
1.3
49.67
57.68
au/ml
0.22
11
64
87
67
13.63
91.84
1.2
1.1
0.51
0.51
ratio
0.03
53
41
173
317
5.96
91.57
1.6
1.6
531.45
836.65
e6/l
0.25
137
249
172
314
5.98
91.39
1.6
1.5
6.19
58.69
e6/l
1.27
128
239
160
295
5.89
84.00
1.6
1.5
—
—
—
0
0
58
27
22.21
78.30
1.1
1.1
—
—
—
0
0
865
4896
2.57
78.04
2.7
2.2
248.90
225.52
u/l
0.36
831
4630
70
69
10.54
62.91
1.1
1.5
5.49
8.40
u/l
0.60
59
55
290
1194
2.72
47.24
2.1
2.7
—
—
—
0
0
288
1203
2.68
45.48
5.1
4.6
5.60
5.15
kpa
11.69
283
1155
328
1472
2.52
44.64
2.3
3.0
67.74
66.35
g/l
3.36
308
1350
280
1177
2.65
43.55
5.0
4.6
7.41
7.41
ph
0.19
246
987
80
155
5.37
39.50
2.0
1.6
—
—
—
0
0
186
709
2.82
34.64
1.6
2.6
3.48
3.67
g/l
1.05
174
648
186
710
2.82
34.54
1.6
2.6
6.97
7.36
g/l
2.78
175
648
186
710
2.82
34.54
1.6
2.6
4.24
4.17
g/l
0.60
175
648
178
664
2.88
34.50
1.6
2.6
2.50
2.95
g/l
8.97
167
602
72
151
4.94
32.47
2.3
1.6
—
—
—
0
0
43
58
7.58
30.20
1.4
1.3
134.74
110.24
nmol/l
0.32
31
40
157
624
2.67
26.81
1.4
2.7
9.89
10.63
g/l
1.23
144
558
1189
13760
0.54
26.67
5.2
6.1
2.71
2.61
mmol/l
3.39
1064
12700
1151
13428
0.55
26.17
4.7
5.2
1.46
1.43
mmol/l
1.33
1039
12359
1162
13516
0.55
26.04
4.7
5.3
4.61
4.51
mmol/l
2.87
1046
12539
112
379
3.09
25.70
4.8
4.1
—
—
—
0
0
378
5940
0.53
25.26
2.0
2.0
1.38
1.34
mmol/l
0.29
321
4934
152
616
2.61
24.93
1.7
2.1
763.92
521.71
ug/l
0.19
144
584
1131
13158
0.58
23.23
6.6
6.9
39.61
39.88
mmol/mol
0.42
1035
12222
340
1999
1.88
21.77
5.8
7.8
5.68
5.11
kpa
8.70
327
1928
339
2000
1.87
21.44
5.7
7.8
11.08
11.91
kpa
3.21
324
1931
179
851
2.23
20.53
5.4
4.9
—
—
—
0
0
1114
12882
0.61
19.87
4.1
4.5
1.30
1.29
mmol/l
0.14
999
11742
332
1990
1.83
19.81
5.8
7.7
3.07
0.91
mmol/l
16.48
284
1638
332
1996
1.83
19.60
5.9
7.9
7.41
7.41
ph
0.14
223
1131
46
102
4.61
19.44
2.0
2.6
17.43
16.15
%
1.57
46
102
1175
13393
0.60
19.38
5.0
5.4
5.96
6.04
mmol/l
1.26
1067
12182
217
1189
1.95
16.93
2.3
3.2
10.81
10.76
g/l
0.05
194
1104
33
62
5.41
16.87
1.1
1.0
14.82
247.99
ng/l
—
6
17
881
7016
1.53
16.29
4.6
5.4
35.82
35.15
g/l
3.05
831
6579
196
1056
1.97
16.03
5.9
7.3
26.65
24.51
mmol/l
7.14
188
1014
21
12
17.70
13.84
1.0
1.0
—
—
—
0
0
134
669
2.09
13.50
5.2
5.1
25.83
24.91
mmol/l
3.26
128
627
281
1791
1.68
13.09
6.1
8.1
94.41
95.28
%
1.08
272
1742
1377
14853
0.61
13.02
29.5
27.5
6.89
6.82
e9/l
0.34
1338
14477
1378
14852
0.61
12.77
29.8
27.6
133.50
134.49
g/l
1.73
1363
14667
1378
14850
0.61
12.72
29.5
27.4
4.42
4.46
e12/l
2.00
1339
14477
1378
14850
0.61
12.72
29.4
27.3
30.37
30.41
pg
0.43
1361
14663
1378
14850
0.61
12.72
30.2
28.0
39.79
40.13
%
1.42
1362
14655
1378
14847
0.61
12.64
29.4
27.4
91.42
91.42
fl
0.01
1361
14662
1378
14846
0.62
12.61
29.5
27.4
250.68
244.12
e9/l
3.37
1346
14529
350
4902
0.64
12.19
3.0
3.4
—
—
—
0
0
390
5246
0.67
10.86
3.7
3.5
83.81
47.70
mg/l
0.80
254
3451
21
22
9.65
10.75
1.1
1.0
—
—
—
0
0
99
487
2.10
10.40
5.2
6.9
1.23
1.37
mmol/l
0.38
86
433
1341
14441
0.66
10.38
13.0
12.9
27.34
26.21
u/l
1.23
1299
14012
938
7962
1.40
10.24
7.6
7.8
1.22
1.21
mmol/l
3.75
818
6866
50
183
2.78
10.08
1.4
1.1
—
—
—
0
0
406
5352
0.68
9.95
4.6
4.2
13.92
8.54
mg/mmol
0.81
261
3411
1367
14631
0.66
9.67
25.5
23.8
71.57
81.54
umol/l
14.49
1351
14441
378
2752
1.48
9.63
3.0
3.6
0.82
0.82
mmol/l
0.06
356
2599
74
336
2.26
9.51
5.8
4.9
3.44
2.69
mmol/l
1.28
66
227
419
5451
0.69
9.42
4.3
3.5
7.23
7.56
mmol/l
0.87
350
4602
19
37
5.18
9.37
1.0
1.5
—
14.17
%
—
0
6
388
2863
1.46
9.18
1.7
1.8
1124.16
1155.86
nmol/l
0.28
313
2162
84
408
2.11
9.14
2.8
2.2
137.94
128.92
g/l
2.97
72
328
885
10141
0.73
8.86
3.8
4.4
—
4209.37
—
0
24
274
1913
1.52
8.47
1.4
1.4
641.25
463.11
titre
0.76
64
424
255
3575
0.66
8.29
2.8
3.4
0.79
0.78
ug/l
0.08
182
2418
28
82
3.46
8.23
2.2
2.0
28.02
98.67
umol/l
—
5
7
458
5708
0.73
7.49
2.2
2.3
—
—
—
0
0
1313
14030
0.71
7.26
17.7
16.3
—
—
—
0
0
421
3303
1.37
6.75
1.6
1.8
54496372.08
27033395.98
pmol/l
0.31
367
2730
35
826
0.41
6.68
1.8
1.8
3.46
3.46
mmol/l
0.00
28
613
218
1533
1.48
6.45
6.4
7.5
1.18
1.39
mmol/l
3.83
207
1501
93
531
1.80
6.39
1.3
1.2
7.33
0.99
u/ml
—
6
34
31
114
2.75
6.29
1.1
1.0
292.00
307.70
ng/l
0.12
23
70
823
7167
1.29
6.13
7.4
7.1
1.21
1.21
mmol/l
1.69
759
6622
561
4661
1.30
5.94
1.7
1.8
20.63
20.02
nmol/l
0.45
493
3935
1030
11284
0.78
5.77
23.7
22.6
13.73
13.76
%
0.33
1022
11121
30
114
2.66
5.75
1.1
1.0
875.00
614.91
ng/l
2.40
17
69
1351
14265
0.74
5.61
24.1
22.0
3.95
4.00
mmol/l
8.96
1326
13967
1350
14245
0.74
5.45
24.1
21.8
139.61
139.65
mmol/l
0.23
1331
13969
856
7565
1.27
5.39
6.0
6.5
0.04
0.04
e9/l
0.98
746
6446
13
21
6.23
5.38
1.1
1.3
54.15
66.90
ug/l
0.98
13
21
867
7686
1.26
5.27
6.1
6.6
2.01
1.89
e9/l
0.28
760
6733
218
1594
1.42
5.25
2.3
2.4
0.21
0.21
g/l
0.60
209
1478
795
6980
1.26
5.23
2.2
2.2
93.47
94.82
pmol/l
0.33
449
3755
852
7544
1.26
5.21
6.0
6.5
0.58
0.60
e9/l
2.37
743
6426
1030
11204
0.79
4.93
25.7
23.8
331.79
332.16
g/l
0.61
1019
11130
558
4727
1.27
4.88
3.8
3.4
—
—
—
0
0
67
1134
0.57
4.82
1.9
2.1
3.50
3.51
ratio
0.03
60
925
44
219
2.04
4.64
1.0
1.1
18.65
78.43
iu/ml
0.75
17
35
150
1047
1.47
4.63
6.7
9.2
25.87
24.21
mmol/l
6.52
144
1026
869
7795
1.24
4.44
6.2
6.8
0.18
0.19
e9/l
2.58
768
6771
836
7487
1.23
4.28
15.0
17.6
1.27
1.31
inr
1.14
695
6282
516
5995
0.80
4.25
5.0
5.8
8.48
3.66
ug/l
0.88
455
5393
18
62
2.92
4.17
2.4
1.7
42.12
39.55
g/l
1.17
18
62
227
1742
1.35
4.08
4.8
4.2
3.21
1.85
mmol/l
5.55
209
1474
15
47
3.21
4.06
1.0
1.1
—
—
—
0
0
15
47
3.21
4.06
1.0
1.1
—
—
—
0
0
15
47
3.21
4.06
1.0
1.1
—
—
—
0
0
552
4785
1.23
3.73
4.1
4.4
7.40
7.40
ph
0.16
390
3484
543
4701
1.23
3.71
4.5
4.6
—
—
—
0
0
782
7022
1.21
3.70
6.0
6.8
0.65
0.67
%
0.48
748
6547
16
402
0.39
3.67
1.3
1.2
—
—
—
0
0
782
7027
1.21
3.66
6.1
6.8
8.65
9.06
%
4.50
746
6559
231
1807
1.32
3.65
4.6
4.3
7.37
7.38
ph
0.52
132
1067
64
391
1.66
3.59
1.8
1.7
—
—
—
0
0
230
1805
1.32
3.56
4.7
4.2
6.20
5.82
kpa
4.31
224
1751
22
477
0.45
3.51
1.2
1.7
—
—
—
0
0
64
396
1.64
3.43
2.8
3.1
31.31
36.61
umol/l
0.84
58
348
13
347
0.37
3.43
1.0
1.2
1.42
1.54
g/l
0.91
13
347
778
7017
1.20
3.43
6.0
6.7
2.60
2.84
%
2.46
743
6544
141
1039
1.39
3.29
4.8
4.6
25.66
24.14
mmol/l
5.98
141
1024
1317
13761
0.81
3.25
21.0
18.2
26.46
26.31
mg/l
0.05
1156
11515
37
199
1.88
3.22
1.3
2.1
—
9.60
—
0
5
343
4060
0.81
3.18
3.1
3.0
348.02
354.19
umol/l
0.46
302
3552
194
1516
1.32
3.11
4.4
3.7
4.56
4.52
kpa
0.10
188
1469
786
7140
1.19
3.09
6.0
6.7
26.29
26.79
%
0.60
754
6746
85
578
1.50
3.07
2.0
1.8
9.16
7.45
iu/ml
0.23
17
133
53
323
1.66
3.05
1.5
1.4
57.76
60.98
mmol/l
0.25
42
263
153
1992
0.75
3.04
1.3
1.3
—
—
—
0
0
584
5174
1.20
3.03
5.5
6.6
—
—
—
0
0
61
387
1.60
3.00
1.3
1.2
2.63
2.47
u/ml
—
8
34
475
5408
0.83
2.94
4.0
3.9
—
0.71
—
0
21
130
967
1.37
2.90
9.2
10.6
17.12
15.87
%
6.80
124
936
766
6994
1.17
2.72
5.9
6.6
58.76
57.87
%
1.22
743
6660
969
9018
1.17
2.71
5.8
5.5
6.65
6.79
mmol/l
1.45
929
8626
362
3095
1.22
2.71
1.4
1.3
1.37
1.64
u/ml
0.18
93
810
188
2341
0.78
2.69
1.3
1.3
4.34
12.56
u/ml
3.26
74
851
64
938
0.67
2.57
1.2
1.3
—
—
—
0
0
105
774
1.38
2.51
4.4
5.6
1.57
1.58
%
0.03
97
735
43
669
0.63
2.32
1.2
1.3
—
—
—
0
0
42
652
0.64
2.25
3.0
3.4
4392.48
6342.16
u/ml
0.13
36
562
105
791
1.35
2.22
4.0
3.4
25.88
25.19
mmol/l
0.96
98
762
268
2269
1.22
2.21
6.0
6.3
1.04
1.05
mmol/l
0.20
252
2099
26
144
1.82
2.15
1.2
1.2
—
—
—
0
0
234
1963
1.22
2.12
1.6
1.7
—
—
—
0
0
79
574
1.39
2.10
4.0
3.5
290.18
282.46
mg/l
0.04
33
242
184
1509
1.25
2.06
9.0
8.9
—
—
—
0
0
217
1813
1.23
2.05
2.0
1.8
—
—
—
0
0
27
154
1.77
2.04
2.1
2.1
—
—
—
0
0
21
111
1.90
2.01
1.3
1.5
1.51
1.04
promille
0.53
16
88
1227
12757
0.86
2.00
5.2
5.3
1.89
1.98
mu/l
1.68
1144
11677
93
706
1.34
1.90
4.4
5.9
0.89
0.87
%
0.15
85
670
142
1748
0.80
1.88
3.3
4.3
10.79
19.36
ug/l
0.62
115
1450
32
197
1.64
1.87
2.1
2.5
1.27
1.45
g/24h
0.11
15
116
899
8453
1.14
1.86
7.9
10.1
4.20
4.21
e9/l
0.04
780
7326
29
175
1.67
1.83
1.2
1.2
—
—
—
0
0
17
87
1.96
1.80
2.7
2.9
—
—
—
0
0
13
62
2.11
1.65
1.2
1.1
1704.54
1597.87
miu/ml
0.08
13
62
172
1438
1.22
1.65
2.0
2.2
384.49
375.90
nmol/l
0.25
154
1342
20
112
1.80
1.64
1.8
2.4
8.48
8.03
mmol/l
0.14
20
112
111
1378
0.79
1.60
2.1
2.4
13.72
13.27
nmol/l
0.21
96
1234
6
20
3.01
1.58
1.2
3.2
—
—
—
0
0
29
183
1.59
1.57
1.6
1.5
273.86
277.73
mosm/kgh2o
0.31
22
135
360
4011
0.87
1.57
3.4
3.2
0.17
0.02
0.40
12
103
178
1502
1.21
1.56
4.7
4.5
7.37
7.36
ph
0.48
137
1085
581
5362
1.13
1.56
2.7
3.5
2.37
2.35
mmol/l
1.55
516
4827
0
42
0.00
1.52
0.0
1.3
—
28.12
—
0
42
18
308
0.58
1.52
1.1
1.3
—
—
—
0
0
11
51
2.16
1.50
1.4
1.4
—
—
—
0
0
617
6628
0.89
1.50
3.1
3.1
158.73
144.12
ug/l
0.38
564
6121
140
1677
0.82
1.47
1.3
1.4
—
—
—
0
0
8
170
0.47
1.46
1.0
1.1
—
—
—
0
0
40
279
1.44
1.41
1.2
1.4
—
9.50
—
0
6
29
189
1.54
1.40
1.3
1.6
19.97
30.36
ng/l
0.90
29
189
0
38
0.00
1.34
0.0
7.8
—
5.09
—
0
38
132
1104
1.21
1.30
1.2
1.2
—
—
—
0
0
11
206
0.53
1.30
1.0
1.3
—
—
—
0
0
724
7654
0.91
1.24
4.6
4.0
0.00
0.00
estimate
-0.00
158
1638
42
572
0.73
1.24
1.1
1.1
—
—
—
0
0
93
755
1.25
1.23
1.3
1.6
—
—
—
0
0
74
586
1.27
1.20
2.5
1.7
0.42
0.33
mg/l
0.45
33
273
21
132
1.60
1.20
1.1
1.1
—
—
—
0
0
526
4891
1.11
1.20
3.7
3.4
33.98
37.97
u/l
0.49
505
4622
72
572
1.27
1.15
1.2
1.2
—
—
—
0
0
18
284
0.63
1.15
1.6
1.7
—
—
—
0
0
737
7761
0.91
1.14
4.7
4.1
0.00
2.95
estimate
1.07
158
1669
7
30
2.34
1.12
1.7
1.1
—
—
—
0
0
5
21
2.38
1.09
2.6
3.3
36.00
43.52
%
—
5
21
5
21
2.38
1.09
5.2
6.6
6.00
8.71
%
—
5
21
83
1012
0.81
1.09
1.3
1.4
—
—
—
0
0
342
3123
1.12
1.08
4.7
5.0
—
—
—
0
0
10
52
1.93
1.06
1.2
1.1
1.57
10.77
u/ml
—
5
9
30
418
0.71
1.05
2.2
1.6
13608.64
16377.06
e6/l
0.14
22
296
17
106
1.61
1.03
1.8
1.8
—
—
—
0
0
7
34
2.06
1.03
1.0
1.4
—
183.00
—
0
6
744
7801
0.92
1.01
4.7
4.1
0.03
0.21
estimate
0.44
150
1556
31
222
1.40
1.01
4.9
5.6
368.86
353.50
umol/l
0.21
25
202
127
1475
0.85
1.00
3.2
2.5
32.46
71.86
u/l
0.63
106
1233
12
201
0.59
1.00
1.2
1.1
—
—
—
0
0
12
200
0.60
0.98
1.2
1.1
—
—
—
0
0
0
29
0.00
0.97
0.0
1.1
—
—
—
0
0
7
36
1.95
0.97
1.7
1.6
—
—
—
0
0
304
2780
1.11
0.95
1.4
1.5
2.38
2.58
g/l
0.93
191
1662
999
9647
1.09
0.94
5.9
5.0
2899.06
1631.23
e6/l
0.27
18
151
19
125
1.53
0.94
2.3
2.3
568.43
657.68
ml
0.51
14
81
21
300
0.70
0.88
1.1
1.3
276.56
212.29
miu/ml
—
9
125
7
130
0.54
0.88
2.3
2.5
—
—
—
0
0
34
256
1.33
0.85
1.8
1.8
4.89
4.70
mmol/24h
0.11
28
227
487
5158
0.92
0.81
2.9
3.3
1347.69
1544.85
ng/l
0.36
408
4461
28
373
0.75
0.79
2.6
3.4
398.33
1061.17
u/ml
0.42
28
353
8
48
1.67
0.78
4.0
3.9
—
—
—
0
0
13
199
0.65
0.78
1.2
1.4
—
—
—
0
0
6
34
1.77
0.76
1.3
1.2
—
—
—
0
0
166
1846
0.89
0.75
1.5
1.5
—
—
—
0
0
425
4510
0.92
0.74
5.9
6.6
—
—
—
0
0
17
116
1.47
0.74
1.1
1.1
103.12
104.47
pmol/l
0.05
17
116
73
616
1.19
0.74
3.1
3.8
34.18
66.21
mg/l
0.99
61
529
143
1273
1.13
0.73
3.0
4.0
1.22
1.22
mmol/l
0.40
116
1098
9
55
1.64
0.73
2.2
1.7
—
—
—
0
0
161
1790
0.89
0.73
3.3
3.2
7.74
8.17
umol/l
0.12
138
1612
7
39
1.80
0.72
1.3
1.5
—
—
—
0
0
10
60
1.67
0.72
3.0
2.3
9.40
10.91
%
—
10
54
32
410
0.78
0.70
1.0
1.1
—
—
—
0
0
9
142
0.63
0.69
1.0
1.2
—
—
—
0
0
31
239
1.30
0.69
2.7
2.9
—
—
—
0
0
19
262
0.72
0.69
5.6
4.1
2.84
1.47
%
0.52
19
244
118
1330
0.88
0.68
1.3
1.4
—
—
—
0
0
5
92
0.54
0.67
1.6
3.6
4.00
20.54
umol/l
—
5
67
152
1371
1.12
0.65
3.2
2.5
1.41
0.46
e6/l
0.47
146
1311
72
616
1.18
0.65
3.1
3.8
44.69
58.82
mg/l
0.66
61
528
122
1366
0.88
0.64
1.7
1.5
—
—
—
0
0
30
381
0.78
0.63
4.0
3.5
0.84
0.82
nmol/l
0.11
25
312
382
4042
0.93
0.62
3.9
3.6
0.02
0.04
estimate
0.52
127
1282
77
887
0.86
0.61
1.2
1.3
376.87
220.97
u/ml
0.68
70
812
8
51
1.57
0.60
2.4
2.4
—
—
—
0
0
0
21
0.00
0.60
0.0
1.0
—
52.24
—
0
21
8
52
1.54
0.59
1.3
1.9
17.13
31.85
%
—
8
52
102
1146
0.88
0.58
3.2
2.8
6.12
6.06
ph
0.34
82
803
20
149
1.35
0.57
4.5
2.6
—
—
—
0
0
594
6175
0.94
0.57
4.1
3.6
6.38
6.24
ph
2.32
332
3430
83
729
1.15
0.56
2.3
2.1
0.00
1.21
estimate
0.50
17
208
10
65
1.54
0.55
1.1
1.2
—
—
—
0
0
155
1694
0.91
0.55
2.4
2.4
140.01
134.61
ug/g
0.09
113
1360
6
38
1.58
0.54
1.0
1.1
—
—
—
0
0
25
317
0.79
0.54
4.0
1.9
—
—
—
0
0
84
950
0.88
0.54
1.5
1.4
—
—
—
0
0
30
240
1.25
0.54
2.4
2.7
—
—
—
0
0
342
3236
1.07
0.53
2.7
3.1
2.46
2.46
mmol/l
0.41
302
2890
148
1353
1.10
0.52
2.6
3.4
161.32
226.42
ng/l
1.25
142
1257
17
126
1.35
0.51
1.1
1.2
—
—
—
0
0
829
8066
1.05
0.51
6.1
6.9
11.56
12.15
umol/l
0.53
794
7706
61
700
0.87
0.49
2.8
2.7
—
—
—
0
0
10
144
0.69
0.49
1.1
1.2
—
—
—
0
0
123
1349
0.90
0.48
4.3
4.3
1.34
0.69
%
0.54
34
439
464
4832
0.95
0.47
3.1
2.7
53.74
77.99
u/l
0.84
435
4475
156
1687
0.92
0.46
1.6
1.6
—
—
—
0
0
197
1838
1.08
0.46
3.3
3.4
5.13
4.95
e9/l
0.10
165
1584
28
342
0.82
0.46
3.6
3.1
59.11
58.75
%
0.05
28
342
558
5773
0.95
0.44
5.0
4.3
160.86
108.61
e6/l
0.45
421
4197
31
256
1.21
0.44
2.5
2.1
0.84
0.89
%
0.27
25
189
237
2513
0.93
0.43
1.3
1.3
30.93
32.15
iu/ml
0.05
57
788
8
56
1.43
0.42
3.5
2.7
0.61
0.60
mmol/l
—
8
56
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
0
16
0.00
0.41
0.0
1.4
—
7.30
—
0
9
83
748
1.12
0.41
2.2
2.0
0.53
1.94
ug/l
2.62
74
667
8
60
1.33
0.40
1.6
1.1
98.38
176.16
iu/ml
—
8
60
680
6617
1.05
0.40
2.6
2.5
77.98
77.78
nmol/l
0.06
606
5908
171
1828
0.93
0.40
4.4
5.2
32.04
32.58
%
0.28
113
1183
108
1177
0.91
0.39
4.5
4.1
—
—
—
0
0
7
102
0.69
0.39
1.4
1.5
—
—
—
0
0
7
105
0.67
0.39
1.4
1.6
—
—
—
0
0
49
430
1.14
0.37
1.1
1.2
—
9.91
—
0
8
5
37
1.35
0.37
2.8
1.8
85.40
88.70
nmol/24h
—
5
37
376
3909
0.95
0.37
1.3
1.4
—
—
—
0
0
65
724
0.89
0.37
1.4
1.3
—
—
—
0
0
104
957
1.09
0.36
1.9
1.9
1.80
1.42
g/l
0.32
92
884
70
631
1.11
0.36
1.0
1.1
—
142.87
—
0
16
71
785
0.90
0.35
3.8
3.7
1.02
1.02
ratio
0.15
66
725
559
5752
0.96
0.35
4.7
4.0
0.03
0.02
estimate
0.07
136
1363
357
3432
1.05
0.35
4.8
4.2
1.02
1.02
kg/l
0.15
248
2324
9
122
0.74
0.35
2.3
1.6
—
—
—
0
0
50
442
1.14
0.35
7.9
11.1
—
—
—
0
0
14
177
0.79
0.33
1.1
1.3
—
—
—
0
0
402
3883
1.05
0.33
5.0
4.5
88.01
86.40
%
0.75
394
3805
6
89
0.67
0.33
1.3
1.2
—
—
—
0
0
76
831
0.91
0.32
1.7
1.8
1.54
1.52
g/l
0.06
69
730
14
176
0.79
0.32
1.2
1.1
1.03
2.16
u/ml
—
7
94
633
6480
0.96
0.31
11.8
12.4
0.00
0.00
e9/l
1.77
508
5256
7
97
0.72
0.31
1.1
1.2
9.53
9.28
mmol/l
—
7
92
7
100
0.70
0.30
3.6
2.7
49.86
38.57
%
—
7
55
8
109
0.73
0.29
1.4
2.6
12.50
19.16
nmol/l
—
8
99
19
227
0.84
0.28
1.1
1.1
1.59
1.52
g/l
0.49
19
207
447
4346
1.04
0.28
4.9
4.1
0.00
0.00
estimate
0.96
142
1492
5
71
0.70
0.26
1.4
1.2
122.74
415.73
u/l
—
5
63
32
282
1.14
0.25
1.5
1.2
—
—
—
0
0
61
560
1.09
0.25
1.8
2.6
20.67
21.35
s
0.40
52
513
23
266
0.86
0.25
1.5
1.5
144.33
143.05
au/ml
—
9
82
17
142
1.20
0.24
5.5
1.8
2.19
4.68
mg/l
5.86
17
137
37
413
0.89
0.24
1.2
1.3
—
—
—
0
0
221
2296
0.96
0.23
1.9
2.1
—
—
—
0
0
15
179
0.84
0.23
1.3
1.2
—
—
—
0
0
17
200
0.85
0.22
1.1
1.4
—
—
—
0
0
60
554
1.09
0.22
2.9
3.7
1.67
3.60
ratio
1.16
32
330
28
316
0.88
0.22
3.6
2.0
—
—
—
0
0
7
93
0.75
0.22
1.4
1.9
59.26
114.90
ng/l
—
7
93
5
40
1.25
0.22
1.4
3.1
4.20
5.47
ug/l
—
5
40
483
4938
0.97
0.22
2.4
2.6
—
—
—
0
0
37
410
0.90
0.22
1.5
1.2
—
—
—
0
0
5
41
1.22
0.22
1.0
1.0
—
—
—
0
0
0
11
0.00
0.21
0.0
1.1
—
0.12
—
0
6
0
10
0.00
0.21
0.0
1.3
—
—
—
0
0
51
469
1.09
0.21
1.5
1.6
16.24
17.84
u/ml
—
7
94
77
721
1.07
0.21
2.1
2.0
—
—
—
0
0
13
108
1.21
0.20
1.2
1.3
—
—
—
0
0
38
417
0.91
0.20
1.4
1.4
42.01
27.41
iu/l
1.23
33
342
138
1442
0.95
0.19
1.6
1.6
—
—
—
0
0
41
376
1.09
0.18
1.1
1.2
—
—
—
0
0
18
156
1.16
0.18
1.1
1.2
—
—
—
0
0
54
503
1.08
0.18
7.0
5.0
1.60
1.64
mg/l
0.11
54
454
131
1256
1.05
0.17
4.7
4.2
90.07
95.75
ng/l
0.30
118
1088
18
157
1.15
0.17
1.3
1.2
1.26
1.45
nmol/l
0.37
13
140
905
9143
0.98
0.16
3.9
3.5
45.65
54.25
u/l
1.58
851
8530
23
256
0.90
0.16
1.4
1.5
117.04
295.48
pmol/l
1.22
23
251
29
318
0.91
0.16
3.5
2.0
—
—
—
0
0
30
328
0.91
0.15
1.9
1.9
5.55
21.83
iu/l
0.45
13
132
20
178
1.13
0.15
1.7
2.4
—
—
—
0
0
320
3133
1.03
0.15
3.6
3.1
511.25
538.03
mosm/kgh2o
1.51
280
2756
207
2127
0.97
0.14
1.3
1.3
—
—
—
0
0
29
316
0.92
0.14
3.5
2.0
—
—
—
0
0
16
181
0.88
0.14
1.1
1.2
—
—
—
0
0
22
243
0.90
0.14
1.1
1.1
—
—
—
0
0
257
2628
0.97
0.13
3.9
3.4
2.70
1.94
e6/l
0.44
148
1354
37
344
1.08
0.13
1.3
1.4
10.89
8.69
u/l
0.47
29
265
35
376
0.93
0.13
2.8
2.4
89.94
103.01
ug/min
0.07
18
226
682
6894
0.98
0.13
2.6
2.9
—
—
estimate
—
0
0
261
2555
1.03
0.13
2.5
2.3
29.58
29.81
s
0.32
253
2478
1056
10630
0.98
0.12
4.1
4.2
15.19
14.93
pmol/l
2.66
980
9654
131
1351
0.97
0.12
4.8
4.8
0.06
0.13
%
0.63
33
370
15
133
1.13
0.12
1.3
1.4
11.47
13.66
u/l
0.91
15
126
85
817
1.04
0.12
2.6
2.4
—
—
—
0
0
13
147
0.88
0.11
2.2
2.2
—
—
—
0
0
14
157
0.89
0.11
1.1
1.1
3.12
4.23
u/ml
—
9
81
19
208
0.91
0.10
1.2
1.4
15013.57
105872.36
e6/l
1.72
14
117
284
2793
1.02
0.10
2.6
2.7
13.21
12.52
umol/l
0.77
257
2607
201
2051
0.98
0.10
2.3
2.8
1.71
1.80
%
0.79
184
1831
5
44
1.14
0.10
1.0
1.2
—
—
—
0
0
5
45
1.11
0.09
1.0
1.0
—
—
—
0
0
81
782
1.04
0.09
2.4
3.5
4.36
4.46
pmol/l
0.39
73
689
524
5187
1.01
0.09
4.3
3.6
42.06
92.18
e6/l
1.95
414
4040
369
3643
1.02
0.09
3.3
2.8
5.84
5.21
e6/l
0.34
340
3333
157
1605
0.98
0.09
8.6
7.4
9.51
10.54
mmol/l
1.02
151
1541
18
196
0.92
0.09
1.3
1.6
—
—
—
0
0
28
298
0.94
0.08
3.6
2.0
—
—
—
0
0
30
318
0.94
0.08
5.6
3.7
22.07
28.16
mg/l
0.78
23
225
5
62
0.81
0.08
1.0
1.3
156.70
179.37
mmol/24h
—
5
62
21
226
0.93
0.08
1.2
1.1
5.61
1.84
u/ml
0.38
13
136
16
146
1.10
0.08
1.3
1.3
—
—
—
0
0
6
71
0.84
0.07
1.2
1.3
—
1.43
%
—
0
14
17
184
0.92
0.07
1.1
1.1
1.55
1.93
u/ml
—
6
88
28
296
0.95
0.07
1.5
1.5
—
—
—
0
0
12
131
0.92
0.05
1.6
1.9
—
—
—
0
0
241
2436
0.99
0.05
2.6
2.7
23.75
22.35
%
0.86
221
2277
146
1439
1.02
0.05
2.6
2.4
7.21
7.06
ug/l
0.02
131
1267
162
1600
1.01
0.04
2.5
2.8
65.86
69.27
e9/l
0.83
123
1187
450
4473
1.01
0.04
4.1
3.5
0.53
0.46
e6/l
0.29
348
3354
142
1439
0.99
0.04
2.1
2.1
0.00
0.02
estimate
0.78
19
280
317
3146
1.01
0.04
3.9
4.2
395.62
417.98
ng/l
0.03
263
2601
24
229
1.05
0.04
1.4
1.6
—
—
—
0
0
24
229
1.05
0.04
1.4
1.6
—
—
—
0
0
24
229
1.05
0.04
1.4
1.6
—
—
—
0
0
24
229
1.05
0.04
1.4
1.6
—
—
—
0
0
319
3213
0.99
0.04
1.8
1.8
1.27
1.37
mg/l
0.22
249
2519
29
279
1.04
0.04
1.2
1.4
254.44
274.98
u/ml
0.24
16
147
132
1337
0.99
0.04
4.6
4.6
0.17
0.11
%
0.26
35
388
21
200
1.05
0.03
1.2
1.2
1.89
5.55
u/ml
—
9
91
12
129
0.93
0.03
1.3
1.4
42.80
28.18
%
—
5
79
47
482
0.97
0.03
1.4
1.5
257.16
272.67
ug/g
0.27
32
297
16
151
1.06
0.03
2.4
3.7
12.75
11.53
index
—
8
90
26
270
0.96
0.03
3.3
3.2
4.26
4.35
e9/l
0.06
26
270
17
179
0.95
0.03
2.4
2.5
—
—
—
0
0
420
4220
0.99
0.03
2.3
2.4
2.89
2.89
mg/l
0.01
355
3622
12
112
1.07
0.03
1.0
1.1
—
—
—
0
0
40
390
1.03
0.02
4.3
4.8
—
—
—
0
0
13
138
0.94
0.02
1.1
1.1
—
—
—
0
0
19
182
1.04
0.02
1.4
1.6
41.20
62.93
%
—
10
114
260
2614
0.99
0.02
2.5
2.7
2.26
2.27
g/l
0.14
233
2420
19
198
0.96
0.02
1.2
1.4
0.67
9.69
nmol/l
0.50
19
188
284
2826
1.01
0.02
3.6
3.2
0.97
1.07
e6/l
0.27
177
1558
1128
11296
1.00
0.02
8.3
8.6
77.10
81.21
u/l
2.48
1072
10704
142
1409
1.01
0.02
4.4
4.5
1.20
0.90
%
0.48
44
460
11
103
1.07
0.02
1.0
1.1
—
—
—
0
0
16
153
1.05
0.01
1.0
1.1
1.00
2.63
eliau/ml
—
6
51
17
177
0.96
0.01
1.3
1.3
—
—
—
0
0
10
94
1.06
0.01
1.4
1.5
128.14
160.42
pmol/l
—
10
94
11
104
1.06
0.01
1.4
1.4
7.34
7.39
ph
0.23
11
75
11
104
1.06
0.01
1.1
1.2
—
—
—
0
0
16
166
0.96
0.00
1.2
1.3
—
—
—
0
0
605
6043
1.00
0.00
4.6
4.2
43.99
77.47
ng/l
1.20
504
4566
422
4226
1.00
0.00
3.8
3.5
—
0.00
estimate
—
0
19
11
105
1.05
0.00
1.8
2.3
3.47
3.00
ug/l
0.15
11
100
14
139
1.01
0.00
1.1
1.2
8.64
13.21
u/l
0.89
14
126
44
441
1.00
0.00
3.2
3.5
2.14
1.77
index
0.15
22
241
19
186
1.02
0.00
1.1
1.1
5.09
5.04
u/ml
—
9
104
23
234
0.98
0.00
5.5
6.8
11.58
12.44
mg/l
0.43
23
219
14
137
1.02
0.00
1.7
1.7
—
—
—
0
0
24
237
1.01
0.00
1.0
1.1
—
—
—
0
0
79
795
0.99
0.00
1.1
1.2
130.93
145.95
u/ml
0.11
24
306
0
9
0.00
0.00
0.0
2.3
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
163.11
—
0
9
0
9
0.00
0.00
0.0
2.0
—
146.33
—
0
9
0
9
0.00
0.00
0.0
4.7
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
7
76
0.92
-0.00
1.0
1.6
—
—
—
0
0
5
52
0.96
-0.00
1.2
2.5
11.94
180.78
ug/l
—
5
43
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
6
63
0.95
-0.00
1.0
1.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
72.73
—
0
6
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
30.86
—
0
5
0
7
0.00
-0.00
0.0
1.4
—
361.43
—
0
7
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.0
—
—
—
0
0
8
87
0.92
-0.00
1.1
1.7
—
—
—
0
0
0
6
0.00
-0.00
0.0
4.2
—
98.00
—
0
6
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
9
90
1.00
-0.00
1.2
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.9
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
10
100
1.00
-0.00
1.3
1.5
77.00
88.69
umol/l
—
10
100

Mortality – FinRegistry

↥

Association

Association between endpoint G6_NEUATR and mortality.

Females

Parameter HR [95% CI] p-value
G6_NEUATR 7.442 [6.44, 8.6] < 0.001
Birth year 0.994 [0.99, 1.0] 0.176

During the follow-up period (1.1.1998 — 31.12.2019), 2750 out of 4587 females with G6_NEUATR died.

Males

Parameter HR [95% CI] p-value
G6_NEUATR 5.431 [4.76, 6.19] < 0.001
Birth year 0.986 [0.98, 1.0] 0.006

During the follow-up period (1.1.1998 — 31.12.2019), 3012 out of 5076 males with G6_NEUATR died.

Mortality risk

Mortality risk for people of age

years, who have G6_NEUATR.

N-year risk Females Males
1 0.823% 0.863%
5 3.911% 5.649%
10 10.404% 14.121%
15 19.039% 26.114%
20 31.816% 40.692%

Relationships between endpoints

↥

Index endpoint: G6_NEUATR – Systemic atrophies primarily affecting the central nervous system

GWS hits: 13

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data